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Systematic Analysis of Structure-Function Relationships of
Conserved Sequence Motifs in the NADH-Binding
Lobe of Cytochrome b5 Reductase
Glenn W. Roma
ABSTRACT

NADH:Cytochrome b5 Reductase (cb5r) catalyzes the reduction of the ferric iron
(Fe3+) atom of the heme cofactor found within cytochrome b5 (cb5) by the reduction of
the FAD cofactor of cb5r from reducing equivalents of the physiological electron donor,
reduced nicotinamide adenine dinucleotide (NADH).

Cb5r is characterized by the

presence of two domains necessary for proper enzyme function: a flavin-binding domain
and a pyridine nucleotide-binding domain. Within these domains are highly conserved
“motifs” necessary for the correct binding and orientation of both the NADH coenzyme
and the FAD cofactor.
To address the importance of these conserved motifs, site-directed mutagenesis
was utilized to generate a series of variants of residues located within the motifs to allow
for the full characterizations.

Second, naturally occurring recessive congenital

methemoglobinemia (RCM) mutants found in proximity to these highly conserved motifs
were analyzed utilizing site-directed mutagenesis. In addition, a canine variant of the cb5r
soluble domain was cloned, generated and characterized and
xvi

compared with the WT rat domain.
The canine construct showed a high degree of sequence homology to that of the
corresponding human and rat sequences. Characterization of the canine variant indicated
that it possessed comparable functional characteristics to the rat variant.
Investigation of the pyrophosphate-associating residues, Y112 and Q210,
indicated that each played a role in the proper association and anchoring of NADH to the
enzyme. The RCM type I mutants, T116S and E212K, caused a moderate decrease in
efficiency of the enzyme. The presence of both mutations interact synergistically to
generate a more substantially decreased function.
Analysis of the “180GtGitP185” NADH-binding motif and the preceding residue
G179 revealed that these residues are vital in enabling proper NADH association. The
residues of this motif were shown to be important in determining nucleotide specificity
and properly positioning the NADH and flavin cofactor for efficient electron transfer.
RCM variants A178T and A178V were shown to decrease catalytic efficiency or protein
stability respectively, leading to disease phenotype.
Analysis of the NADH-binding motif “273CGxxxM278” indicated that this motif
facilitates electron transfer from substrate to cofactor and is important in release of NAD+
from the enzyme after electron transfer.

xvii

1. INTRODUCTION

Electron Transfer
Electron transfer is the process by which one electron moves from one atom or
molecule to another. It is a mechanistic representation of the thermodynamic principle of
oxidation-reduction. Numerous biological processes are dependent upon the proper
transfer of electrons, including photosynthesis and respiration. Additionally, pathways
involved in metabolism and detoxification are dependent upon appropriate electron
transfer reactions. Regardless of the intended function, the ability of the cell to harness
the energy from dietary and storage molecules is dependent upon converting energetic
raw materials of macromolecules to a usable form. To this end, cells use a limited
number of molecules to couple reactions.

Most notable of these molecules are

nucleotides such as ATP/ADP, NAD(P)/NADP(H), and FAD/FADH2. The reducing
power of these latter molecules is used to drive many reactions in anabolic pathways in
the cell that would not normally occur due to unfavorable energy requirements.
In biological systems, the majority of enzymes involved in electron transfer
reactions do so by the use of cofactor molecules and coenzymes which alter the
electrostatic potential of the enzymes active site. These components span a large range of
redox potentials, enabling them to carry out a large variety of processes within and
equally widely varied number of environments and conditions.
1

Electron transfer

reactions often utilize transition metal complexes, though many examples of organic
molecules are now known. Common cofactors utilized to carry out electron transfer in
cells include metal compounds such as Fe-S clusters, hemes and other porphyrin ring
structures, and highly conjugated ring like those present in flavin nucleotides. Many
complex electron transfer systems maximize the ability to move energy by clustering
several such cofactors within a multi-center complex. Electrons are free to move through
the electrochemical gradient by passing from one factor to the next. In other cases,
systems show less efficiency by having separate compartments, but are able to interact
with a variety of donor and acceptor molecules. Multiple examples of enzymes of each
condition exist. Indeed, the list would be quite long. Virtually every oxidation or
reduction reaction that occurs in the cell is catalyzed and regulated by an electron transfer
protein. In general, electron transfer proteins serve to couple energetically unfavorable
endergonic reactions to energy releasing exergonic reactions.

Methemoglobin
Methemoglobin is the form of hemoglobin in which the iron atom of the heme
prosthetic group is present in the oxidized, or ferric (Fe3+) state, compared to the reduced,
or ferrous (Fe2+) state found in normal hemoglobin. For tetrameric hemoglobin, this
corresponds to a four-electron loss. Since methemoglobin is incapable of binding
molecular oxygen this results in a loss of biological function of the hemoglobin molecule.
Observations from as early as the nineteenth century showed that methemoglobin
could be generated in red blood cells in a variety of ways. Table I illustrates the
assortment of toxic compounds that, when ingested, generate varying levels of
2

methemoglobin depending on the nature of the compound. This is typical in third-world
countries where poor water supplies and living conditions often lead to high levels of
nitrates in common well water sources [1]. Methemoglobin is also generated as a result
of a reaction to certain drugs that are used in treating patients for various conditions
including dapsone, local anesthetics, and anti-malarial drugs [2]. Additionally,
methemoglobin is produced as a result of certain hereditary disorders.
Table I. Compounds Capable of Generating Methemoglobin.

Acetanlid
Alloxan
Aniline dyes
Aromantic Amines
Arsine
Benzene Derivatives
Benzocaine
Bivalent Copper
Bismuth Subnitrate

Chlorates
Chloroquine
Dapsone
Dimethyl Sulfoxide
Dimethyltoluidine
Dinitrophenol
Ferricyanide
Flutamide
Hydroxylamine

Lidocaine Hydrochloride
Naphthalene
Nitrates
Nitric Oxide
Nitrites
Nitrofuran
Nitroglycerine
Nitrophenol
Nitrosobenzene

Phenacitin
Phenytoin
Pyridium
Resorcinol
Rifampin
Silver Nitrate
Sulfasalazine
Sulfonamides
Trinitrotoluene

The steady-state levels of methemoglobin within normal erythrocytes is very low,
corresponding to <1% total hemoglobin, indicating that the capacity to reduce
methemoglobin far exceeds the rate of hemoglobin oxidation [3].

Methemoglobin

homeostasis shows that electrons for methemoglobin reduction are generated in a variety
of reactions. Primarily amongst these is the glycolytic pathway, which generates reducing
equivalents in the form of NADH. However, the rapid reduction of methemoglobin by
non-glycolytic substrates suggests that additional pathways may be involved with the
generation of NADH, perhaps in response to elevate levels of methemoglobin. The
steady-state levels of methemoglobin are a consequence of the methemoglobin-reducing
reactions as well as the methemoglobin-generating reactions in erythrocytes.
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Concentrations of methemoglobin in erythrocytes can become elevated as a result
of accelerated oxidation or decreased reduction resulting from either environmental
factors such as those described earlier or from hereditary abnormalities.

The most

frequent cause of methemoglobinemia is rapid oxidation resulting from ingestion of toxic
compounds which are oxidants, or give rise to oxidants, such as peroxide and oxygen
radicals, during their metabolism [3]. Methemoglobinemia also arises from oxidation of
mutant hemoglobin belonging to the hemoglobin M class [4]. Methemoglobinemia
resulting from decreased rates of reduction is most commonly the result of a deficiency in
cytochrome b5 reductase (cb5r) found in circulating erythrocytes. The most infrequent
cause of decreased methemoglobin reduction has been attributed to deficiency in
cytochrome b5 (cb5) [5]. These latter two cases form the basis of the disease known as
recessive congenital methemoglobinemia (RCM).

History of Methemoglobinemia
Methemoglobinemia stemming from decreased functionality of cb5r, now known
as recessive congenital methemoglobinemia (RCM), is an extremely rare disorder that
has been under investigation for over one year and the French physician, Francios,
detailed an individual with long-standing cyanosis lacking any obvious signs of cardiac
or pulmonary abnormalities [6]. Another vital piece of the puzzle was determined in
1891 when it was first suggested that methemoglobin was reduced to hemoglobin in
circulating erythrocytes [7]. Forty years later, while describing a familial incidence of
idiopathic cyanosis, Hitzenberger suggested the possibility of congenital, familial
methemoglobinemia [8].
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These key findings and others culminated in the classic investigations performed
by Quentin Gibson at Queen's University, Belfast. Gibson’s patients were two brothers,
Russell and Fred Martin from Banbridge in Northern Ireland. The brothers presented
with a blue appearance. At the time, Dr. James Deeny, a local physician, advocated the
use of ascorbic acid in the treatment of heart disease, and his work demonstrated the
benefits of vitamin C [9]. When Russell was treated with vitamin C, the cyanosis was
ameliorated and he turned pink. Although Deeny assumed that he had corrected an
underlying heart condition, cardiologists could find no cardiac abnormality in either
brother. The physiologist Henry Barcroft carried out a detailed study of these cases
during treatment and found elevated levels of methemoglobin [10]. Following this,
Quentin Gibson conducted further work which correctly identified the pathway involved
in the reduction of methemoglobin. This was the first description of an hereditary trait
involving a specific enzyme deficiency [11]
In 1959, Scott and Griffith identified a normal human erythrocitic enzyme that
catalyzed methemoglobin reduction in the presence of reduced nicotinamide adenine
dinucleotide (NADH). They called this enzyme “diaphorase” [12]. Following further
analyses, this enzyme was given additional names, including NADH-dehydrogenase,
NADH-methemoglobin reductase, NADH-methemoglobin-ferricyanide reductase, or
NADH-ferricyanide reductase. It was also demonstrated at this time that a deficiency in
this enzyme resulted in hereditary methemoglobinemia. This deficiency was observed in
diverse populations including Athabaskan Indians (Eskimos) of Alaska [13] and Navajo
Indians [14], as well as an isolated community, the ‘blue Fugates’ living in the BlueRidge Mountains of Kentucky [15].

It was later demonstrated that a generalized
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deficiency of cb5r occurred in cases of methemoglobinemia with mental retardation. The
enzyme may be identical to NADH diaphorase. Leukocytes of patients with neurological
disorder lack cb5r, whereas the enzyme is normal in others. [16]. Previously, NADH-cb5r
(cb5r) and was shown to be involved, with the participation of cytochrome b5, in
methemoglobin reduction within erythrocytes [17]. The combined cb5r -cb5 redox system
is the most important for the conversion of methemoglobin to hemoglobin in circulating
erythrocytes, and the activity of this system is dramatically reduced in the erythrocytes of
patients described with enzymopenic hereditary methemoglobinemia, or RCM.

Cytochrome b5 Reductase
NADH:Cytochrome b5 reductase (cb5r, EC 1.6.6.2) is a member of the
ferredoxin:NADP+ reductase super-family of flavoprotein transhydrogenases [18] which
catalyze the transfer of reducing equivalents between nicotinamide dinucleotides and one
electron carriers. Notable members of this family include ferredoxin:NADP+ reductase
(FNR) [19], plant and fungal NAD(P)H:nitrate reductase [20], NADPH: cytochrome
P450 reductase [21], NADPH:sulphite reductase, phthalate dioxygenase reductase [22],
and nitric oxide synthase [23]. The enzymes found within this flavoprotein family have
been demonstrated to possess distinct structural domains responsible for flavin-binding
and pyridine nucleotide-binding. Cytochrome b5 reductase catalyzes the single electron
reduction of ferricytochrome b5 to ferrocytochrome b5 using the reduced pyridine
nucleotide NADH as the physiological electron donor. The rate-limiting step in catalysis
has been identified as a hydride ion transfer step involving the donation of one proton and
two electrons from the nicotinamide moiety of NADH to the oxidized FAD prosthetic
6

group of cb5r [24]. Additionally, in mammalian species, microsomal and cytosolic cb5r
isozymes provide reducing equivalents for a variety of physiologically important
metabolic processes that include methemoglobin reduction [17, 25], fatty acid elongation
and desaturation [26], cholesterol biosynthesis [27] and the cytochrome P450-mediated
hydroxylations of steroid hormones and xenobiotics [28], such as the reaction catalyzed
by cytochrome P450 3A4 [29] and the reduction of N-hydroxylamine [30]. Recently, it
has been shown to be part of the microsomal cytochrome b5 reductase-cytochrome b5
pathway directly involved in the reductive detoxification of arylhydroxylamine
carcinogens in human liver [31].
Cytochrome b5 reductase is encoded by the DIA1 gene (Figure 1), located on the
human chromosome 22q13-qter [33, 34]. It transcribes two isoforms of cb5r by the use
of alternative promoters [16, 35]. Each isoform is localized to separate regions of the cell
and thus perform separate functions.

The first isoform is the microsomal isozyme

generated through the transcription of all 9 exons of the DIA1 gene. The microsomal
isozyme comprises 300 amino acid residues with a molecular weight of ~34 kDa. This
isozyme, primarily localized to the cytosolic face of the endoplasmic reticulum, is also
found associated with the mitochondrial, nuclear, and plasma membranes of somatic
cells. The amino terminal 25 amino acids of the isozyme are primarily hydrophobic [36,
37] allowing for the microsomal association. Additionally, a myristoylation signature
sequence has been shown to be present in this 25 amino acid region, believed to be
involved in cb5r’s membrane association [38]. The microsomal form of the enzyme
accounts for the majority of the transcribed protein and is responsible for the majority of
the electron transfer reactions described above, excluding methemoglobin reduction.
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Figure 1. Structure of the Human DIA1 Gene that Encodes Cytochrome b5
Reductase. The DIA1 gene (A) is composed of exons 1-9 [32]. There are two alternate
transcription start sites, 1a and 1b, which yield the two isoforms of cb5r. (B) Represents
the membrane-bound cb5r isoform containing exon 1a-9, but not 1b, and consists of 300
amino acids (GAQLÆCFVF), including the myristoylation signature in exon 1a. (C)
Represents the soluble cb5r isoform containing exons 2-9, but not exon 1, and consisting
of the 275 amino acids that comprise the diaphorase domain (LFQRÆCFVF).
The second isoform corresponds to the soluble, truncated form of cb5r. It is
comprised of only exons 2-9 of the DIA1 gene producing a 275 amino acid residue
soluble form of cb5r, having a mass of ~31kDa. It is this form that is found primarily in
circulating erythrocytes and is responsible, via interaction with cb5, for the reduction of
methemoglobin to hemoglobin [17, 39]. In 1992, it was demonstrated that this truncated
isoform is produced by the use of alternative promoter/alternate exons: the full length
membrane-binding transcript is generated from an upstream housekeeping promoter,
while the erythrocyte transcript originates from a downstream, erythroid-specific
promoter [40]. Later, it was shown that the soluble form contains a non-coding new first
exon located between the first 2 exons of the human cb5r gene previously identified. In
addition, this new first exon shares 62% homology with the first exon and its 3-primeflanking intron sequences of rat erythroid-specific b5R mRNA, whereas the 5-prime
flanking region of the new first exon possesses features of a housekeeping gene [41].
8

The mechanism of electron transfer for the soluble form of cb5r from the
physiological substrate, NADH and the FAD cofactor of cb5r is shown in Figure 2. In
this schematic, two electrons are first transferred from NADH to FAD by a hydride ion

cb5rox (FAD)

A.

cb5rred (FADH2)

NADH + 2cb5(Fe3+)

NAD+ + H+ + 2cb5(Fe2+)

(1)

NADH

B.

E-FAD-.NAD+

E-FAD

E-FAD- -NAD+
e-

e- NAD+

H+

Figure 2. Mechanism of Cytochrome b5 Reductase Mediated Cytochrome b5
Reduction. (A) represents the chemical reaction (equation 1) catalyzed by cb5r . (B)
illustrates the mechanism of cb5r transfer where each electron (e-) reduces one molecule
of cb5 [42].
(H-) transfer. The two-electron reduced enzyme-NAD+ complex (E-FADH—NAD+) then
transfers one electron to each of two separate molecules of cb5 (E-FAD·- - NAD+),
which returns the reduced enzyme to its oxidized state [43]. The reduction of FAD by
NADH has been determined to be the rate-limiting step in the electron transfer process
catalyzed by cb5r [44-46]. In the porcine variant of cb5r , it was also determined that the
binding of NAD+ stabilized the anionic red semiquinone of FAD [47, 48]. Further
studies by Meyer et al. showed that binding of NAD+ also modulates the electron transfer
to cb5 [49], demonstrating the importance of the anionic red semiquinone form of cb5r
(E-FAD·- - NAD+) in the catalytic process. Recent studies by Iyanagi et al. generated a
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new scheme for the electron transfer sequence of cb5r

involving the neutral blue

semiquinone form and the oxidized enzyme-NADH-NAD+ ternary complex (Figure 3)
[43].
NAD+ E-FAD

NADH
(i)

E-FAD-NADH-NAD+

E-FAD-NADH
(viii)

NADH

H- transfer

(vii)

(ii)

(vi)

E-FAD-NAD+

E-FADH- - NAD+

E-FAD-NADH*
(iii)
(v)

E-FAD●--

-NAD+

e-

H+

(iv)
E-FADH●

-NAD+
e-

Figure 3. New Model of the Reaction Sequence of Cytochrome b5 Reductase. This
new model represents the reaction sequence of cytochrome b5 reductase containing the
neutral blue semi-quinone form and the oxidized enzyme-NADH-NAD+ ternary complex
as intermediates [43].
This scheme involves the following seven-step process: (i) formation of the oxidized
enzyme-NADH complex (E-FAD-NADH), (ii) conversion of E-FAD-NADH to a form
that has the ability to transfer a hydride ion (E-FAD-NADH), (iii) hydride (H-) transfer
from NADH to FAD, (iv) the first one-electron transfer from the two-electron reduced
enzyme complex (E-FADH -NAD+), (v) rapid conversion of the neutral blue
semiquinone form (E-FADH· -NAD+) to the anionic red semiquinone form (E-FAD· NAD+), (vi) the second one-electron transfer from E-FAD· -NAD+, (vii) formation of the
oxidized enzyme-NADH-NAD+ ternary complex (E-FAD-NADH-NAD+) by binding of
NADH, and finally (viii) release of NAD+.
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Recessive Congenital Methemoglobinemia
The efficiency of oxygen transport from the lungs to the extremities cannot occur
without a properly functioning cb5r –cb5 electron transport system.

A result of

alterations to this system causes a deficiency in methemoglobin reduction and leads to the
manifestation of the disease methemoglobinemia. The first sign of the onset of this
disease is the characteristic bluish coloration of the skin illustrated in Figure 4. This
coloration is common in newborns since the methemoglobin reducing capacity of their
erythrocytes is only 50-60% that of an adult and this medical condition is commonly
known as “blue baby syndrome”. The disease can arise from various environmental as
well as genetic factors.

A

B

Figure 4. Clinical Indications of Cyanosis as a Result of Increased Levels of
Methemoglobin in the Blood (A) This patient has the characteristic darkened or
“chocolate brown” lips, which occurs when methemoglobin levels reach 10-20% total
hemoglobin [50]. (B) A patient with drug-induced methemoglobinemia causing the
noticeable bluish coloration of the skin (right) [51].
This disease, now classified as recessive congenital methemoglobinemia (RCM,
OMIM 250800), arises from defects related to cb5r functionality and was the first disease
to be directly associated with enzyme deficiency [52]. The most common cause of
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recessive congenital methemoglobinemia (RCM) is a deficiency in the function of cb5r.
This function is critical since elevated levels of methemoglobinemia give rise to cellular
hypoxia, which results in death when levels of methemoglobin reach 70% or greater.
Levels of methemoglobin concentration with corresponding symptoms are shown in
Table II. Individuals with RCM are unable to effectively control the increasing levels of
reduced methemoglobin continuously being formed through the deoxygenation of
hemoglobin in circulating erythrocytes. Defects in the expression of cb5r give rise to two
major clinical-biochemical classifications of methemoglobinemia, simply known as type
I and type II, which are classified based on the patient pathophysiology.
Type I RCM, exhibited by the majority of patients, is due primarily to a
deficiency of the soluble form of cb5r found in circulating erythrocytes.

This form of

methemoglobinemia is inherited in an autosomal recessive pattern. Though exhibited
worldwide, type I RCM has been shown to be endemic in certain populations including
the Athabaskan Alaskans, Navajo Indians, and Yakutsk natives of Siberia.

Those

individuals with type I RCM have methemoglobin concentrations ranging between 10 to
40%. The predominant symptom of type I RCM is a well-tolerated cyanosis that may
result in additional mild complaints such as headaches, fatigue, and shortness of breath
during exercise.

Life expectancy of these patients is unaffected.

Type II RCM represents a significantly more severe form of the disorder and
occurs in less than 10-15% of patients where the defect is attributed to a generalized cb5r
deficiency, which includes the membrane-associated form present in somatic cells [3].
Type II RCM results in severe developmental abnormalities including mental retardation,
microcephaly, opisthotonus, strabismus, and generalized hypertonia often leading to
12

premature death [12, 53, and 54]. A third form of RCM, type III, which occurs with a
substantially lower frequency, has been associated with a deficiency of cb5 (OMIM
250790) [5].
Table II. Levels of Methemoglobin Concentration and Symptoms.

% Methemoglobin
Diagnosis
Normal
0-3%
Possible slight discoloration of skin.
3-10%
10-20%
Relatively asymptomatic, cyanosis is prevalent.
Constant headache, lightheadedness, weakness, and
30-40%
confusion.
40-50%
Dyspnea, Lethargy, palpitations. and chest pain.
Acidosis, arrhythmias, bradycardia, hypoxia,
50-60
seizures, and coma.
>70%
Death

Both forms of RCM stem from the transcript of one gene, the DIA1 gene, coding
for cb5r. Due to this fact, the difference in severity of the resultant phenotypes of type I
and type II must be due to the underlying effect that the mutation has on the function of
the mature protein. It is because of this that it is believed that patients presenting with the
less severe type I methemoglobinemia are producing the gene product at a normal rate,
however the resulting protein is unstable. Since mature red blood cells cannot synthesize
proteins, they are affected, whereas other somatic cells are able to continuously replace
the cb5r as it degrades in the cell. Mutations that give rise to type I RCM tend to be
single amino acid substitutions. Conversely, in patients expressing type II, mutations in
the DIA1 gene tend to introduce premature stops or deletions of amino acids or even an
entire exon. These alterations give rise to decreased expression or reduced catalytic
activity of cytochrome b5 reductase and the deficiency is ubiquitous. Thus far, about 40
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amino acid mutations have been identified within the DIA1 gene giving rise to either type
I or type II methemoglobinemia [35, 42, 55-57].

Crystal Structure of Cytochrome b5 Reductase
High resolution crystal structures of the soluble, diaphorase domain of R.
norvegicus cb5r have been solved in both the absence (2.0 Å, PDB 1I7P) and presence
(2.3 Å, PDB 1IB0) of bound NAD+ [58] (Figure 5). The structures possessed a classical
two domain arrangement, containing an amino terminal FAD-binding lobe (amino acid
residues I33-R142) and a carboxy-terminal NADH-binding lobe (amino acid residues
K172-F300). Residues G148-V171 comprise the “linker” or “hinge” region, a 28 amino
acid residue segment that forms a three stranded, anti parallel β-sheet demonstrated to be
of critical importance in determining correct orientation of the two lobes and modulation
of electron transfer between that of the FAD- and NADH-binding domain [59, 60].
The amino-terminal FAD-binding domain (Figure 6) is comprised of a sevenstranded anti-parallel β-barrel, labeled as Fβ1-Fβ7, oriented towards the si-face of the
flavin isoalloxazine ring and capped by a single α-helix found in the FAD-binding
domain. A majority of the interactions with the FAD- prosthetic group occur via the
adenine dinucleotide moiety of the flavin and with a long loop of the FAD-binding
domain which is comprised of amino acid residues K110-K125 forming a “lid” and is
situated between Fβ6 and the α-helix.
The “hinge” or “linker” region (Figure 7) is situated between the FAD-binding
and NADH-binding domains and is comprised of a three-stranded anti-parallel β-sheet
structure designated as Hβ1-Hβ3. Studies of this linker region by Davis et al. [60]
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demonstrated that it is this “linker” region which is actively involved in properly
orienting the FAD- and NADH-binding lobes of cb5r for efficient electron transfer and
suggested that any disruption within the conformation of the β-sheet architecture would
lead to a significant decrease in catalysis.
The NADH binding domain (Figure 8) is composed of a canonical Rossman fold
[61] formed by 3 α/β/α layers arranged into a five-stranded parallel β-sheet that is
oriented towards the re-face of the isoalloxazine ring of the FAD prosthetic group. The
isoalloxazine ring is the only region of the FAD- cofactor that forms interactions via
hydrogen bonds between the NADH-binding site and the isoalloxazine ring. This occurs
through the FAD-binding domain loop strands Fβ3 and Fβ4 (amino acid residues P92K110) and the NADH-binding domain Nβ1-NαA (amino acid residues T181-T184).

Cytochrome b5 Reductase Sequence Homology
Cytochrome b5 reductase sequences, or those of closely related homologs, have
been identified within the genomes of a diverse array of eukaryotic organisms that
include fungi (M. alpine) [62], yeast (S. cerevisiae) [63], plants (A. thaliana) [64],
nematodes (C. elegans) [65] insects (D. melogaster) [66], fish (D. rerio) [67], amphibians
(X. laevis) [68], birds (G. gallus) [69] and mammals (R. norvegicus) [70]. Multiple
sequence alignments have revealed extensive primary structure conservation within cb5r
homologs with the most diverse sequences, corresponding to those of H. sapiens [71] and
P. yoelii [23], retaining approximately 25% sequence identity.
Cytochrome b5 reductase variants have been isolated from a limited number of
eukaryotic sources. The majority of the early studies utilized enzymes isolated from
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Figure 5. The Tertiary Structure of Rat Cytochrome b5 Reductase. The 2.0Å
resolution X-ray crystal structure derived from soluble recombinant rat liver cb5r (PDB
1IB0) [58] is illustrated as a schematic model where the red portions represent α-helices,
the yellow ribbons with directional arrows represent β-sheet structures, and the green
tubes are indicative of random coils and flexible loop structures. The FAD cofactor (left)
and NAD+ (right) are shown in stick configurations with standard CPK coloration.
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“Lid”

Fα1

Fβ1b
Fβ6
Fβ1a

Fβ2

FAD
Fβ4

Fβ5
Fβ3

Figure 6. The Structure of the FAD-Binding Domain of Cytochrome b5 Reductase.
A view of the N-terminal FAD-binding domain of rat cb5r (PDB 1IB0) [58] with FAD
bound. The re-face of the isoalloxazine ring faces towards the right. FAD is shown in
stick configuration with standard CPK coloration. The polypeptide backbone is shown in
green with the single α-helix in red and β-sheets colored yellow and are labeled
accordingly.
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Fβ6

Hβ1

Hβ2

Nβ1
Hβ3

Figure 7. The Structure of the “Hinge” Region of Cytochrome b5 Reductase. A
view of the “hinge” region of rat cb5r (PDB 1IB0) [58] located between the FAD and
NADH-binding domains. The polypeptide backbone is shown in green with the single αhelix in red and β-sheets colored yellow and are labeled accordingly.
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NAD+
NαD

NαC

Nβ2

NαB

Nβ5
Nβ4
NαA
Nβ3

Nβ1

Figure 8. The Structure of the NADH-Binding Domain of Cytochrome b5
Reductase. C-terminal NADH-binding domain of rat cb5r (PDB 1IB0) [58] with NAD+
bound. NAD+ is shown in stick configuration with standard CPK coloration. The
polypeptide backbone is shown in green with the single α-helix in red and β-sheets
colored yellow and are labeled accordingly.
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either bovine or porcine liver [38, 47]. More recently, an array of recombinant expression
systems have been developed for the production of several cb5r variants that include the
soluble, diaphorase domains of the human [73], bovine [74], porcine [43] and rat [75]
enzymes. The recombinant forms have been generated using an array of suitable
expression vectors which resulted in various amino-terminal modifications, such as the
addition of a poly-histidine tag [75] or glutathione S-transferase [76].

All the

recombinant cb5r variants have been isolated as functional enzymes with a range of
NADH:ferricyanide reductase specific activities (kcat) that have varied from 368 s-1 for
the human enzyme [76] to 1060 s-1 for the bovine variant [74]. Standardization of these
kinetic parameters across the various commonly used animal systems, along with
additional parameters such as thermal stability, redox potentials, and spectral properties,
would be of benefit to universalize the information, thereby giving a rational foundation
on which further investigations could be based.

Sequence Motifs in the FNR Family of Flavoprotein Oxidoreductases.
Through a sequence alignment utilizing the X-ray crystal structure of spinach ferredoxinNADP+ reductase [77], a family of flavin-dependent oxidoreductases have

been

identified which include: cytochrome b5 reductase, cytochrome P-450 reductase,
methionine synthase reductase, ferredoxin:NADP+ reductase, as well as many others. Of
significant interest was the pattern of conserved residues detected within the flavin- and
nucleotide-binding domains characteristic of the FNR super-family (Figure 9).

The

structural motif of members of the FNR family is that of a two-domain module with one
binding the flavin and the other binding the pyridine nucleotide. In regards to function,
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the FNR family is typically classified by the two electron reduction of a flavin prosthetic
group (FAD/FMN) by a pyridine dinucleotide coenzyme (NAD(P)H), followed by the
sequential transfer of electrons in one electron reactions with carriers. An additional
feature of the proteins found within the FNR super-family is the varying levels of
complexity based on the structural domains and modulation of electron transfer.
Cytochrome b5 reductase and FNR are examples of the simplest members of the FNR
family in that they each consist of only two domains and reduce molecules which are able
to bind and then rapidly disassociate following electron transfer. In contrast, cytochrome
P450 reductase, sulfite reductase-α, and PDR represent more complex enzymes.
Although the structures also consist of two domains, the one-electron acceptor molecule
is actually fused to the two-domain core by a linker region. Finally, the most complex
members of the FNR family contain additional sequences and prosthetic groups
indicative of more than three structural domains.

These enzymes include: nitrate

reductase and nitric oxide synthase.
The conservation of the “RxYTSxxSN”, “GRxxST”, “GxGxxP”, and “CGxxx-M”
sequence motifs found within the members of the FNR flavoprotein family, clearly
demonstrates the importance of these structural motifs towards the interactions of flavincofactor and pyridine nucleotide binding and utilization.

Research Aims and Approaches
The general goal of this research was to gain further insight into the roles of the
conserved motifs found within cytochrome b5 reductase that are involved in NADHbinding. To achieve this objective, analyses of the residues directly forming these motifs
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Figure 9. Alignment of Conserved Flavin-Binding and NADH-Binding Motifs from
Various Enzymes Belonging to the “FNR Family” of Flavoprotein
Transhydrogenases. Each of the published amino acid sequences was obtained from the
GenBank protein database [78] with the corresponding accession number and reference.
The superscripted numbers indicate the amino acid positions of the first and last residue
of each motif within the full-length sequence of each protein. Abbreviations are: CB5R ,
cytochrome b5 reductase, NR, nitrate reductase, FNR, ferredoxin:NADP+ reductase,
CPR, cytochrome P450 reductase, NOS, nitric oxide synthase, PDR, phthalate
dioxygenase reductase, MSR, methionine synthase reductase, SR, sulfite reductase, FHG,
flavohemoglobin, B5B5R, cytochrome b5-cytochrome b5 reductase fusion protein, ETP,
electron transfer protein, NDR, naphthalene dioxygenase reductase, PH, phenol
hydroxylase, NFR, NADPH:flavin reductase, CDPGR, CDP-glucose dehydratase
reductase, CMR, p-cymene monooxygenase reductase, XMR, xylene monooxygenase
reductase, NMR, nitrotoluene monooxygenase reductase, DQMR, dihydorquinoline
monooxgenase reductase, MMOR, methane monooxygenase reductase, ADR,
anthranilate dioxygenase reductase, TDR, toluate dioxygenase reductase, BDR, benzoate
dioxygenase reductase, HBDR, hydroxybenzoate dioxygenase reductase, NQR1, Na+
translocating NADH:quinone reductase 1, UNK1, unknown M. loti gene product, UNK2,
unknown Halobacterium sp. NRC-1 gene product, HYPR, hypothetical Xanthobacter
reductase.
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Enzyme

Motif 1

CB5R

91

NR

722

FNR

Motif 3

Motif 4

125

GKMS128

181

GTGIT-P186

274

CGPPP-M279

RAYTPPS728

755

GVMS758

805

GTGIT-P810

898

CGPPP-M903

139

RLYSIAS145

176

GVCS179

217

GTGIA-P222

318

CGLKG-M323

CPR

454

RYYSIAS460

488

GVAT491

534

GTGVA-P539

629

CGDARNM635

NOS

1178

PDR

51

MSR

478

RPYSCAS484

514

SR

386

RLYSIAS392

FHG

204

B5B5R

289

ETP

RPYTPVS97

Motif 2

RYYSISS1184

RNYSLSN57

56

1214

83

GVCS1217

RGGS87

1255

GTGIA-P1260

1354

CGDVT-M1359

123

GIGIT-P128

202

CGPRPLM208

GVCT517

573

GTGIA-P578

677

CGDKANM683

420

GASS423

461

GTGIA-P466

552

CGDANRM558

RQYSLTR210

227

GQVS230

268

GVGQT-P273

362

CGPVGFM368

KPYTPVS295

323

GLFT326

364

GTGFT-P369

458

CGPTPFT464

RCYSITS62

80

120

GSGIA-P125

203

CGPEPFM209

GRVS83

NDR

142

RPYSMAG148

165

GRVT168

206

GTGLA-P211

295

CGAPA-M300

PH

149

RAFSLAN155

173

GAAT176

214

GSGLSSP220

306

CGPPP-M311

RPFSMAS64

77

123

GTGFSYA129

212

AGRFE-M217

NFR

58

GASE80

CDPGR

141

RSYSIAN147

164

GQMS167

204

GTGFA-P209

292

CGSPV-M297

CMR

159

RSYSFAN165

185

GEFT188

225

GSGLA-P230

315

CGPPP-M320

XMR

160

RSYSFAT166

184

GIFS187

224

GTGLA-P229

315

CGPPP-M320

NMR

161

RSYSFSA167

185

GVFS188

225

GTGLA-P230

316

CGPPP-M321

DQMR

155

RSYSPSS161

179

GAMS182

221

GTGLA-P226

310

CGPQP-M315

MMOR

159

RSYSPAN165

183

GRFS186

224

GTGLA-P229

314

CGPPG-M319

ADR

154

RSYSFAN160

178

GVMS181

218

GTGLS-A223

307

CGPPP-M312

TDR

153

RAYSFSS159

176

GLMS179

216

GTGLA-P221

304

CGPPP-M309

BDR

166

RSYSFSS172

189

GKMS192

229

GTGIA-P234

317

CGPVP-M322

HBDR

152

RAYSYSS158

175

GKMS178

215

GTGLA-P220

305

CGPPP-M310

NQR1

222

KAYSLAS228

259

GVCS262

298

GAGSSFG304

401

CGPPLHN407

UNK1

168

RLYLVST174

201

GSSP204

383

GIGIT-P388

471

SGPQA-M476

UNK2

51

RYYTLSS57

102

GEPS105

112

GPGVG-P117

188

CGAATDA194

HYPR

142

RAYSVAN148

166

GAGT169

207

GSGLA-P212

297

AGPAP-M302

RxYTSxxSN

GxxST
RxxSN

Consensus

(FAD)

GxGxxP

(FMN)

23

CGxxx-M

GenBank
Accession/Ref
NP_620232 /
[34]
P23312 /
[79]
P10933 /
[80]
P16435 /
[81]
P29475 /
[82]
Q05182 /
[22]
Q9UBK8 /
[83]
P38038 /
[84]
P24232 /
[85]
NP_596918 /
[86]
BAA12809 /
direct submission
AAD02134 /
[87]
AAA25944 /
[88]
AAN83224 /
[89]
P26395 /
[90]
AAB62300 /
[91]
AAB70826 /
direct submission
AAC38360 /
[92]
CAA73201 /
[93]
P22868 /
[94]
AAC34815 /
[95]
AAD31449 /
direct submission
P07771 /
[96]
Q51603 /
[97]
Q9Z723 /
[98]
NP_107088 /
[99]
NP_279534 /
[100]
CAA09916 /
[101]

as well as naturally occurring methemoglobinemia variants which occur in proximity to
these motifs were investigated. This was carried out by determining desired mutations of
the residues under consideration. The desired variants were then generated utilizing sitedirected mutagenesis of an affinity-tagged R. norvegicus cytochrome b5 reductase
construct [102]. Each cb5r variant generated was then subsequently characterized using
biophysical, potentiometric, and enzymological techniques.

Additional insight was

obtained through comparison of enzymatic properties of the wild type isoform of R.
norvegicus cytochrome b5 reductase to that of C. familiaris.
The initial specific aim was to generate an expression construct of the canine
variant of cytochrome b5 reductase and compare the biophysical and enzymological
properties of the resultant recombinant enzyme to those of the previously established rat
isoform. Completion of a survey sequence of the canine (boxer) genome [103] resulted
in the identification of two putative cb5r sequences based upon sequence conservation
with the products of the human and mouse genomes. Analysis of the two sequences
indicated the putative proteins had equivalent carboxyl-termini. However, the aminoterminal sequences exhibited marked heterogeneity to other mammalian cb5r sequences.
The generation and expression of a full length canine cb5r cDNA containing the
membrane associated amino acids was carried out to investigate the discrepancies in the
sequence homology between the canine variants reported in GenBank (XM_531708,
ENSCAFP000000000953) and that of the rodent and human sequences, thus confirming
the primary sequence of the canine variant. Additionally, a viable protein containing
only the 275 amino acid catalytic diaphorase domain of the canine isoform was generated
and purified to homogeneity to investigate the structural and functional parameters of the
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canine cb5r and compare the results to those of the rodent isoform.
The second specific aim was directed at the elucidation of the roles of two
residues, tyrosine 112 (Y112) and glutamine 210 (Q210), in the correct binding and
orientation of NADH to cb5r and thereby correct function of the enzyme. Through the
analysis of the crystal structure of cytochrome b5 reductase (PDB - 1IB0) it was shown
that these two residues are found on opposite sides of the binding cleft for NADH and
that each of these residues formed a hydrogen bond interaction with the pyrophosphate
backbone of NAD+. Because of this, it was hypothesized that the residues would act to
properly orient and anchor the NADH into position for efficient electron transfer.
Additionally, two naturally occurring type I RCM variants are found in proximity to these
residues, with one variant located near each residue. The variants, T116S and E212K,
have both been detected in patients with RCM. Upon inspection of the crystal structure
of cb5r, each of these residues were found on the external surface of the protein and did
not interact with either the flavin or NADH environments. Thus, we proposed that the
effects of these mutations were likely to be moderate in nature and occur as a result of
effects on nearby residues and structures. In order to better understand the causation of
the pathology of these RCM variants, as well as the roles played by the nearby
pyrophosphate associated residues, a series of variants were generated and analyzed for
their effects on various functional parameters.
Specific aim three focused on the highly conserved NADH-binding motif
180

GxGxxP185. Analysis of the crystal structure of cb5r allowed for visualization of the

importance of this motif in the proper orientation of the NADH substrate. This motif is
located at the N-terminus of the 16-residue helical segment Nα1. The leading three
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residues, along with the preceding residue G179, form a compact segment that effectively
reverses the direction of the polypeptide backbone, generating a “flattened” surface
against which the NAD+ can reside. The two conserved glycine residues, corresponding
to G180 and G182, participate in hydrophobic contacts with the nicotinamide portion of
the pyridine nucleotide substrate, while the intervening residue, T181, forms a hydrogen
bond interaction with the nicotinamide ribose. T181, together with residue P185, also
contributes to the hydrophobic interactions of the environment surrounding the
isoalloxazine ring of the FAD cofactor, with which residue T184 forms two hydrogen
bonds. The high level of interaction of the residues of this motif with both the cofactor
and substrate suggest a pivotal role for this motif in the proper functioning of cb5r.
Additionally, the preceding residue, G179, shows a high level of homogeneity amongst
FNR family members, suggesting it too has a critical role in the association of NADH
with cb5r.

To further access the importance of this region of cb5r, the naturally

occurring type I RCM mutants A178T and A178V were also characterized.
The fourth specific aim of this research involved the investigation of the
conserved “273CGxxxM278” motif which is located within the NADH-binding domain of
cb5r and is involved in the regulation of NADH-binding. While the residues comprising
this motif do not form any direct electrostatic or hydrogen bond contacts with the bound
NAD+, the residues form a loop that provides an extensive framework of hydrophobic
contacts that could orient the nicotinamide portion of the reduced pyridine nucleotide for
subsequent efficient hydride transfer to the FAD prosthetic group. Residue C273 has
been suggested to be important in facilitating electron transfer or in maintaining proper
NADH-binding and orientation (104). The conserved glycine of the motif, corresponding
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to G274, forms two critical hydrogen bonds with bound NAD+. Previous studies have
been conducted giving additional preliminary insight into the role this motif may play.
Analysis of the type II RCM variant M272- demonstrated that the proper placement of
this motif is vital to the proper functioning of the enzyme and the analysis of the type I
RCM variant P275L suggested that, at least in part, this motif functions as a scaffold
around which NADH lays for proper orientation [105]. These initial findings suggested
that the

273

CGxxxM278 motif is essential in proper orientation of the NADH substrate to

facilitate proper electron transfer. By analyzing additional variants of these residues, a
clearer picture could be obtained as to the function that these residues contribute.
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2. MATERIALS & METHODS

MATERIALS

Molecular Biology Reagents
Restriction enzymes were purchased from New England Biolabs (Beverly, MA).
Plasmid preparation and agarose gel extraction kits were purchased from Qiagen Inc.
(Valencia, CA).

Oligonucleotide primers were obtained from Integrated DNA

Technologies (Coralville, IA). Native Pfu and PfuTurbo Polymerases and Epicurian coli
BL21(DE3)-RIL cells were obtained from Stratagene (La Jolla, CA). The pET-23b
vector was purchased from Novagen (Madison, WI). T4 DNA ligase was purchased
from Promega (Madison, WI). Rapid DNA ligation kits were purchased from Roche
Scientific (Palo Alto, CA). Triton X-100 and Hot Start Micro 50 PCR tubes were
obtained from Molecular-Bio Products Inc. (San Diego, CA). DMSO and pCMB were
obtained from Sigma Chemical Co. (St. Louis, MO). The Molecular Biology Core
Facility at the H. Lee Moffitt Cancer Center and Research Institute performed nucleotide
sequencing.
Microbiology and Protein Purification Reagents
Plastic and glassware were purchased from Fisher Scientific (Pittsburg, PA),
VWR International (Suwannee, GA), and Midwest Scientific (St. Louis, MO). Tryptone
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and yeast extract were obtained from EM Science (Gibbstown, NJ) and “Ultrol” grade
MOPS buffer was purchased from Calbiochem (La Jolla, CA). IPTG and Ampicillin were
obtained from Research Products International (Mt. Prospect, IL). Ni-NTA agarose was
purchased from Qiagen Inc. (Valencia, CA). PMSF was purchased from Sigma Chemical
Co. (St. Louis, MO).

Enzyme Assay and Spectroscopy Reagents
Chemicals including NADH, NAD+, 5’-ADP-agarose, 2’5’-ADP, ADP-ribose,
AMP, a-NAD+, e-NAD+, APAD+, APHD+, NADPH, NHD+, nicotinamide; NMN+, oNAD+, PCA, PCAAD+, PAAD+, PMSF, TNAD+, K3Fe(CN)6, glucose, FAD, bovine
serum albumin, potassium phosphate, riboflavin, ferric citrate, trifluoroacetic acid and
Tris

base

were

purchased

Tetrahydronicotinamide

from

adenine

Sigma

dinucleotides

Chemical
(H4-NAD

Co.
and

(St.

Louis,

MO).

H4-NADP)

were

synthesized according to the protocol described by Murataliev and Feyereisen [106] by
bubbling molecular hydrogen through a stirred solution of 100 mM NAD+ or NADP+
contained in 50 mM Tris-HCl buffer, pH 8.0, in the presence of palladium catalyst (5
mg/mL). Sinapinic acid (3,5-dimethoxy-4-hydroxy cinnamic acid) was purchased from
Aldrich Chemical Co. (Milwaukee, WI).
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METHODS
Protein Expression and Purification
Expression of the wild-type and mutant cb5r or NCR variants were accomplished
using E. coli BL21(DE3)-RIL cells harboring either the pH4CB5R [102], or mutant
constructs. Cells were grown aerobically in TB media supplemented with riboflavin (100
µM), ferric citrate (100 µM), and ampicillin (125 µM) overnight at 37°C, and
recombinant protein expression was induced by addition of IPTG (0.4 mM) followed by
an additional 6-8 h incubation at 25 °C. The cells were pelleted by centrifugation
(5000xg, 10 min.), resuspended in lysis buffer (50 mM Tris-HCl, containing 300 mm
NaCl and 5 mM imidazole, pH 8.0) and disrupted by sonication in the presence of PMSF
(1.2 mg/ml). Lysates were clarified by centrifugation (30,000xg, 30 min.) at 4oC followed
by incubation with Ni-NTA agarose with gentle agitation (1 ml matrix/10 ml lysate) for
up to 1h at 4°C. The His-tagged-(cb5r or NCR)-Ni-NTA matrix suspension was collected
by centrifugation (1000xg, 5 min.), washed twice with 25 mM phosphate buffer,
containing 300 mM NaCl and 5 mM imidazole, pH 8.0 and transferred to a
chromatography column (2.5 x 10 cm).

Bound proteins were eluted with 25 mM

phosphate buffer, containing 300 mM NaCl and 250 mM imidazole, pH 8.0. Fractions
were pooled, assayed for NADH:FR activity and concentrated centrifugally using 10,000
MWCO concentrators (Fischer Scientific, Pittsburg, PA).

Final purification was

achieved by size-exclusion FPLC using either a Superdex 75 or Superdex 200 column (1
x 30 cm) equilibrated with 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0.
Fractions exhibiting NADH:FR activity were pooled, concentrated, beaded and stored
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under liquid N2 until required. Wild-type NCR concentrations were estimated using
ε413nm = 130 cm-1 mM-1 and wild-type cb5r concentrations were estimated using ε461nm =
10.6 cm-1 mM-1.
The recombinant soluble, heme domain of rat cytochrome b5 was produced as
described by Beck-von Bodman et al., [107] using an expression construct provided by
Dr. Steven Sligar (University of Illinois, Urbana, IL). Briefly, E. coli BL21(DE3) cells
harboring the pUC18 expression construct, which contained a codon-optimized gene
encoding the soluble heme-containing domain of rat cb5, were grown overnight at 37°C
in TB medium supplemented with ferric citrate (100 µM) and ampicillin (125 µM).
Protein expression was induced at 25°C by addition of IPTG (0.4 mM), and the cells
were harvested 8 hours later by centrifugation, yielding pink pellets. Lysis of the cells
was achieved as described for cb5r. During fractionation of the cleared lysate, however,
cb5 was precipitated by 95% (w/v) (NH4)2SO4. The pellet was resuspended in the
minimum volume of low ionic strength phosphate buffer and dialyzed twice against a
large volume of the same buffer before separation on DE52 anion exchange
chromatographic media. Elution was achieved by a gradient of 0-1M NaCl before final
purification by FPLC on a Superdex 75 10/30 HR column. Red fractions containing cb5
protein were pooled, concentrated, beaded, and stored under liquid N2.
SDS-polyacrylamide gel electrophoresis was performed as described by Laemmli
[108] using 12.5% acrylamide/bis-acrylamide gels. 2-5 µg of protein was solubilzed in
up to 30 µL of SDS loading buffer (10 mM Tris-HCl, pH 6.8, containing 1% SDS, 10%
glycerol, 1 mM DTT, and 0.1% bromophenol blue) by boiling in water for 5 minutes
before loading the gel. Gels were run at 150 volts in SDS running buffer (25 mM Tris31

HCl, pH 8.3, containing 192 mM glycine, 0.1% SDS) until the blue dye front traversed
the gel. Gels were stained with Coomassie Brilliant Blue dye to visualize protein bands.

Site-directed Mutagenesis
The pH4CB5R [102] expression construct was specifically mutagenized using a
modification of the Stratagene QuikChange™ (La Jolla, CA) protocol.
Mutagenic Oligonucleotide Primer Design
Complimentary oligonucleotide primers (30-40 mers) containing the desired
codon change as well as a silent mutation (either inserting or deleting a restriction
enzyme recognition sequence) were designed using the Primer Generator program
(http://www.med.jhu.edu/medcenter/primer/primer.cgi) [109]. The sense strand annealing
primers used in the construction of the various mutant proteins are listed in Appendices
A, B and C.

Vector Polymerase Chain Reaction
Vector PCR was performed using Pfu Turbo polymerase (1.25 units) in the
presence of cloned Pfu buffer (20 mM Tris-HCl, pH 8.8 containing 2 mM MgSO4, 10
mM KCl, 10 mM (NH4)2SO4, 0.1% Triton® X-100, and 0.1 mg/ml nuclease-free BSA)
containing 10 ng vector DNA (pH4CB5R or pH6NCR), 125 ng of each synthetic primer,
5% DMSO, and 200 µM dNTP’s with cycling parameters (20 cycles) of 1 min at 94 °C, 1
min at 55°C, 10 min at 68 °C. DpnI restriction enzyme was added directly to the cooled
PCR reaction tube following the PCR cycling reaction to cleave only the methylated
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template DNA.

This step greatly reduced the percentage of wild-type background

transformants. PCR products were subsequently purified using the Qiagen PCR Cleanup
Kit. Products were eluted in 30µL of sterile elution buffer and stored at -20°C until ready
for use.

Preparation of Competent Cells and Linear DNA Transformation
Competent E. coli DH5α cells were prepared according to the protocol by
Yuckenberg et al. [110] for storage at -70°C. In brief, an overnight culture of bacteria,
grown in LB, was used to inoculate a fresh 250 mL culture. The culture was incubated
with shaking until an O.D.600nm of approximately 0.9 was reached. Cells were then
harvested by centrifugation at 0°C and washed in a solution of ice-cold 100 mM MgCl2.
Cells were again harvested and resuspended in ice-cold 100 mM CaCl2, where they were
then incubated on ice for 90 minutes. Cells were finally harvested and resuspended in
85 mM CaCl2 containing 15% glycerol before being snap frozen in liquid N2 and stored
at -80°C prior to use. This protocol was also used for the preparation of all other
competent E. coli strains.
Competent E. coli DH5α cells were transformed with linear DNA constructs
according to the protocol provided with the Quikchange™ Mutagenesis Kit (Stratagene)
Frozen cells were thawed slowly on ice and 50 µL aliquots were transferred to sterile 15
mL polypropylene conical tubes maintained on ice. Up to 10 µL of the purified linear
DNA construct was mixed carefully with the cells by swirling the pipette tip as the DNA
was expelled. The mixture was then incubated on ice for 20 minutes before being heat33

shocked at 42°C for 45 seconds and then returned to ice for 2 more minutes. Finally, 1
mL of SOB media was added and the cells were allowed to recover for 1 hour at 37°C
with gentle shaking before being plated on the appropriate selection media.

Mutagenic Screen by DNA Restriction Digest
Following overnight incubation at 37°C on ampicillin-containing SOB-agar
plates, colonies were subcultured into 5 mL of liquid SOB media, containing ampicillin
(125 µM). Clones were analyzed and screened for the silent mutations, introduced during
mutagenesis, by restriction enzyme digestion using the appropriate enzymes listed in
Table 3 and 4. Each digest was separated using polyacrylamide gel electrophoresis or
agarose gel electrophoresis and the restriction pattern visualized by ethidum bromide
staining of the gel. Figure 14 illustrates the result of a typical gel observed during
screening of mutants. Mutant constructs exhibiting the predicted pattern that
differentiated them from the wild-type construct were verified by nucleotide sequencing
in both the forward and reverse directions. Positive constructs were subsequently used to
transform competent E. coli BL21(DE3)-RIL cells to proliferate the generation of the
mutant enzymes.

Homology modeling
The structure of the canine cb5r variant and point mutation variants of rat cb5r
were generated using the automated comparative protein modeling server SWISSMODEL [111] utilizing the ‘‘first approach mode’’ since the query sequence and the
templates shared an average of 95.6% sequence identity. The X-ray coordinates of rat
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cb5r (PDB ID: 1IP7; 90.7% identity) and rat cb5r complexed with NAD+ (PDB ID: 1IB0)
[58] together with those of the erythrocytic form of H. sapiens cb5r (PDB ID: 1UMK;
92.9% identity) [112] were used as templates. The modeling results were analyzed using
the program ‘‘What If’’ to verify the fidelity of the calculated structure [113], and were
visualized using the molecular modeling software Web Lab Viewer Pro [114].

Ultraviolet and Visible Absorbance Spectroscopy
Absorbance spectra in the far (190-250 nm) and near UV (250-350 nm), visible
(360-750 nm), and near IR (750-1000 nm) wavelength range were obtained for wild type
and mutant enzymes using a Hewlett Packard (Agilent Technologies, Palo Alto, CA)
8453 diode-array spectrophotometer utilizing micro-cuvettes of 200 µL capacity and with
1 cm path length.

Ultraviolet and Visible Circular Dichroism Spectroscopy
UV and visible CD spectra were obtained using a JASCO (Easton, MD) J710
spectropolarimeter calibrated for both signal intensity and wavelength maxima using an
aqueous solution of d-10-camphosulfonic acid [115]. UV CD spectra were obtained in 10
mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0 using a cylindrical quartz cell
of 0.1 cm path length (300 µl total volume) while visible CD spectra were obtained in 10
mM MOPS buffer, containing 0.1 mM EDTA, pH 7.0 using a 1 cm path length cell (90
µl total volume). All spectra were corrected for the appropriate buffer contributions and
are expressed in terms of molar ellipticities (M-1 cm-1).
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Fluorescence Spectroscopy
Fluorescence spectra were obtained using a Shimadzu Scientific Inst. Inc. RF5301PC spectrofluorophotometer. Excitation and emission spectra were obtained using a
slit width of 3 nm and emission and excitation wavelengths of 520 nm and 450 nm,
respectively. Following acquisition of the wild type and mutant spectra, the enzymes
samples were heated to 100oC for 30 min, centrifuged to remove protein aggregates and
the corresponding spectra for the liberated FAD were subsequently recorded. All spectra
were corrected for the appropriate buffer contribution.

Steady-State Enzyme Activities
NADH:FR and NADH:CR activities were determined at 25°C under conditions of
constant ionic strength and pH in 116 mM MOPS buffer (µ = 0.05), containing 0.1 mM
EDTA, pH 7.0, while NADH:BR activities were determined at 25°C under conditions of
constant ionic strength and pH in 10mM potassium phosphate buffer (µ = 0.01),
containing 0.1mM EDTA, pH 7.0. NADH:FR activities were typically determined as the
decrease in absorbance at 340 nm in the presence of NAD(P)H (250 µM) and
ferricyanide (500 µM). NADH:BR activity was determined as the increase in absorbance
at 423 nm in the presence of NADH (250 µM) and rat cb5 (30 µM). All substrates were
quantitated spectroscopically using the established calculated molar extinction
coefficients for NADH, H4NAD, NAD+, cb5, 2’-5’, and ADP-ribose (Siegel 1959, Beck
von Bodman 1986, The Merck Index 1989, Murataliev 2000). Activities are expressed as
initial rates for the oxidation of NAD(P)H (µmol of NAD(P)H consumed/min/nmol
FAD). Initial rate data at varying NAD(P)H, ferricyanide, or cb5 concentrations were
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analyzed using the software “ENZFIT” (Elsevier Biosoft, Ferguson, MO) to determine
apparent kcat and Km values.

Spectral Binding Constant Determination by Differential Spectroscopy
Spectral binding constants, Ks, for various NADH analogs were determined by
differential spectroscopic titrations as described by Sancho and Gomez-Moreno [116] and
Barber et al. [117]. A Shimadzu UV2501-PC was used to measure the difference spectra
of samples in matched split-cell quartz cuvettes with 0.439 cm pathlength and 2.5 ml
capacity. Enzyme and NADH analogs were suspended in 10mM phosphate buffer, pH
7.0, containing 0.1mM EDTA for all spectral determinations. All analog concentrations
were

determined

spectrophotometrically

using

previously

published

extinction

coefficients.
The reference cuvette contained 50 µM enzyme (as determined by FAD
concentration) in the front compartment and analog-titrated buffer in the rear
compartment. The sample cuvette contained analog-titrated enzyme (50 µM) in the front
compartment and buffer in the rear compartment. The appropriate buffer was added to
the enzyme compartment of the reference cuvette to correct for the dilution caused by
analog addition to the enzyme compartment of the sample cuvette. Following sample
addition, each compartment was stirred briefly to insure thorough mixing. Spectra were
then recorded over the wavelength range from 300-800 nm depending on the titration.
The magnitude of the absorbance change was determined for each spectrum via peak to
trough subtraction in order to compensate for any baseline drift between spectra.
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Absorbance changes were plotted versus nucleotide concentration and the resulting plots
were fit to the hyperbolic equation:
∆Absorbance = ∆Absorbancemax*[nucleotide] / [Ks + (nucleotide)]
in order to determine the spectral binding constant (Ks), which was defined as the
concentration of analog at which half maximal spectral perturbation was observed.

Thermal Stability Measurements
Thermal stabilities of wild type and mutant enzymes were determined as
described by Trimboli et. al. [93] by monitoring both the release of the FAD prosthetic
group, as indicated by the change in flavin fluorescence, and the loss of NADH:FR
activity over the temperature range from 0-100°C.

Determination of Flavin Midpoint Potential
Flavin oxidation-reduction midpoint potentials were determined by dye
equilibration using the method of Massey [118]. Xanthine (30 µM) and xanthine oxidase
(50 nM) were used to reduce a mixture of enzyme (40 µM FAD) and the indicator dye,
phenosafranine (15 µM, E0’ = -252mV) in 100 mM phosphate buffer containing 0.1 mM
EDTA, first made anaerobic by repeated evacuation and flushing with oxygen-free argon.
Benzyl viologen (6 µM) and methyl viologen (1 µM) were included to facilitate
equilibration of the system. Visible absorbance spectra were collected over the course of
each 3-hour equilibration. Flavin reduction was monitored at 410 nm while
phenosafranine reduction was monitored at 530 nm. E0’ values were calculated by
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graphical analysis of the plot [log (ox)/(red)]phenosafranine versus [log (ox)/(red)]FAD using
the published midpoint potential of phenosafranine of –252 mV [117].

39

3. RESULTS AND DISCUSSION

Expression and Characterization of a Functional Canine Variant of Cytochrome b5
Reductase
Cytochrome b5 reductase sequences have been identified within the genomes of a
diverse array of eukaryotic organisms ranging from fungi and plants to insects and
nematodes to several different vertebrates. Multiple sequence alignments demonstrated
extensive primary structure conservation among these sequences.

Of these various

genomes, only a limited number have had the cb5r variant isolated. The human, bovine,
porcine, and rat enzyme variants have been developed into recombinant expression
systems, all of which have been isolated as functional enzymes with a range of
NADH:ferricyanide reductase specific activities (kcat) that have varied from 368 s-1 for
the human enzyme [76] to 1060 s-1 for the bovine variant [74].
Within the pharmaceutical industry, dogs represent the most extensively utilized
non-rodent species in preclinical xenobiotic safety studies. However, little information is
generally available concerning either the specific metabolic roles of various enzymes
within the species or evaluative studies that compare and contrast the specific activities of
individual enzymes with their human or more frequently studied rodent orthologs.
Completion of a survey sequence of the canine (boxer) genome [118] has resulted
in the identification of two putative cb5r sequences based upon sequence conservation
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with the products of the human and mouse genomes. Automated computational analyses
using GNOMON identified an ORF of 1441 bp on chromosome 10 encoding a 355
residue protein (GenBank XM_531708) while GeneWise identified an ORF of 906 bp
coding for 301 amino acid residues (Ensemble ENSCAFP00000000953). While both
sequences indicated the putative proteins retained equivalent carboxyl-terminal residues,
the amino-terminal sequences exhibited marked heterogeneity with little similarity to
other mammalian cb5r primary structures.
To confirm the primary structure of a canine variant of cb5r and to compare and
contrast the functional properties of a recombinant form of the enzyme with those of the
corresponding rat enzyme, we have cloned, expressed and characterized the soluble
diaphorase domain of canine cb5r from beagle lung tissue.
Alignment of fifty, full-length translated amino acid sequences deposited in
GenBank [119] that embrace known members of the cb5r flavoprotein family from a
variety of diverse organisms indicated that seven sequences, corresponding to those from
mammalian (human, monkey, steer, pig, rat and mouse) and avian (chicken) sources
encompassed a group of conserved sequences that comprised 301 residues with aminoand carboxyl-terminal sequences of “MGAQLS” and “RMCRFAVTF”, respectively. In
contrast, predicted primary structures available for canine variants of cb5r suggested
amino and carboxyl-terminal sequences of “MSLHLF” and “RCFAF” (XM_531708) and
“MGLSLS” and “RCFAF” (ENSCAFP0000000000953), respectively. To accurately
define the primary structure of canine cb5r, we constructed the oligonucleotide primers
shown in Table 3, that corresponded to the various predicted amino-terminal sequences
and the conserved carboxyl-terminal sequence. Extensive PCR analyses revealed that an
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appropriately sized product of approximately 906 bp could only be obtained using
Primer’s 3 and 4, indicating “MGAQLS” and “RCFAF” to be the correct amino- and
carboxyl-terminal sequences, respectively, of the microsomal variant of canine cb5r.
Table 3. Oligonucleotide primers used to amplify the full-length canine cb5r cDNA
sequence.
Sequencea

Primer

a

1

5’-

A CCC ATG TCC CTG CAC CTC TTC CAT CTC CAG -3’
NMet Ser Leu His Leu Phe His Leu Gln

2

5’- CGC CAC ATG GGT CTG TCC TTG TCA TTT CAG -3’
NMet Gly Leu Ser Leu Ser Phe Gln

3

5’- CAC ATG GGG GCC CAG CTG AGC ACG -3’
N- Met Gly Ala Gln Leu Ser Thr

4

5’-

GC TTC GCC TTC TGA TGG CCA GGC GC -3’
N- Cys Phe Ala Phe ***

Additional nucleotides were included in the primers as either 5’ or 3’ extensions for PCR purposes.

To confirm the full-length canine cb5r cDNA sequence, the ~906-bp PCR product
was purified and sequenced in both the forward and reverse directions and yielded the
nucleotide sequence shown in Figure 10. The translated amino acid sequence indicated a
full-length protein comprising 301 residues that exhibited marked sequence similarity to
the corresponding human (92.7% similarity) and rat (89.7% similarity) cb5r variants.
Following the successful cloning of the full-length canine cb5r cDNA, further
rounds of PCR utilizing the primers described in “Methods” were used to construct an
appropriate pET-based expression vector for the production of a six-histidine-tagged
variant of the soluble, diaphorase domain of the enzyme using an identical strategy to that
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Figure 10. Complete nucleotide sequence of canine cb5r. The cDNA
sequence corresponding to the 903-bp full-length, membrane-associated
form of canine cb5r (Cf) is shown together with the corresponding
deduced amino acid sequence. Also shown are the corresponding human
(Hs) and rat (Rn) cb5r primary sequences (GenBank accession number’s
P00387 and P20070). Amino acid residues that are not conserved between
the three sequences are indicated in red. The amino-terminal myristylation
signature sequence is shown in italics while the conserved flavoprotein
transhydrogenase sequence motifs that are involved in either flavinbinding and selectivity or NADH binding, are shown underlined. Also
shown underlined in bold italics is residue I33 which corresponds to the
initial residue used for heterologous expression of the histidine-tagged
soluble diaphorase domain in E. coli. For consistency, amino acid residues
are numbered beginning with the amino-terminal residue of the mature
protein (G1).
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1
Cf
Hs
Rn
61
Cf
Hs
Rn
121
Cf
Hs
Rn
181
Cf
Hs
Rn
241
Cf
Hs
Rn
301
Cf
Hs
Rn
361
Cf
Hs
Rn
421
Cf
Hs
Rn
481
Cf
Hs
Rn
541
Cf
Hs
Rn
601
Cf
Hs
Rn
661
Cf
Hs
Rn
721
Cf
Hs
Rn
781
Cf
Hs
Rn
841
Cf
Hs
Rn
901
Cf
Hs
Rn

atgggggcccagctcagcacgctcggccacgtggtcctctccccagtctggttcctctat
M G A Q L S T L G H V V L S P V W F L Y
M G A Q L S T L G H M V L F P V W F L Y
M G A Q L S T L S R V V L S P V W F V Y
aacctgctcatgaagctgttccagcgctcgaccccggccatcacccttgagagcccggac
N L L M K L F Q R S T P A I T L E S P D
S L L M K L F Q R S T P A I T L E S P D
S L F M K L F Q R S S P A I T L E N P D
atcaagtacccactgcggctcatcgacaaggaggttatcaaccatgacacccggcggttc
I K Y P L R L I D K E V I N H D T R R F
I K Y P L R L I D R E I I S H D T R R F
I K Y P L R L I D K E I I S H D T R R F
cgcttcgctctgccgtcgccccagcacatcctgggcctcccagtcggccagcacatctac
R F A L P S P Q H I L G L P V G Q H I Y
R F A L P S P Q H I L G L P V G Q H I Y
R F A L P S P Q H I L G L P I G Q H I Y
ctctcagctcggatcgatggaaacctggtcattcggccctacacgcccgtctccagtgac
L S A R I D G N L V I R P Y T P V S S D
L S A R I D G N L V V R P Y T P I S S D
L S T R I D G N L V I R P Y T P V S S D
gatgacaaaggctttgtggacctggtcatcaaggtttacttcaaagacacccatcccaag
D D K G F V D L V I K V Y F K D T H P K
D D K G F V D L V I K V Y F K D T H P K
D D K G F V D L V V K V Y F K D T H P K
tttcctgctggagggaagatgtcccagtacctggaaagcatgaagattggagacaccatt
F P A G G K M S Q Y L E S M K I G D T I
F P A G G K M S Q Y L E S M Q I G D T I
F P A G G K M S Q Y L E N M N I G D T I
gagttccggggcccgaatggactgctggtctaccagggcaaaggaaagtttgccatccgt
E F R G P N G L L V Y Q G K G K F A I R
E F R G P S G L L V Y Q G K G K F A I R
E F R G P N G L L V Y Q G K G K F A I R
ccagacaagaagtccaaccccatcatcaagacggtgaagtctgtcggcatgatcgccgga
P D K K S N P I I K T V K S V G M I A G
P D K K S N P I I R T V K S V G M I A G
A D K K S N P V V R T V K S V G M I A G
ggaaccggcatcaccccgatgctgcaggtgatccgtgccatcatcaaagacccacacgac
G T G I T P M L Q V I R A I I K D P H D
G T G I T P M L Q V I R A I M K D P D D
G T G I T P M L Q V I R A V L K D P N D
cccaccgtgtgccacctactatttgccaaccagactgagaaggacatcctgctgcggccc
P T V C H L L F A N Q T E K D I L L R P
H T V C H L L F A N Q T E K D I L L R P
H T V C Y L L F A N Q S E K D I L L R P
gagctggaggaactgcggaatgaacattctgctcgcttcaagctctggtacacagtggac
E L E E L R N E H S A R F K L W Y T V D
E L E E L R N K H S A R F K L W Y T L D
E L E E L R N E H S S R F K L W Y T V D
aaagccccagaagcctgggactacagccagggcttcgtaaatgaagagatgatccgggac
K A P E A W D Y S Q G F V N E E M I R D
R A P E A W D Y G Q G F V N E E M I R D
K A P D A W D Y S Q G F V N E E M I R D
caccttccacctccagaggaggagccgctgatactgatgtgtggacccccgcccatgatc
H L P P P E E E P L I L M C G P P P M I
H L P P P E E E P L V L M C G P P P M I
H L P P P G E E T L I L M C G P P P M I
cagtatgcctgcctgcccaacctggaccgcgtgggccaccccaaggagcgctgcttcgcc
Q Y A C L P N L D R V G H P K E R C F A
Q Y A C L P N L D H V G H P T E R C F V
Q F A C L P N L E R V G H P K E R C F T
ttctga
F * 300
F *
F *
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60
19

120
39

180
59

240
79

300
99

360
119

420
139

480
159

540
179

600
199

660
219

721
239

780
259

840
279

900
299

previously developed for production of the corresponding histidine-tagged rat cb5r
diaphorase domain [102].
The Cfh6cb5r plasmid encoding the soluble, diaphorase domain of canine cb5r,
corresponding to residues I33 to F300, was used to transform E. coli BL21(DE3)-RIL
cells The cells were disrupted by sonication and the canine cb5r purified to homogeneity
by a combination of metal-affinity chromatography and gel filtration FPLC as previously
described [102]. Evaluation of the expression yield of the diaphorase domain (Table 4)
indicated that the protein was very efficiently expressed yielding approximately 32 mg of
purified protein per L of bacterial culture, which represents the highest level of
Table 4. Purification of canine cb5r.

Fraction

Total
Protein
(mg)

Volume
(mL)

Lysate
Ni-NTA Agarose
Superdex 75

260
63
32

21.5
5.5
1.5

Specific
Activity
Activity Yield
NADH:FR
NADH:FR
(%)
(unitsa)
(units/mg)
100
6.2
615
82
8.0
501
77
14.9
476

a

units = µmoles NADH consumed/min.

expression of a cb5r variant to date. The application of the simple two-step purification
protocol revealed the diaphorase domain was purified to apparent homogeneity as evident
by the presence of a single protein band following SDS-PAGE analysis of the final FPLC
fraction as shown in Figure 11, which indicated a molecular mass (Mr) of approx. 32
kDa, as anticipated from the deduced amino acid sequence. MALDI-TOF mass
spectrometry (Figure 11) confirmed a molecular mass (m/z) of 31,364 for the purified
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protein, in excellent agreement with the value of 31,391 calculated for the apoprotein
from the deduced primary sequence.
The oxidized form of the purified C. familiaris cb5r diaphorase domain was
yellow in color indicating the incorporation of a flavin prosthetic group which was
subsequently confirmed by MALDI-TOF mass spectrometry by the presence of a peak in
the low mass range at 798 (m/z) that identified FAD as the sole prosthetic group.
UV/visible absorbance spectra were obtained for oxidized samples of the purified
canine enzyme and were compared with the spectra obtained for the corresponding rat
domain in Figure 12A. The canine cb5r diaphorase domain exhibited spectra comparable
to those that have been previously obtained for other cb5r variants, including the human
and rat enzymes [71, 120] that are characterized by an absorption maximum detected at
273 nm in the UV region of the spectrum, and a peak at 461 nm with an associated
pronounced shoulder in the range of 485-500 nm in the visible region of the spectrum, the
latter peak attributable to protein-bound flavin. The A273 nm/462 nm absorbance ratio of the
canine enzyme was within the range 5.5+0.2 which was comparable to values previously
obtained for rat cb5r (5.6+0.2) [120], indicating a full complement of the FAD prosthetic
group.
To assess the secondary structural content of the canine cb5r diaphorase domain,
CD spectra were recorded in the UV wavelength range (190-300 nm). As shown in Fig.
12B, the canine protein exhibited positive CD from 190-210 nm and negative CD from
210-250 nm with the spectrum retaining both positive and negative intensities very
similar to that of the rat domain. The absence of any significant differences between the
spectra of the canine and rat proteins suggested conservation of the secondary structure
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Figure 11. SDS-PAGE and MALDI-TOF mass spectrometric analyses of canine
cb5r diaphorase domain expression. Upper panel: A sample (2 µg protein) obtained
from the final FPLC gel filtration in the canine cb5r diaphorase domain isolation
procedure analyzed using a 15% polyacrylamide gel as described in “Methods”.
Individual lanes correspond to: S, protein molecular weight standards with indicated
molecular masses; A, purified recombinant canine cb5r. B, purified recombinant rat cb5r.
Lower panel: MALDI-TOF mass spectrum obtained for a purified sample (10 pmole) of
canine cb5r in the presence of sinapinic acid.
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architecture and that none of the amino acid substitutions had any substantial effects on
the folding of the protein.
Visible CD spectroscopy was utilized to examine the environment of the FAD
prosthetic group. As shown in Figure 12C, the canine cb5r diaphorase domain exhibited a
visible CD spectrum that was virtually indistinguishable from that of the corresponding
rat domain and indicated that none of the amino acid substitutions had any significant
effect on the conformation of the bound chromophore. Previous spectroscopic analyses of
cb5r variants containing altered residues that are involved in FAD-binding, such as Y93
[121] and S127 [122], have revealed visible CD to be a sensitive indicator of flavin
conformation changes.
The extent of quenching of the intrinsic fluorescence due to the FAD prosthetic
group of cb5r has also proven to be a sensitive indicator of the retention of the native
flavin environment. To probe the flavin fluorescence quenching of the canine cb5r
variant, both excitation and emission fluorescence spectra were recorded prior to and
following heat denaturation of the recombinant protein. Prior to denaturation, canine cb5r
quenched the intrinsic flavin fluorescence by 96%, equivalent to that of the rat cb5r
protein.
To examine the influence of the various amino acid substitutions on the stability
of the resulting protein, thermal denaturation profiles were generated for the canine cb5r
diaphorase by measuring both changes in the intrinsic flavin fluorescence emission
intensity (λex=450 nm, λem=523 nm) and retention of NADH:FR activity following
incubation of the protein at temperatures ranging from 0–100 °C (Figure 13). Changes in
the intrinsic fluorescence of the cofactor or the retention of NADH:FR activity following
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Figure 12. Ultra-Violet, Visible, and Circular Dichroism Spectra Obtained for the
Canine cb5r Variant. (A) UV/visible absorption spectra were obtained for an oxidized
sample of canine cb5r (1.7 µM FAD) in 10 mM phosphate buffer, containing 0.1 mM
EDTA, pH 7.0. The inset shows an expanded region of the visible spectrum where the
flavin prosthetic group makes a major contribution. Individual spectra correspond to
canine (___) and rat (….) cb5r. (B) UV CD spectra were recorded using enzyme samples
(7 µM FAD) in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0. (C) Visible
CD spectra were recorded using enzyme samples (50 µM FAD) in 10 mM phosphate
buffer, containing 0.1 mM EDTA, pH 7.0. Line styles shown in “B” and “C” are the
same as those depicted in “A”.
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thermal denaturation, was an effective indicator of the stability of the core structure of the
protein. T50 values (the temperature at which 50% of maximum fluorescence or 50%
retention of NADH:FR activity was detected) of 57 °C were observed which could be
compared with the same values obtained for the corresponding rat domain, suggesting the
canine and rat variants exhibited comparable protein folding and bound the flavin
prosthetic group with similar affinities.
Initial-rate kinetic analyses were performed for the canine diaphorase cb5r
domain to evaluate the effects of the various residue substitutions on both NAD(P)H and
cytochrome b5 (cb5) utilization. Values derived for the various kinetic constants for both
the NAD(P)H:FR and NADH:BR activities are given in Tables 5A and 5C respectively.
The canine enzyme exhibited kcat‘s of 767 and 600 s-1 for the NADH:FR and NADH:BR
activities with Km values of 7, 8 and 12 µM for NADH, ferricyanide and cb5 respectively.
As predicted by the conserved glycine, aspartate and phenylalanine residues at
positions 179, 239 and 251 in the primary sequence, the canine diaphorase domain
showed the same degree of specificity for NADH compared to NADPH, as previously
described for the rat domain [123, 124]. The value for the NAD(P)H specificity constant
(defined as ratio of {kcat/KmNADPH}/{kcat/KmNADH}) listed in Table 5C, which reflect the
magnitudes of the individual kcat and Km values obtained for both NADH and NADPH,
respectively, was observed to be comparable to that observed for rat cb5r, indicating the
canine enzyme retained a similar preference for NADH as the physiological reductant.
To compare the interaction of the canine cb5r variant with various pyridine
nucleotides and probe the effect of alterations and deletion of the nicotinamide moiety,
differential spectroscopy was utilized to monitor complex formation. Examples of
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alterations of the flavin visible absorbance difference spectrum are shown in Fig. 14. The
formation of spectrally-detectable complexes were observed for the diaphorase domain
during titrations with H4NAD, NAD+, ADP-ribose and a variety of NAD+ analogs,
including APAD+, PAAD+ and NHD+.

Figure 13. Thermal Stability Profile Obtained for the Canine cb5r Variant.
Oxidized samples of canine cb5r and the human and rat variants (18-20 µM FAD) were
incubated at the indicated temperatures and aliquots were withdrawn and assayed for both
residual NADH:FR activity (open symbols) and intrinsic flavin fluorescence (closed
symbols) in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0, the latter using
excitation and emission wavelengths of 450 nm and 523 nm, respectively. Excitation and
emission spectra were scaled relative to that of a sample of free FAD at the equivalent
concentration which was assigned a fluorescence intensity of 100%. The plots correspond
to canine ({, z) and rat ( , ) cb5r, respectively. T50 values correspond to 57 °C for
both canine and rat cb5r.
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Table 5. NAD(P)H:FR and NADH:BR kinetic constants obtained for canine and
rat cb5r.
A.
Variant
Canine
Rat

kcat
(s-1)
767+10
800+17

NADH:FR
kcat/KmNADH
(s-1 M-1)
(µM)
7+1
1.1+0.2x108
6+1
1.4+0.3x108

KmNADH

B.
NADPH:FR
Variant

KmFe(CN)6
(µM)
8+1
8+1

Nucleotide
Specificity
Constant

kcat
(s-1)

KmNADPH
(µM)

kcat/KmNADPH
(s-1 M-1)

∆a

Canine

50+3

1040+33

4.8+0.4x104

4.4x10-4

Rat

33+5

924+15

3.6+0.3x104

2.6x10-4

a

The nucleotide specificity constant, ∆, is defined as the ratio
{(kcat/KmNADPH)/(kcat/KmNADH)}.
C.
Variant
Canine
Rat

kcat
(s-1)
600+20
600+17

NADH:BR
Kmcyt b5
kcat/Kmcyt b5
(s-1 M-1)
(µM)
5.4+1.5x107
12+3
5.2+1.0x107
12+2

For H4NAD, the tetrahydronicotinamide derivative did not function as a hydride
donor when substituted for NADH in either the NADH:FR or NADH:BR cb5r assays
[111, 120] but provided a valuable tool for estimating the binding affinity for NADH.
The H4-nucleotide is a close isosteric analogue and is assumed to involve the same
contacts at the active site as NADH, but lacks the positive charge on the nicotinamide
ring that is present on NAD+. The spectral changes observed following H4NAD binding
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were identical to those previously detected for the corresponding titrations of the rat
enzyme and yielded positive absorbance changes with maxima at 421, 449 and 481 nm

Figure 14. Differential Spectra Obtained Following Binding of Various Pyridine
Nucleotides to the Canine cb5r Variant. Difference spectra were obtained for canine
cb5r (50 µM FAD) in 20 mM MOPS buffer, containing 0.1 mM EDTA, pH 7.0 following
titrations with either (A) H4NAD or (B) PAAD+ as described in “Methods”. The insert
panels correspond to plots of the magnitudes of the observed spectral perturbations (peak
to trough measurements at the indicated wavelengths) versus ligand concentration. The
corresponding Ks values are given in Table 4. (C) The final difference spectra obtained
for NAD+ (….), ADP-ribose ( __ __ ), ADP ( ---- ), AMP ( -.-.- ) Nicotinamide ( _ _ _ )
and NMN+ ( -..-..- ) . (D) Final spectra obtained for the NAD+-analogs α-NAD+ ( ___ ),
TNAD+ ( …. ), PAAD+ ( _ _ _ ), ε-NAD+ ( -.-.- ), APHD+ ( -..-..- ), NHD+ ( --- ) and
PCAAD+ ( __ __ ).
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and negative absorption changes at 396, 466 and 497 nm, respectively. The value
obtained for the spectroscopic binding constant (Ks), shown in Table 6, was comparable
to that obtained for rat cb5r.
For the binding of NAD+ and the various NAD+ analogs, differential flavin
spectra were observed for 13 of the 15 analogs examined. NAD+ binding yielded the
largest spectral perturbation observed for any of the compounds tested, with positive
absorbance maxima at 407 nm and 509 nm and negative absorbance maxima at 456 nm
and 487 nm, respectively. The Ks value of 788 µM was identical to that obtained for the
rat domain. Deletions of portions of the NAD+ structure (Fig. 14) resulted in significant
changes in both the lineshape and intensity of the resulting difference spectra. Removal
of the nicotinamide ring effectively abolished the absorbance changes from 380 to 440
nm; however difference spectra were still observed for 5’-ADP-ribose, 5’-ADP and
AMP, although the intensity of the difference spectra decreased as the NAD+ molecular
was truncated. Only minimal spectral changes were detected with NMN+.
For the various NAD+-analogs, the greatest spectral perturbations were observed
for TNAD+ with positive maxima at 405 and 485 nm and negative maxima at 389, 441
and 463 nm, respectively. PAAD+ also effected significant spectral perturbations while
α-NAD+ had the least effect. The magnitude of the spectral changes was inversely
proportional to the value of the spectroscopic binding constants (Ks). The analog binding
studies also revealed the importance of the two amino substituents on either the adenine
or nicotinamide moieties on influencing NAD+ affinity. Substitution of the nicotinamide
amino group by a methyl group (APAD+), resulted in an 11-fold increase in analog
affinity while removal of the group (PAAD+) only increased affinity by 40%. In contrast,
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substitution of the adenine amino moiety by a hydroxyl (NHD+), decreased affinity
by50%, reinforcing the important role of the adenine moiety in NAD+ binding.

Table 6. Spectroscopic binding constants obtained for canine cb5r in the presence
of various pyridine nucleotides.

Nucleotide
H4NAD

67 + 5

APAD+

71 + 7

ADP-ribose

77 + 6

ADP

Rat cb5ra Chlorella
NRb
Ks
Ki
∆G
(µM)
(kcal.Mol-1)
(µM)
45 + 10

5.688
1390

5.653

750

5.605

165 + 12

2040

5.154

ε-NAD

297 + 11

6340

4.806

PAAD+

540 + 24

740

4.474

AMP

587 + 29

5010

4.403

TNAD+

590 + 34

6490

4.400

NAD+

549 + 36

2170

4.229

APHD+

1007 + 94

2300

4.084

PCAAD

1260 + 31

4650

3.951

NHD+

1350 + 156

4480

3.910

α-NAD+

2005 + 250

1150

3.676

o-NAD+

7898 + 924

4660

2.865

4070

<2.056

PCA+

a

Canine cb5r
Ks
(µM)

100 + 20

553 + 30

>31000 + 1000
*

NMN+

ND

Nicotinamide

ND*

11760

Spectroscopic binding constants for rat cb5r were taken from Marohnic et al.[123].

b

Inhibition constants for Chlorella nitrate reductase (NR) taken from Trimboli and Barber [125].

*ND indicates that the spectroscopic binding constant could not be determined, due to insufficient
spectral change.
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To examine whether the thermodynamic properties of the flavin prosthetic group
were similar to those of the corresponding rat enzyme, potentiometric titrations were
performed using the dye equilibration method for the canine cb5r diaphorase domain in
the presence of phenosafranine (Eo’= -252 mV) as indicator. Flavin midpoint potentials
(Eo’, n=2) were determined for the enzyme alone and in complex with NAD+. Spectra
obtained during representative titrations of canine cb5r in the absence and presence of
NAD+ are shown in Fig. 15A and B, respectively. Qualitative analysis of the individual
spectra obtained from the various titrations indicated that the majority of the
phenosafranine was reduced prior to FAD reduction in canine cb5r in the absence of any
pyridine nucleotide, suggesting the flavin midpoint potential was more negative than that
of phenosafranine. In contrast, analysis of the spectra obtained for the protein in the
presence of NAD+ revealed that the majority of the flavin was reduced prior to the dye,
suggesting that complex formation significantly perturbed the flavin midpoint potentials
to values more positive than that for phenosafranine. Spectra obtained from the redox
titration of canine cb5r in the presence of NAD+ also revealed the formation of the
characteristic charge-transfer complex resulting in the increased absorbance in the 700800 nm region of spectrum.
The flavin redox potentials (n=2) for canine cb5r alone or in the presence of
NAD+ were determined from the Nernst semi-log plots shown in Fig. 15C. The standard
midpoint potentials obtained for the FAD/FADH2 couple in both the native enzyme (Eo’=
-273 mV) and in the enzyme-NAD+ complex (Eo’= -190 mV) were significantly
different, spanning a range of 83 mV.
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Figure 15. Oxidation-Reduction Midpoint Potentials Obtained for the FAD
Prosthetic Group in the Canine cb5r Variant. Reductive dye-equilibration titrations of
canine cb5r (40 µM FAD) were performed as described under “Methods” in 100 mM
phosphate buffer, containing 0.1 mM EDTA, pH 7.0 in the presence of phenosafranine
(15 µM, Eo’= -252 mV) as the indicator dye [117]. Individual spectra were collected at
30-90 sec intervals during the time course of the titrations. Upper Panels: representative
spectra obtained during titrations of canine cb5r in the (A) absence and (B) presence of 2
mM NAD+ are shown (a limited number of spectra are shown for clarity). (C) Nernst
plots obtained for the FAD/FADH2 couple (n=2) of the canine and rat cb5r variants.
Canine cb5r in the absence (z, Eo’=-273+5 mV) and presence of NAD+ ({; Eo’=-190+5
mV); rat cb5r in the absence (, Eo’=-272+5 mV) and presence of NAD+ ( ; Eo’=191+5 mV).
57

Summary of Expression and Characterization of a Functional Canine Variant of
Cytochrome b5 Reductase
These results provide the first documented insights into the structure and function
of a catalytically-active canine variant of microsomal cb5r. Utilizing a consensus
sequence developed from an alignment of several higher eukaryotic cb5r primary
structures, we constructed PCR primers that could be used to amplify either the fulllength, membrane-associated cb5r nucleotide sequence or that of a truncated, soluble
form of the cb5r diaphorase domain comprising 258 residues (I33 to F300), equivalent to
those previously used to develop a heterologous expression system for the rat variant
[102]. The PCR results obtained using the primers designed to generate the full-length
cDNA confirmed that the first six residues of the amino-terminal sequence of the
membrane-associated canine cb5r corresponded to the residues “GAQLST” which were
identical to the corresponding residues of both the human and rat enzymes. In addition,
the first three residues, “GAQ”, indicated the presence of a ProSite signature sequence
[126], that suggested the mature, membrane-associated protein would be myristylated, as
previously demonstrated for the steer protein [38].
The primary sequence of the full-length membrane-associated form of canine cb5r
shared maximum similarity with the corresponding sequence of the human enzyme at
92.7% compared to 89.7% similarity to the corresponding rat sequence. Examination of
the canine sequence revealed the presence of four conserved sequence motifs that are
associated with flavin binding (91RxYTSxxSN97), FAD/FMN selectivity (124GRxxST127) and
NADH-binding (180GxGxxP185 and 273CGxxxM278) that have been identified as diagnostic
for members of the FNR family of flavoprotein transhydrogenases [127].
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Comparison

of

the

results

obtained

from

the

spectroscopic,

kinetic,

thermodynamic and stability studies confirmed predictions generated from the pair-wise
sequence alignments that the structural and functional properties of the recombinant
canine cb5r diaphorase domain were directly comparable to those of the corresponding
rat domain. The ability to generate both domains using identical expression systems and
characterize their biophysical properties under equivalent conditions revealed that in
addition to identical spectroscopic properties, the two cb5r variants exhibit identical
kinetic properties including catalytic efficiency, affinities for both the reducing and
oxidizing substrates and specificity for NAD(P)H. The equivalence in the kinetic
properties is particularly significant and suggests that other cb5r variants exhibiting
conserved sequences should retain comparable kinetic properties. Our preliminary results
obtained using an identical Danio cb5r expression system, the Danio cb5r diaphorase
domain shares 70.8% and 69.8% sequence similarity with the canine and rat domains,
respectively, have confirmed this prediction. In addition to the conserved kinetic
properties, the oxidation-reduction potentials of the FAD prosthetic groups were
equivalent indicating a conserved flavin-binding environment.
The binding studies performed utilizing a variety of NADH- and NAD+-analogs
have provided further insight into the roles of the different portions of the pyridine
nucleotide that are critical to regulating reducing substrate/product affinity as indicated
by perturbation of the flavin prosthetic group’s visible spectrum. The results obtained
from the titrations using NAD+ and various NAD+-fragments confirm that the greatest
spectral changes were produced by the binding of NAD+ and that the positively-charged
nicotinamide moiety was primarily responsible for the spectral perturbations, since ADP59

ribose and ADP were effective inhibitors but affected only modest spectral changes. In
contrast, examination of the various NAD+-analogs revealed a diverse array of spectral
changes with TNAD+ producing the most dramatic effects. There appeared to be a good
correlation between the magnitude of the spectral changes and the affinity for the NAD+analog. The nicotinamide portion alone, in the form of NMN+, also affected only modest
spectral changes owing to its very low binding constant coupled with the requirement for
the presence of the ADP moiety to firmly anchor the inhibitor in the correct orientation.
These results were confirmed by comparison of the binding constants obtained for
H4NAD (Ks = 67 µM) and ADP-ribose (Ks = 77 µM) which indicated the presence of the
nicotinamide moiety conferred only a modest increase in substrate affinity. In addition,
loss of the ribose moiety resulted in a 2-fold decrease in affinity. In contrast to the
binding constants obtained for the majority of the NAD+-analogs, which were
substantially greater than the values determined for ADP-ribose and ADP, the binding
constant observed for APAD+ was very similar in magnitude to that obtained for H4NAD,
despite the presence of the positively charged nicotinamide moiety, suggesting that this
analog may bind in a different conformation than the remaining analogs. Similar results
have been obtained from binding studies using a variety of NADP+ analogs and the
related flavoprotein, cytochrome P450 reductase [106] which shares substantial structural
similarity in the FAD- and pyridine nucleotide-binding sites.
Combination of the results obtained with the canine enzyme and the various
NAD+-analogs with those obtained from mutagenesis studies of the corresponding rat
cb5r diaphorase domain regarding residue side-chain substitutions and their effects of
NAD(P)+ specificity [123], provides important insights into structural features regulating
60

pyridine nucleotide binding.
The results of the binding studies indicated that the magnitudes of the spectralbinding constants obtained for the various NAD+-analogs showed the same general
transition as the results previously obtained for the closely related FAD-containing
diaphorase domain of assimilatory NADH:nitrate reductase (NR) which were obtained
using classical inhibitor-binding kinetic studies (Table 6) [125] reinforcing the striking
structural similarity between the diaphorase domains of cb5r and NR that has been
suggested by X-ray crystallographic studies.
To evaluate the structural organization of the canine cb5r soluble, diaphorase
domain, comparative modeling was utilized to predict the tertiary structure of the
recombinant protein. Homology modeling, utilizing the experimental structures
determined for recombinant forms of the rat diaphorase domain in the absence (PDB =
1I7P) and in the presence (PDB = 1IB0) of NAD+ [58] and the erythrocytic variant of
human cb5r (PDB = 1UMK) [112] yielded a model that was nearly identical to that of the
human domain and very similar to that of the rat domain, as revealed by the structural
overlay shown in Figure 16. Comparison of the backbone structures indicated the canine
model and the human and rat structures were nearly identical over the lengths of the
entire polypeptide backbones with only minor differences among the three structures. The
most notable difference was seen between the canine and human structures and the rat
structure. This difference is confined to a small region of the sequence comprising
residues P263 to L269. In the canine and human cb5r proteins, this region includes the
sequence ‘‘263PPEEEPL269’’ while the rat sequence corresponds to ‘‘263PPGEETL269’’.
The substitution of a glycine residue at position 265 in the rat protein introduces a
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substantial deviation in the conformation of the backbone within this region, resulting in
the disruption of the short α-helical region between P264 and E266 in the human and
canine structures and the introduction of a β-bend between helix N α3 and β-strand N β5
in the rat NADH-binding lobe. However, this sequence region is not directly involved in
any contacts with the FAD prosthetic group or either of the physiological substrates,
NADH or cb5, and is unlikely to significantly affect the catalytic efficiency of the
enzyme, in agreement with the results of the initial-rate kinetic studies.
A number of mutations of the human cb5r sequence have been reported that give
rise to RCM [128]. Examination of the canine sequence indicated that all of the
approximately 40 residues that have been identified so far as giving rise to either the type
I or type II forms of RCM were conserved within the canine sequence with the exception
of E227 which corresponds to K227 in the human variant. Thus, studies of the individual
methemoglobinemia mutations in canine cb5r would be expected to be directly relevant
to the human variant.
Comparative studies of the endogenous activity of cb5r have been applied as a
predictor of an organism’s capacity to convert methemoglobin to hemoglobin and have
been used as an important component in evaluating the anti-cyanide effectiveness of
various methemoglobin formers as potential prophylactics to minimize the effects of
cyanide toxicity. Cytochrome b5 reductase is the rate-limiting enzyme controlling the
toxicokinetics of methemoglobin reduction, effectively regulating the anti-cyanide
efficacy of methemoglobin formers. While cb5r activity has been determined in humans
and a diverse array of animal species including chimpanzee, baboon, horse, steer, sheep,
goat, kangaroo, wallaby, dog, cat, rabbit, guinea pig, rat, mice, and platypus [129-131],
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Figure 16. Comparison of the Predicted Structure of the Canine cb5r Diaphorase
Domain with the Corresponding Human and Rat Diaphorase Domain Structures.
The structure of the canine cb5r diaphorase domain, corresponding to residues T30 to
F300, was predicted using SWISS-MODEL as described in “Methods”. The diagram
shows the canine structure model (cyan ribbon) as a ribbon representation superimposed
on the corresponding structures of the human (yellow ribbon; PDB ID: 1UMK) and rat
(green ribbon, PDB ID: 1IB0) proteins. Also shown are the FAD prosthetic group and the
NAD+ product in “stick” configuration using the CPK coloring scheme.

63

systematic evaluations of cb5r activity in different species have been primarily limited to
non-human primates and have focused on determining hemolysate enzyme activities
using the NADH:ferricyanide assay [132] in contrast to evaluating the specific activity of
the enzyme using the physiological NADH:cytochrome b5 assay.
Limited in vivo comparative studies of cb5r functionality in hamsters, rodents and
Beagles [50] has suggested that the erythrocytic concentrations of the enzyme are
significantly lower in dogs than in the other mammals based upon conventional activity
assays and PAGE studies and that the decreased concentrations of cb5r confer a high
degree of susceptibility of Beagle erythrocytes to methemoglobin form. The results
presented in this work confirm these initial results and indicate that it is changes in cb5r
protein levels in dogs, rather than decreased specific activity that predisposes canines to
cyanosis.
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Analysis of residues, Y112 and Q210, involved in anchoring of the pyrophosphate
backbone of NAD+
Multiple sequence alignments of the cb5r sequences from a wide variety of
species, ranging from “simple” single cellular organisms to more “complex” members of
the avian and mammalian classes reveal a great number of highly conserved residues,
indicating that these particular residues play a vital role in proper enzymatic function,
thus were conserved through evolution. This, taken in combination with crystallography
studies of the rat variant of cb5r [58] identifies two residues distinct from the highly
conserved motif regions found in members of the flavoprotein transhydrogenases [127],
that appear to play a role in the correct interaction of cb5r with its physiological substrate
NADH. Based on X-ray crystallographic studies of rat cb5r in the presence of NAD+
(PDB ID = 1IB0), residues Y112 and Q210 were shown to form hydrogen bond linkages
with oxygens in the nicotinamide and adenine pyrophosphates of NAD+ respectively as
shown in Figure 17. These interactions appeared to serve to anchor the NAD+ into
position from the external side of the FAD- and NADH-binding pocket.
Residue Y112 is located in “lid” region of cb5r comprised of residues Y112K125. The flavin ADP moiety made extensive interactions with residues in this lid
forming a hydrophobic pocket that housed the adenine moiety, specifically between the
planar rings of Y112 and F120. Additionally, the location of Y112 in the FAD binding
domain of cb5r makes it unique in that it is the only residue of the FAD-binding domain
to directly interact with NADH/NAD+, forming a hydrogen bond interaction between
NO2 of the nicotinamide pyrophosphate of NAD+ and the hydroxyl group of the tyrosine
side chain. It was previously determined that, in the type II RCM variant S127P, the Oç
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Figure 17. Electrostatic Interaction of Amino Acid Residues Y112 and Q210 with
NAD+ Bound to Cytochrome b5 Reductase. (A) Ligplot [99] of 1IB0. C, O, N, and P
atoms are represented as white, blue, red, and violet spheres, respectively, while covalent
bonds are violet sticks within NAD+ and orange sticks within amino acid residues of the
NADH-binding lobe. Hydrogen bonds are drawn as green dashed lines with distances
between atoms labeled.
Residues contributing to hydrophobic interactions are
represented as arcs with rays and colored red. (B) Structural model of cb5r with NAD+
and residues Y112 and Q210 shown in stick representation. (C) Enlarged view of the
NADH binding pocket (atoms colored in CPK).
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atom of residue S127 was within hydrogen bonding distance of the amide nitrogen atom
of Y112 and may assist in stabilizing this loop conformation. A major conformational
change in the lid region noted in the X-ray crystal structure of S127P was proposed to be
partially due to the removal of the interaction of the side chain of S127 with the amide
nitrogen atom of Y112 [122].
In order to further probe the role of Y112, a series of variants were created as
described in “Methods” utilizing the original four-histidine tagged cb5r expression
construct and the corresponding oligonucleotide primers listed in Appendix A.
In multiple sequence alignments, Y112 is shown to be both ubiquitously
conserved across species variants as well as highly conserved among members of the
FNR family. Thus, the variants generated corresponded to a survey of alternate amino
acid residues that cover the general properties of the side chains, allowing for
investigation of polarity, charge, and steric interference on the overall structure and
function of cb5r. The variants generated consisted of Y112A, Y112D, Y112F, Y112H,
and Y112L.
Residue Q210 is located at the carboxy terminus of β-strand Nβ2. The NE2 of the
glutamine side chain forms a hydrogen bond with AO2 of the adenosine pyrophosphate
of NAD+. Through multiple sequence alignments, Q210 has been shown to be highly
conserved across FNR family members and among species variants. To further probe the
role of Q210, a series of mutants were generated as described in “Methods and
Materials,” utilizing the original four-histidine tagged cb5r expression construct and the
corresponding oligonucleotide primers listed in Appendix A.

These mutants

corresponded to alternate residues that occur in the same residue position within
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additional GenBank sequences of other members of the FNR superfamily and cb5r
variants. These variants consist of Q210A, Q210R, and Q210 V.
The fidelity of each variant was confirmed by nucleotide sequencing in both
forward and reverse directions and the mutant proteins were then recombinantly
expressed in BL21 (DE3)-RIL cells. Purification to homogeneity was carried out through
the utilization of a combination of Ni-NTA affinity and gel filtration chromatography for
the mutant proteins, all being expressed at levels comparable to that of the WT domain as
observed by the appearance of single protein bands following SDS-PAGE analysis.
UV/visible absorption spectra were obtained for oxidized samples of each of the
purified variants together with WT cb5 and are presented in Figure 18A (Y112 series)
and Figure 19A (Q210 series). Both series of mutants displayed spectra comparable to
that of the WT domain, attributable to protein-bound flavin with an aromatic absorption
maxima detected at 272 nm in the UV region of the spectrum and a peak at 461 nm with
a pronounced shoulder within the range of 485-500 nm in the visible region of the
spectrum. The absorption ratios (A276/A461) for each viable mutant were within a range
of 5.5 to 5.9 which indicated a full flavin complement.
To examine the effects of each mutation upon the secondary structure of the
protein, UV circular dichroism spectra were determined in the UV wavelength range (190
– 300 nm). As shown in Figures 18B and 19B, all of the generated mutants displayed
line shapes comparable to WT cytochrome b5 reductase with positive CD from 190-210
nm and negative spectra from 210-250 nm, with minor alterations in the intensity of the
negative deflections of the spectra. Alterations may indicate an adverse structural change
within the overall α-helical or β-sheet components of the two variants. However, due to
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Figure 18. Ultra-Violet, Visible, and Circular Dichroism Spectra Obtained for the
Y112 Series of cb5r Variants. (A) Oxidized samples of WT and mutant cb5rs (20µM),
(B) 7µM, and (C) 60µM FAD in 10mM phosphate with 0.1mM EDTA, pH 7.0 buffer.
The inset shows an expanded region of the visible spectrum where the flavin cofactor
makes a major contribution. Individual spectra correspond to (____) H4cb5r; (____ ____)
Y112A; (__ __ __) Y112D; (_ _ _ _) Y112F; (__ . __) Y112H and (__ . . __) Y112L.
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Figure 19. Ultra-Violet, Visible, and Circular Dichroism Spectra Obtained for the
Q210 Series of cb5r Variants. (A) Oxidized samples of WT and mutant cb5rs (20µM),
(B) 7µM, and (C) 60µM FAD in 10mM phosphate with 0.1mM EDTA, pH 7.0 buffer.
The inset shows an expanded region of the visible spectrum where the flavin cofactor
makes a major contribution. Individual spectra correspond to (____) H4cb5r; (____ ____)
Q210A; (__ . __) Q210R; (__ . . __) and Q210V.
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the minimal nature of these alterations, it is more likely a result of the noise reduction
process involved with analysis of the data. In order to examine the flavin environment of
each variant, visible CD spectra were obtained as shown in Figure 18C and 19C.
Representative spectra demonstrated that each variant retained a similar line shape to that
of WT cb5r, processing positive maxima at 310 and 390 nm and negative maxima at 460
and 485 nm. Again, minor alterations were observed in the intensity of both the positive
and negative deflections, mostly attributable to noise reduction.
To establish effects of the alterations of the side chains on the catalytic function of
the enzyme, initial-rate kinetic parameters for NADH:FR assays were determined for the
WT cb5r and for each purified variant. The values obtained for the NADH:FR assays for
the Y112 and Q210 series of variants are presented in Tables 7 and 8, respectively. For
the Y112 series, the NADH catalytic efficiencies (kcat/KmNADH) were at least moderately
decreased for all variants, having values that ranged between 2 and 27% compared to WT
cb5r, with Y112D yielding the lowest catalytic efficiency (Table 7). The observed
decrease on overall catalytic efficiency was attributable to both a decreased kcat for each
of the variants (>50% in all cases) as well as a decrease in substrate affinity, with
observed KmNADH of each mutant being 2-2.5 times greater than that of WT cb5r. Most
notable of the results was Y112D, which had the most profound effect on catalytic
efficiency, reducing it to 2% of WT activity.
For the Q210 series, the NADH catalytic efficiencies (kcat/KmNADH) for all variants
were decreased with values that ranged between 21 and 47% compared to WT cb5r, with
Q210A yielding the lowest catalytic efficiency (Table 8). The decrease in efficiency was
again due equally to decreased affinity for substrate and decreased rate of turn-over.
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Table 7. NADH:FR Kinetic Constants and Thermal Stability (T50) Values for the
Y112 Series of cb5r Variants.

NADH:FR
cb5r
Variant

kcat
(s-1)

KmNADH
(µM)

KmFeCN6
(µM)

kcat/KmNADH
(s-1 M-1)

WT H4cb5r
Y112A
Y112D
Y112F
Y112H
Y112L

800 ± 21
325 ± 5
45 ± 2
400 ± 17
333 ± 28
397 ± 20

6±1
12 ± 0.3
15 ± 2.6
11 ± 0.9
10 ± 1.1
11 ± 1.2

8±1
7±1
8±1
8±1
7±1
8±1

1.4 ± 0.3 x 108
2.8 ± 0.1 x 107
3.1 ± 0.7 x 106
3.7 ± 0.5 x 107
3.4 ± 0.7 x 107
3.8 ± 0.6 x 107

T50
(°C)
56.1
51.4
51.2
54.3
56.3
57.2

Protein stability was evaluated by monitoring the thermal NADH:FR inactivation
profile coupled with the increase in intrinsic flavin fluorescence and emission intensity of
each of the variants which was compared to values obtained for WT cytochrome b5
reductase. The results obtained for the thermal denaturation profiles and changes in
intrinsic flavin fluorescence are shown in Figure 20. For the Y112 variants, T50 values
(the temperature at which 50% of maximum fluorescence and 50% retention of
NADH:FR activity was detected) indicated a slightly decreased protein thermal stability
for Y112A, D, and F as compared to the T50 value of 56 °C for WT cb5r, whereas the
values for both the Y112H and Y112L variants were comparable to WT (Table 7).
Similar results occurred for the Q210 variants, with all three having slightly decreased
values compared to WT (Table 8). Overall, these results indicated alteration to either of
these residue results in a decreased stability of the protein.
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Table 8. NADH:FR Kinetic Constants and Thermal Stability (T
Q210 Series of cb5r Variants.

50)

Values for the

NADH:FR
cb5r
Variant

kcat
(s-1)

WT H4cb5r
Q210A
Q210R
Q210V

800 ± 21
437 ± 42
510 ± 5
565 ± 17

KmNADH KmFeCN6
(µM)
(µM)
6±1
15 ± 1.5
8 ± 0.3
13 ± 1.8

8±1
8±1
7±1
8±1

kcat/KmNADH
(s-1 M-1)

T50
(°C)

1.4 ± 0.3 x 108
2.9 ± 0.6 x 107
6.6 ± 0.3 x 107
4.3 ± 0.7 x 107

56.1
52.7
52.9
52.3

From the kinetic data obtained it was demonstrated that each of the variants
generated displayed an elevated KmNADH for both the Y112 and Q210 variants, on the
order of 2 fold as compared to WT cb5r for most variants. To further establish the
binding affinity of the substrate NADH and the product NAD+, spectroscopic binding
constants were determined utilizing differential spectroscopy.
As stated in “Methods” the isosteric analog 1,4,5,6-tetrahydro-NAD (H4NAD)
was utilized as an alternative substrate analog to evaluate the affinity for the
physiological substrate NADH [106]. Differential spectroscopy was used to monitor
complex formation during titrations with either H4NAD or the physiological product
NAD+. The results are shown in Figures 21 and 22 for Y112 and in Figure 23 for the
Q210 variants. In the case of Y112, spectra obtained for each of the titrations carried out
in the presence of H4NAD displayed a line shape comparable to WT cb5r with varying
intensities of the negative maxima at 395nm. Values observed for the spectroscopic
binding constant (Ks) for the H4NAD titrations, shown in Table 9, demonstrated that the
binding affinity for each of the variants was not significantly altered, with the exception
of Y112D, which had a value approximately 9 times greater than that of WT cb5r.
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Figure 20. Thermal Stability Profiles of the Y112 and Q210 Series of Variants.
Oxidized samples of cb5r variants and WT H4cb5r (5 µM FAD) were incubated at the
indicated temperatures, and aliquots were withdrawn and assayed for both residual
NADH:FR activity (closed symbols) and intrinsic flavin fluorescence (open symbols) in
10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0 using excitation and
emission wavelengths of 450 nm and 523 nm, respectively. (A) Points correspond to:
(●,○) H4cb5r; (■, □) Y112A; (▲, ∆) Y112D; (▼, ) Y112F; (♦, ◊) Y112H; and (x)
Y112L. (B) Points correspond to: (●,○) H4cb5r; (■, □) Q210A; (▲, ∆) Q210R; and
(▼, ) Q210V
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While little alteration for the affinity for the substrate analog H4NAD was observed for
the Y112 series of variants, the spectra obtained in the NAD+ titrations demonstrate a
high level of alteration in both degree of affinity and in conformation of binding. As seen
in Figure 21, all variants, with the exception of Y112H, demonstrated an altered line
shape in the titration spectra. Moreover, the spectra for Y112A, D, F, and L were more
reminiscent of the spectra obtained for WT enzyme in the presence of H4NAD.
Additionally, the intensities of the differential spectra were greatly diminished in
comparison to WT enzyme.

The Ks values were markedly altered for all variants,

displaying an moderately enhanced binding affinity for the NAD+ product in the case of
Y112A and Y112L, while the Y112F, Y112H, and most notable the Y1112D variants
demonstrated dramatically increased values as compared to WT cb5r (Table 9). These
results are in good agreement with the kinetic values obtained in that the substrate
H4NAD is still able to bind efficiently, but at a decreased affinity. In respect to affinity
for the product NAD+, the altered conformation indicated by the differing line shape of
the spectra indicates improper orientation leading to decreased turnover as evidenced by
the decreased kcat values for the NADH:FR assays.
For the Q210 series of variants, titrations carried out in the presence of H4NAD
yield spectra retaining the line shape shown in titrations of WT enzyme. Values obtained
for the Ks for H4NAD were comparable to that of WT (Table 10), with Q210R showing
an increased affinity for substrate. Results obtained for titrations in the presence of
NAD+, showed that all variants maintained the same line shape as that for WT. Q210A
showed a Ks value on par with WT, whereas values for Q210R and Q210V indicated and
increased affinity for substrate (Table 10).
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Figure 21. Spectroscopic Titrations of WT cb5r and the Y112 Series of Variants in
the Presence of H4NAD. Titrations of all mutants (50µM) were performed in split cell
optical cuvettes in 10mM phosphate buffer containing 0.1mM EDTA, pH 7.0 at 23 °C.
Difference spectra were recorded following the addition of solution containing H4NAD
(5mM). The inset panel corresponds to a plot of the magnitude of the spectral
perturbations at the indicated wavelengths versus pyridine nucleotide concentration
where a difference spectrum was observed. Plots of the relative absorbance changes
observed are as follows: (A) H4cb5r; (B) Y112A; (C) Y112D; (D) Y112F; (E) Y112H;
and (F) Y112L.
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Figure 22. Spectroscopic Titrations of WT cb5r and the Y112 Series of Variants in
the Presence of NAD+. Titrations of all mutants (50µM) were performed in split cell
optical cuvettes in 10mM phosphate buffer containing 0.1mM EDTA, pH 7.0 at 23 °C.
Difference spectra were recorded following the addition of solution containing NAD+
(30mM). The inset panel corresponds to a plot of the magnitude of the spectral
perturbations at the indicated wavelengths versus pyridine nucleotide concentration
where a difference spectrum was observed. Plots of the relative absorbance changes
observed are as follows: (A) H4cb5r; (B) Y112A; (C) Y112D; (D) Y112F; (E) Y112H;
and (F) Y112L.
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Figure 23. Spectroscopic Titrations of WT cb5r and the Q210 Series of Variants in
the Presence of H4NAD and NAD+. Titrations of all mutants (50µM) were performed
in split cell optical cuvettes in 10mM phosphate buffer containing 0.1mM EDTA, pH 7.0
at 23 °C. Difference spectra were recorded following the addition of solution containing
H4NAD (5mM) (A, C, E, G) NAD+ (30mM) (B, D, F, H). The inset panel corresponds to
a plot of the magnitude of the spectral perturbations at the indicated wavelengths versus
pyridine nucleotide concentration where a difference spectrum was observed. Plots of
the relative absorbance changes observed are as follows: (A, B) H4cb5r; (C, D) Q210A;
(E, F) Q210R; and (G, H) Q210V.

80

81

Table 9. Spectral Binding Constants (Ks) and Standard Midpoint Potentials (Eo′)
Obtained for the Y112 Series Variants.

cb5r
Variant

Ks H4NAD
(µM)

KsNAD+
(µM)

WT H4cb5r 45 ± 10 553 ± 30
359 ± 62
37 ± 4
Y112A
414 ± 47 7958 ± 410
Y112D
69 ± 9 2234 ± 242
Y112F
28 ± 3 2808 ± 267
Y112H
313 ± 50
56 ± 4
Y112L

E°′ FAD/FADH2
(mV)

+

-NAD

+NAD+

-271
-271
-261
-269
-266
-271

-190
-219
-201
-193
-217
-197

Effects of potential structural changes on the properties of the flavin prosthetic
group were examined by determining oxidation-reduction potentials for the FAD cofactor
utilizing dye-equilibration titrations in the presence of phenosafranine (E°′ = -252 mV) as
described in Methods [117]. Flavin midpoint potentials (E°′, n = 2) for the FAD/FADH2
couple were determined for the variants alone and in the presence of NAD+.

The flavin

redox potentials (n = 2) for the WT cytochrome b5 reductase and generated variants for
the FAD/FADH2 couple were determined from the Nernst semi-log plots of the log
([oxidized]/[reduced])FAD versus potential (mV) and are shown in Figures 24 and 25 for
the Y112 and Q210 series respectively, with the standard midpoint potential values
obtained for each shown in Tables 9 and 10, respectively. For the standard flavin
midpoint potentials of the Y112 variants in the absence of NAD+, all potentials were
nearly identical to that of the WT domain, indicating that the introduction of structural
alterations of these variants did not have a dramatic effect on the environment of the FAD
as inferred from flavin midpoint potential.

In the presence of NAD+ however, the

resulting midpoint potentials of the variants, with the exception of Y112A, were more
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negative than that of the WT domain (-191mV), having a value more comparable to the
value obtained for the midpoint potential of free flavin (-220 mV) [133]. Similar results
were noted for the Q210 series, with values in the absence of NAD+ being similar to that
of WT and values in the presence of NAD+ being midway between the expected value for
WT and that of free flavin.

Table 10. Spectral Binding Constants (Ks) and Standard Midpoint Potentials (Eo′)
Obtained for the Q210 Series Variants.

cb5r
Variant

Ks H4NAD
(µM)

WT H4cb5r 45 ± 10
78 ± 5
Q210A
22 ± 3
Q210R
64 ± 8
Q210V

KsNAD+
(µM)
553 ± 30
578 ± 42
48 ± 8
205 ± 29
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E°′ FAD/FADH2
(mV)
-NAD+ +NAD+
-271
-277
-271
-271

-191
-210
-204
-206

Figure 24. Oxidation-Reduction Midpoint Potentials for the FAD Prosthetic Group
in the WT cb5r and Y112 cb5r Variants. Reductive dye titrations were performed at
25 °C as described in “Materials and Methods” using phenosafranine as the indicator dye
in 100 mM phosphate buffer containing 0.1 mM EDTA, pH 7.0. Nernst plots in the
absence (A) and presence (B) of 2 mM NAD+. Plots correspond to (●) H4cb5r; (■)
Y112A; (▲) Y112D; (▼) Y112F; (♦)Y112H; and (x) Y112L.
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Figure 25. Oxidation-Reduction Midpoint Potentials for the FAD Prosthetic Group
in the WT cb5r and Q210 cb5r Variants. Reductive dye titrations were performed at
25 °C as described in “Materials and Methods” using phenosafranine as the indicator dye
in 100 mM phosphate buffer containing 0.1 mM EDTA, pH 7.0. Nernst plots in the
absence (A) and presence (B) of 2 mM NAD+. Plots correspond to (●) H4cb5r; (■)
Q210A; (▲) Q210R; and (▼) Q210V.
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Summary of Analysis of residues, Y112 and Q210, involved in anchoring of the
pyrophosphate backbone of NAD+
Multiple sequence alignments have demonstrated that residues Y112 and Q210
have a high level of conservation, occurring with only a few exceptions across cb5r
proteins from divergent species as well as amongst the members of the FNR family of
transhydrogenases. This fact, coupled with the implication of both residues in interactions
with the pyrophosphate backbone of bound NAD+ as demonstrated by X-ray
crystallographic studies of the rat variant of cb5r in the presence of the substrate, indicate
that these two residues potentially play a vital role in proper structure-function
interactions yielding proper enzymatic activity of cb5r. The location of Y112 in the vital
FAD associated “lid” region further suggests that this residue in particular may function
in some way to ensure proper orientation of both the cofactor and the coenzyme.
In order to fully elucidate the role of each residue, a series of variants were
generated corresponding to naturally occurring substitutions observed within the FNR
superfamily or in variants of cb5r from divergent species. These included Y112A, D, F,
H, and L and Q210A, R, and V. The data presented here provides further insight into the
role of these two residues towards correct orientation and binding of the NADH substrate.
While both series of variants generated impaired functionality of cb5r to some level, the
Y112 variants appeared to demonstrate a greater impact than the Q210 variants.
Additionally, among the Y112 variants, the greatest impact was noted in the substitution
of the native residue with residues carrying a charge, either positive (H) or negative (D).
Substitution of residue Y112 with any of the chosen residue alterations resulted in
some degree of impaired function, regardless of side chain characteristics. In general an
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approximate 2 fold decrease in substrate affinity coupled with an approximate 2 fold
decrease in rate of turnover was observed for all substitutions in regards to NADH:FR
activity. A notable exception to this was the Y112D variant which had a much more
profound impact on the turnover rate. These data indicate that changing the side chain at
position 112 causes a mild impairment in the binding of NADH, via disruption of the
anchoring effect of the hydroxyl group found on the tyrosine side chain.

The

introduction of a negative charge into this position greatly affected the ability of the
protein to not only properly associate with NADH; it directly impacted the ability of the
protein to properly function. This is due to disruption of the electrostatic environment
near the FAD.
While absorbance spectra and circular dichroism analyses indicate that the flavin
environment was not affected, the introduction of the negative charge would impact the
ability of FAD to properly accept electrons from the NADH. Analysis of an in silico
model of Y112 in relation to FAD compared to that of Y112D, suggested that the adenine
moiety of FAD in situated close to and associates with Y112.

In the WT protein,

analysis indicated a moderate positive charge toward the backbone portion of Y112 with
the end of the side chain having a mildly negative charge. This polarity compliments the
charge dispersal on the adenine moiety of FAD.

The proposed model of D112 in

association with FAD indicates a highly negative region being introduced into a pocket of
positive charges found in the FAD. The introduction of this level of strong negative
charge into a region normally occupied by a mild electronegative charge would be
sufficient to disrupt the electron transfer properties of FAD, rendering it unable to
efficiently accept electrons from NADH. This would support the drastic effects observed
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Figure 26. Structures of WT cb5r and the Y112D Variant with FAD Generated in
silica. The molecular model of cb5r displaying the charged surfaces of (A) residue Y112
and (B) cb5r variant Y112D in association with FAD generated utilizing the automated
comparative protein modeling server SWISS-MODEL [111] and analyzed using the
molecular modeling software Web Lab Viewer Pro [134]. This model represents a
surface representation of cb5r in complex with FAD (1IB0 ) where the acidic residues are
red, basic residues are blue, and neutral residues are displayed as white clouds.

seen on the kcat value for Y112D, being one-twentieth that of WT and the midpoint
potential in the presence of NAD+ being comparable to that of free flavin. These effects
may also be indirect, with alterations of the Y112 residue affecting nearby residues in the
“lid” region responsible for proper FAD incorporation. Additionally, the presence of the
negative charge from the carboxylic acid side chain would prevent the NADH from
associating correctly. This latter fact is made more evident by the 10-fold+ greater
spectral binding constants for H4NAD and NAD+.
Of notable importance is the fact that all substitutions at residue Y112 resulted in
altered and/or diminished differential spectra when titrated with NAD+. This indicates
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that the hydroxyl group of Y112 is important to properly orient the product. In its
absence, the NAD+ adopts an altered conformation for binding. Despite this fact, the
differential spectra for the variants in the presence of H4NAD retained similar line shape
to WT, with only diminished intensities. This indicates that the isosteric analog was
bound similar in the variant.
Unlike Y112, residue Q210 demonstrated a moderately higher level of tolerance
to substitutions made to the side chain. In the case of all variants, catalytic efficiency was
decreased, but not to the magnitude observed in Y112. Interestingly, affinity for binding
of substrate, as indicated by both the Km value from NADH:FR assays and the Ks values
in the presence of H4NAD and NAD+, was increased in the case of Q210R. From in
silica modeling of the cb5r structure with the Q210R mutation we observed that the
positive charge on the WT residue centered in the area between the pyrophosphate and
adenine moieties of NAD+ would be diminished in the Q210R variant. This change
might result in a decrease in the attraction in this area, but would not eliminate it entirely,
thus not decreasing the binding constants associated with it. Furthermore, the distal end
of the side chain in Q210R redirects away from the NAD+ as compared to the WT. This
would decrease any physical/steric obstruction that would exist in the native structure,
thereby allowing for easier access of NAD+ to the environment, explaining the increased
affinity observed for Q210R. Q210V also showed an increased affinity for NAD+, as
determined by differential spectroscopy, which was also likely due to the decreased steric
hindrance from the shortened side chain. Due to the greater affinity shown for NAD+ in
both Q210R and V, we conducted inhibition assays in the presence of NAD+. The
resulting Ki values (data not shown) for the Q210R and Q210V variants (639 µM and 677
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µM respectively) were not significantly different than the value for WT cb5r (675 µM),
indicating that the decreased catalytic efficiency was not due to product inhibition, and
instead likely results from misalignment between the cofactor and substrate.
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NAD

Q210
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B
Figure 27. Structures of WT cb5r and the Q210R Variant with FAD Generated in
silica. The molecular model of cb5r displaying the charged surfaces of (A) residue Q210
and (B) cb5r variant Q210R in association with FAD generated utilizing the automated
comparative protein modeling server SWISS-MODEL [111] and analyzed using the
molecular modeling software Web Lab Viewer Pro [134]. This model represents a
surface representation of cb5r in complex with FAD (1IB0 ) where the acidic residues are
red, basic residues are blue, and neutral residues are displayed as white clouds.
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Characterization of the Type I Recessive Congenital Methemoglobinemia Mutants
T116S and E212K
In proximity to the two highly conserved NAD+ phosphate backbone binding
residues, Y112 and Q210, are two additional residues of which naturally occurring
mutants have been identified that result in a diagnosis with type I Recessive Congenital
Methemoglobinemia. These naturally occurring mutations are T116S and E212K, both
originally discovered in patients of African American decent.
Previous studies first identified a transversion of C-to-G at codon 116 in exon 5 of
cb5r, resulting in a T116S mutant, which was found in two unrelated African American
methemoglobinemic patients.

Further analysis demonstrated that not only did both

patients have the variant, their asymptomatic relatives as well as unselected healthy
African-American controls with normal enzymatic function were also either
heterozygous or homozygous for this substitution, with an allelic frequency of 0.23 [135].
The T116S mutation was not, however, found in Caucasian, Asian, Indo-Aryan, of
Arabic subjects tested, thus suggesting that this was a high frequency polymorphism
unique to African American populations. To date, however, no selective advantage has
been linked to the presence of this polymorphism [135].
Further studies were carried out on one of the patients having the T116S mutation.
The patient was found to also be homozygous for a G to A transition in exon 8 at codon
212 resulting in the amino acid substitution E212K. The patient’s mother was also
shown to be heterozygous for this mutation, and displayed decreased enzymatic activity.
Unlike the T116S mutation, analysis indicated that among 62 African-American and 54
unselected white individuals, the E212K mutation occurred only in the propositus and her
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mother, indicating that E212K is not a polymorphism.

The combination of a

polymorphism and a single pathogenic mutation has been shown to result in disease
phenotypes in the case of fatal familial insomnia, Creutzfeld-Jacob disease, and primary
hyperoxaluria type I. Thus it is possible that the E212K mutation is alone causative of
RCM type I in the patient, or it may interact with the T116S, and this combination leads
to the disease phenotype [135].
To further elucidate the effects of the naturally occurring T116S polymorphism
and the E212K mutation on the functioning of cb5r, a series of variants were generated
including T116S, E212K and a double mutant T116s/E212K as described in “Methods
and Materials,” utilizing the original four-histidine tagged cb5r expression construct and
the corresponding oligonucleotide primers listed in Appendix A. These variants were
characterized on the basis of kinetic, spectral, and thermal stability parameters.
UV/visible absorbance spectra were obtained for oxidized samples of the purified
RCM variants T116S, E212K, and T116S/E212K and were compared with the spectra
obtained for the corresponding WT domain in (Figure 28A). All three variants exhibited
spectra identical to that of the WT domain, characterized by absorption maximum
detected at 273 nm in the UV range of the spectrum, and a peak at 461 nm with an
associated pronounced shoulder in the range of 485-500 nm in the visible region of the
spectrum, the latter peak attributable to protein- bound flavin.

The A273

nm/A461 nm

absorbance ratios of the variants were within the range of 5.9 ± 0.2, comparable to values
previously obtained for WT rat cb5r of 5.7 ± 0.2 [121], indicating a full complement of
the FAD prosthetic group.
To assess any alterations in the secondary structural content of the different type I
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Figure 28. Ultra-Violet, Visible, and Circular Dichroism Spectra Obtained for the
RCM Type I Associated Mutants T116S, E212K and T116S/E212K (A) UV/visible
absorption spectra were obtained for oxidized samples of cb5r and the T116S, E212K
and T116S/E212K mutants at equivalent flavin concentrations (1.7 µM FAD) in 10 mM
phosphate buffer, containing 0.1 mM EDTA, pH 7.0. The inset shows an expanded
region of the visible spectrum where the flavin prosthetic group makes a major
contribution. Individual spectra correspond to WT cb5r (____); T116S (--- ---); E212K ( .-.- ); and T116S/E212K (-..-..-); (B) UV CD spectra were recorded using enzyme
samples (7 µM FAD) in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0.
(C) Visible CD spectra were recorded using enzyme samples (50 µM FAD) in 10 mM
phosphate buffer, containing 0.1 mM EDTA, pH 7.0. Line styles shown in “B” and “C”
are the same as those depicted in “A”.
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RCM cb5r variants, circular dichroism spectra were recorded in the UV wavelength
range (190-300 nm). As shown in Figure 28B, all three variants exhibited positive CD
spectra from 190-210 nm and negative CD spectra from 210-250 nm with the spectra
retaining both positive and negative intensities very similar to that of the WT domain.
The absence of any significant differences between the spectra of the various mutants and
the WT domain suggested conservation of the secondary structure architecture and that
none of the amino acid substitutions or deletions had any substantial effects on the
folding of the protein. Visible CD spectroscopy was utilized to examine the environment
of the FAD prosthetic group. As shown in Figure 28C, all three variants generated
exhibited visible CD spectra that were virtually indistinguishable from that of WT cb5r,
indicating that none of the amino acid substitutions had any significant effect on the
conformation of the bound FAD prosthetic group.
To assess the effect of the mutations on the catalytic function of the enzyme,
initial rate kinetic parameters for NADH:FR assays were determined for the WT cb5r and
for each purified variant. The values obtained for the NADH:FR assays are presented in
Table 11. Of the three mutations, the double mutant T116S/E212K demonstrated the
greatest decrease in both kcat and KmNADH, retaining approximately 31% of WT catalytic
efficiency (kcat/KmNADH) with the individual mutations T116S and E212K retaining 45%
and 37% of WT efficiency respectively. The observed decrease on overall catalytic
efficiency was attributable to both moderate decreases of the kcat as well as a decrease in
substrate affinity, with observed KmNADH of each mutant being 1-1.5 times greater than
that of WT enzyme.
To examine the influence of the various amino acid substitutions on protein
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stability, the thermal NADH:FR inactivation profile coupled with the increase in intrinsic
flavin fluorescence and emission intensity of each of the variants was monitored and was
compared to values obtained for WT enzyme. The results obtained for the thermal
denaturation profiles and changes in intrinsic flavin fluorescence are shown in Figure 29.
Changes in the intrinsic fluorescence of the cofactor or the retention of NADH:FR
activity following thermal denaturation was an effective indicator of the stability of the
core structure of the protein. T50 values (the temperature at which 50% of maximum
fluorescence and 50% retention of NADH:FR activity was detected) are reported in Table
11 and ranged from of 49.6 °C for the T116S/E212K mutant to a high of 55.5 °C for the
T116S variant as compared to a T50 of 56 °C obtained for WT cb5r.

Table 11. NADH:FR Kinetic Constants and Thermal Stability (T 50) Values for the
Type I RCM Associated Mutants T116S, E212K, and T116S/E212K

cb5r
Variant
WT H4cb5r
T116S
E212K
T1116S/E212K

NADH:FR
kcat
(s-1)

KmNADH
(µM)

800 ± 17 6.0 ± 1
676 ± 11 10.8 ± 0.8
546 ± 10 10.5 ± 0.9
498 ± 23 11.4 ± 0.9

KmFeCN6
(µM)
8±1
8±1
7±1
8±1

kcat/KmNADH
(s-1 M-1)

T50
(°C)

1.4 ± 0.3 x 108
6.4 ± 0.6 x 107
5.2 ± 0.5 x 107
4.4 ± 0.6 x 107

56.1
55.5
51.2
49.6

Differential spectroscopy was used to evaluate the effect of the RCM mutations
on the binding affinity for both the isosteric NADH analog H4NAD and NAD+. As
shown in Figure 30, both of the individual mutations resulted in similar line shapes for
the spectra in both titrations, and exhibited moderately increased affinity, as indicated by
decreased Ks values, for both titrated compounds (Table 12). The T116S/E212K double
96

% Fluorescence Intensity
Figure 29. Temperature Stability Profiles Obtained for the Type I RCM Associated
Mutants T116S, E212K, and T116S/E212K. Oxidized samples of WT H4cb5r (5 µM
FAD) and cb5r RCM variants were incubated at the indicated temperatures, and aliquots
were withdrawn and assayed for both residual NADH:FR activity (closed symbols) and
intrinsic flavin fluorescence (open symbols) in 10 mM phosphate buffer, containing 0.1
mM EDTA, pH 7.0 using excitation and emission wavelengths of 450 nm and 523 nm,
respectively. Points correspond to (●,○) H4cb5r; (■, □) T116S; (▲, ∆) E212K; and
(▼, ) T116S/E212K

mutant showed lineshape and Ks value comparable to that of WT for the H4NAD titration.
In titrations with NAD+, however, a diminished intensity was noted in the titrated
spectra, while maintaining similar line shape.

The binding constant again, was

significantly decreased (187µM compared to 553µM for WT) indicating increased
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affinity for the product.
Effects of potential structural changes on the properties of the flavin prosthetic
group were examined by determining the oxidation-reduction potentials for the FAD
cofactor as described in the “Methods” section. Flavin midpoint potentials (E°′, n = 2)
for the FAD/FADH2 couple were determined for the variants alone and in the presence of
NAD+. Spectra obtained during a representative titration of the WT cb5r protein are
shown in Figure 31. With out the addition of NAD+ to the titration, each of the mutations
demonstrated midpoint potentials equivalent to that of WT, ranging from -272mV to 266mV. In the presence of NAD+ however, all the mutations had midpoint values that
ranged from -208mV to -200 mV, showing a positive shift, as was observed for WT cb5r.
Values for midpoints at reported in Table 12.

Table 12. Spectral Binding Constants (Ks) and Standard Midpoint Potentials (Eo′)
Obtained for the Type I RCM mutants T116S, E212K and T116S/E212K

cb5r
Variant

Ks H4NAD
(µM)

KsNAD+
(µM)

WT H4cb5r
T116S
E212K
T116S/E212K

45 ± 10
37 ± 12
20 ± 2
56 ± 3

553 ± 30
261 ± 23
88 ± 6
187 ± 13
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E°′ FAD/FADH2
(mV)

+

-NAD
-271
-269
-266
-272

+NAD+
-191
-200
-205
-208

Figure 30. Spectroscopic Titrations of WT cb5r and the Type I RCM Mutants
T116S, E212K, and T116S/E212K in the presence of H4NAD and NAD+. Titrations
of all mutants (50µM) were performed in split cell optical cuvettes in 10mM phosphate
buffer containing 0.1mM EDTA, pH 7.0 at 23 °C. Difference spectra were recorded
following the addition of solution containing H4NAD (5mM) (A, C, E, G) NAD+ (30mM)
(B, D, F, H). The inset panel corresponds to a plot of the magnitude of the spectral
perturbations at the indicated wavelengths versus pyridine nucleotide concentration
where a difference spectrum was observed. Plots of the relative absorbance changes
observed are as follows: (A, B) WT cb5r; (C, D) T116S; (E, F) E212K; and (G, H)
T116S/E212K.

99

100

Summary of the Characterization of the Type I Recessive Congenital Methemoglobinemia
Mutants T116S and E212K
Previous investigations by Prchal et. al. [135] identified two unique point
mutations in the DIA1 gene of individuals of African American decent displaying disease
phenotype for Type I RCM. The two mutations correspond to two distinct amino acid
substitutions in the cb5r protein, T116S and E212K, with one individual being
homozygous for both mutations. After further investigation including samples from a
large pool of unselected individuals of diverse ethnic backgrounds, it was concluded that,
while the E212K mutation was unique to individuals expressing a disease phenotype, the
T116S mutation was a polymorphism, occurring in approximately 20% of healthy
African American subjects, but not found in subjects of different ethnic backgrounds
[135]. Thus, it is likely that the E212K mutation is the causative agent in the presentation
of RCM in the patient. The data here further investigated the properties of E212K, as
well as T116S and a double mutant T1116S/E212K, in order to determine the nature of
these variants and how their contribution to the presentation of the disease.
Both residues are located on the external surface of the cb5r protein as shown in
Figure 32. Neither residue is involved in any contacts between the protein and its cofactor or substrate. Thus, any effect on the catalytic function of the enzyme would likely
be the result of alterations to interactions between residues, protein structure, or stability.
Analysis of the structure of the mutants through the use of UV/Visible absorbance
and circular dichroism spectroscopy indicated that the mutants did not differ significantly
in overall secondary structure from the WT protein, and incorporated the FAD cofactor in
a similar manner. Initial-rate kinetic studies indicated that the mutants maintained greater
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than 50% of the rate of turn-over exhibited by the WT enzyme, and did not significantly
differ in the binding affinity for substrate as indicated by similar Km values. In addition,
differential spectroscopy indicated that each of the three mutants bound H4NAD, a nonreactive analog of NADH, in a manner similar to WT and with equal or greater affinity.
The mutants did, however, differ from WT in two significant properties. First,
thermal stability studies, monitoring decrease of activity and increase of intrinsic
fluorescence as a function of increasing temperature, showed that each of the mutations,
not just E212K or the double mutant, resulted in decreased stability, with T50 values
significantly lower than that of WT, particularly in the case of the double mutation. This
would indicate a potential causation for the disease phenotype.

Since circulating

erythrocytes do not generate additional copies of proteins during their lifespan, proteins
with a decreased stability would degrade over time and thus not be able to properly and
efficiently carry out their functions. This is a common cause for type I RCM, which is
limited to dysfunction in the soluble cb5r found in circulating erythrocytes.
The second notable difference found in all the mutants as compared to WT, was
an increased affinity for NAD+ as shown in differential spectroscopy. While the line
shapes for the spectra resulting from titration with increasing amounts of NAD+ were
similar to that of WT, each of the three mutant proteins exhibited lower Ks values,
suggesting that they were able to bind NAD+ more efficiently than WT. This suggests
the possibility of competitive inhibition of catalytic function
The premise that E212K is itself sufficient to elicit the disease phenotype
observed in a homozygous individual having the mutation is plausible. The mutation
clearly does decrease the catalytic properties of the protein, albeit only moderately, which
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Figure 31. Oxidation-Reduction Midpoint Potentials for the FAD Prosthetic Group
in the WT cb5r and the Type I RCM Associated Mutants T116S, E212K, and
T116S/E212K. Reductive dye titrations were performed at 25 °C as described in
“Materials and Methods” using phenosafranine as the indicator dye in 100 mM phosphate
buffer containing 0.1 mM EDTA, pH 7.0. Nernst plots in the absence (A) and presence
(B) of 2 mM NAD+. Plots correspond to (●) H4cb5r; (■) T116S; (▲) E212K; and (▼)
T116S/E212K
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would likely invoke the minor phenotypic presentation of symptoms seen in the patient;
the patient had slightly elevated methemoglobin levels and exhibited enzyme activity
close to that of a heterozygous individual. Additionally, the decreased stability generated
by the E212K mutation likely adds to the presentation, limiting the amount of partially
functional protein available to reduce methemoglobin. The stability issue is potentially
due to the introduction of a lysine which can become involved in cross linkages in the
protein, destabilizing interactions among residues leading to a less thermally stable
protein overall. This alteration to structure is likely only minor, as no significant changes
in CD spectra were noted, but enough to cause the decrease in stability.

T116

E212

Figure 32. Structural Model of cb5r Showing Position of Residues T116 and E212.
Ribbon depiction of the tertiary structure of WT cb5r. Residues T116 and E212 are
presented in CPK form. Residues are located on the external surface of the protein
outside the FAD and NADH- binding pocket.
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Most interesting of the results, however, is the fact that the T116S substitution,
reported as a polymorphism that occurs in 20% of the African American population, was
also responsible for causing decreased functionality of the protein. The results for T116S
were along the same degree of severity as the E212K mutation. The main difference
appeared in the stability of the variant, with T116S demonstrating a thermal stability
equivalent to that of WT. Since the T116S variant is not unstable, it would not degrade
in the circulating erythrocytes, and thus not generate the same level of presentation as the
E212K mutation. This could explain why individuals with the polymorphism appear
healthy and without signs of methemoglobinemia.

The combination of the T116S

substitution with E212K does however increase the detrimental effects of both mutations.
The proposition that the presence of the polymorphism T116S in conjunction with
the mutation E212K may potentially increase the effect of the mutation was analyzed by
characterization of a double mutant containing both substitutions.

Similar results were

observed for the double mutant as were observed in the E212K variant, with the
detrimental effects to catalytic efficiency and stability presenting to an even greater
degree than with the E212K substitution alone. Again, it would seem that the greatest
impact of the mutations is in decreasing the stability of the protein, decreasing the life
span of the protein in the erythrocytes.
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Mutagenesis of conserved residue G179: Role in Pyridine Nucleotide Specificity
Within the cb5r primary structure, four sequence motifs have been identified that
are involved in either flavin binding (“RxYTSxxSN”) and FAD/FMN selectivity
(“GxxST”), or reduced pyridine nucleotide binding (“GxGxxP” and “CGxxxxM”) [22,
136] together with several residues that have been shown to regulate NADH/NADPH
sepcificity [123]. One of the conserved motifs involved in pyridine nucleotide binding
corresponds to the six amino acid residue motif, “GxGxxP”, that comprises residues
G180 to P185 in the carboxyl-terminal lobe of rat cb5r (Figure 33). However, structural
studies have identified a number of additional residues that also surround this motif in the
primary sequence and which are potentially involved in regulating nucleotide binding,
including G179, which is obligatorily conserved in all cb5r primary structures identified
to date with the exception of the outer mitochondrial membrane form of S. cerevisiae
cb5r [137].
Within the X-ray structure of the rat cb5r diaphorase domain (PDB=1I7P), G179
has been shown to be located at the terminus of the strand Nβ1, which is part of a sixstranded parallel β-sheet motif, and just prior to the start of the helix NαΑ, which
comprises residues G180 to K195, both of which comprise part of the pyridine
nucleotide-binding lobe [58]. Residues G179 to G182 form a compact four residue
segment of the sequence that effectively reverses the direction of the polypeptide
backbone and initiates the start of the α-helical segment. In addition, analysis of the
diaphorase domain structure obtained in complex with NAD+ (PDB=1IB0) has revealed
that while G179 provides no direct electrostatic or hydrogen bond contacts with either the
nicotinamide or ribose moieties of the bound NAD+, the two conserved glycine residues
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in the adjacent “GxGxxP” motif, corresponding to G180 and G182, do participate in
Species
H. sapiens
B. taurus
S. scrofa
R. norvegicus
M. musculus
G. gallus
D. rerio
I. furcatus
X. laevis
D. melanogaster
A. gambiae
C. elegans
S. japonicum
A. thaliana
C. maxima
Z. mays
O. sativa
M. acuminata
S. pombe
N. crassa
M. alpina
L. major
G. zeae
D. disciodeum
P. falciparum
S. cerevisiae
S. cerevisiaeOM

Sequence
173

SVGMIAGGTGITPMLQVIRAI193
173
SVGMIAGGTGITPMLQVIRAI193
145
SVGMIAGGTGITPMLQVIRAI163
173
SVGMIAGGTGITPMLQVIRAV193
176
KLGMIAGGTGITPMLQLIRAI197
127
HLGMIAGGTGITPMLQLIRHI147
176
SLGLIAGGTGITPMLQLIRDI196
173
HLGMIAGGTGITPMLQIIRGI193
173
HLGMIAGGTGITPMLQLIRAI193
184
RVNMIAGGTGITPMLQLAREV204
229
QVGLIAGGTGITPMLQLIREV249
182
HLSMIAGGTGITPMLQVIAAI202
177
RVNMICGGSGITPMFQLLSYI197
155
AFGMLAGGSGITPMFQVARAI175
189
HIGMIAGGTGITPMLQVIDAI209
153
AFGMLAGGSGITPMFQVARAI173
179
QIGMIAGGTGITPMLQVVRAI199
38
DIGMIAGGTGITPMLQVIKAI58
168
HFGMIAGGTGITPMLQIIRAV188
175
HFGMVAGGTGITPMLQVIRAI195
165
AIGMIAGGTGLTPMLQIIRAI185
167
AYAAIAGGTGITPILQIIHAI187
142
KIGLIAGGTGITPMFQVIRAV162
161
SIGMLAGGTGITPMLQVIKAI181
220
HIVMIAGGTGMTPFFRLINHL240
186
HLGMIAGGTGIAPMYQIMKAI206
161
SITLLGAGTGINPLYQLAHHI181
:: :*:*::*: ::

Accession #
NP_000389
P07514
1NDH
P20070
NP_084063
XP_416445
AAH45880
CK408748
BC045265
NM_168479
XM_309347
NP_504638
AAP05890
T52470
AAK69398
AAD17694
AK071324
AAR88781
NP_587852
XP_322302
AB020034
CAB92390
BAC66099
EAL64774
CAD52795
CAA86908
P36060

Figure 33.
Multiple sequence alignment of cb5r primary structures. Various
eukaryotic cb5r amino acid sequences deposited in GenBank were retrieved, aligned
using the CLUSTAL X algorithm and the alignment optimized for maximum sequence
conservation. Only the portions of the sequences surrounding the conserved pyridine
nucleotide-binding “GxGxxP” motif are shown for clarity. Beginning and ending residue
numbers within the translated GenBank sequences are indicated by superscripts while the
conserved glycine residue corresponding to G179 in R. norvegicus cb5r is shown in bold
face and underlined. The consensus sequence is also shown below with identical residues
indicated by “*” and similar residues indicated by “:”. S. cerevisciaeOM corresponds to
the sequence of the outer mitochondrial form of S. cerevisciae cb5r.
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hydrophobic contacts with the nicotinamide portion of the pyridine nucleotide substrate
(Figure 34).
The “GxGxxP” pyridine nucleotide-binding motif is conserved in all other
members

of

the

ferredoxin:NADP+

reductase

superfamily

of

flavoprotein

transhydrogenases, including the prototypical member, FNR [22]. However, the nature of
the residue preceding the motif exhibits some heterogeneity, although amino acids with
primarily hydrophobic side chains appear to comprise the most frequently utilized
residues. Further, studies of the determinants of coenzyme specificity in Anabaena
PCC7119 FNR have indicated that amino acid residues that are not directly situated in the
2’-phosphate NADP+ interacting region, such as T155 (which is equivalent to G179 in
cb5r), may influence NADP+/NAD+ selectivity [138].
To probe the role of G179 in cb5r structure and function, mutant constructs
encoding for the variants G179A, P, T, and V were generated through site-directed
mutagenesis as described in “Methods” utilizing the original four-histidine tagged cb5r
expression construct and the corresponding oligonucleotide primers listed in Appendix B.
The selected amino acid residues (A, P, T and V) have been shown to commonly occur at
the equivalent positions within other members of the FNR superfamily. The goal of these
mutations was to examine the effects of these substitutions on the spectroscopic and
thermodynamic properties of the FAD prosthetic group and interactions with the
physiological reducing substrate, NADH.
Mutant constructs encoding the four different cb5r variants, G179A, P, T and V,
which corresponded to the most frequently encountered amino acid residues occurring at
positions corresponding to G179 in the FNR superfamily of pyridine nucleotide108

dependent flavoprotein transhydrogenases, were generated through directed mutagenesis
of the original four-histidine tagged cb5r construct. Nucleotide sequencing confirmed the

NAD+
G180

G179

G182

T181
T184

I183

P185

Figure 34. Structural Model of G179 and the “GxGxxP” Motif. Schematic diagram
of a portion of the R. norvegicus cb5r X-ray crystal structure (PDB = 1IB0) showing the
arrangements of the amino acids that comprise the conserved “GxGxxP” motif and
residue G179 that precedes the motif. Amino acid residues are shown in “ball and stick”
representation using the CPK color scheme while the appropriate portion of the peptide
backbone is displayed as a ribbon diagram. The location of the complexed NAD+ is
shown in “stick” representation using the CPK color scheme.
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fidelity of each construct and each of the mutant proteins was subsequently expressed in
the E. coli strain BL21(DE3)-RIL and purified to homogeneity by Ni-chelate
chromatography and gel filtration FPLC. Evaluation of the expression yields of the
various mutants indicated that all four G179 variants were expressed at levels comparable
to that of the WT domain. All four mutants were purified to apparent homogeneity as
evident by the presence of single protein bands following SDS-PAGE analysis of the
various mutants, which also indicated molecular masses comparable to that of the native
enzyme (Mr approx. 32 kDa).
The oxidized forms of all four purified G179 variants were yellow in color
indicating the incorporation of a flavin prosthetic group and confirming that G179 did not
provide backbone or side-chain contacts that were essential for the stable incorporation of
the flavin prosthetic group into any of the cb5r variants.
UV/visible absorbance spectra were obtained for oxidized samples of each mutant
and WT cb5r and are compared in Figure 35A. The G179A, G179P, G179T and G179V
variants each exhibited spectra comparable to that of the WT enzyme with an aromatic
absorption maximum detected at 270 nm in the UV region of the spectrum, and a peak at
461 nm with an associated pronounced shoulder in the range of 485-500 nm in the visible
region of the spectrum, attributable to protein-bound flavin. None of the mutant visible
spectra were blue-shifted with respect that of the WT protein, as has been previously
demonstrated for mutations of other residues, such as R91P [102] and Y93H [1221],
suggesting that none of the G179 substitutions had any significant influence on the
spectroscopic properties of the FAD. Blue shifts in the visible absorbance spectra of
flavoproteins have previously been attributed to changes in the hydrophilicity of the
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flavin environment near the N(5) locus of the isoalloxazine ring

Figure 35.
Ultra-Violet, Visible, and Circular Dichroism Spectra Obtained for
the G179 Series of cb5r Variants. (A) UV/visible absorption spectra were obtained for
oxidized samples of cb5r and the various G179 mutants at equivalent flavin
concentrations (1.7 µM FAD) in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH
7.0. The inset shows an expanded region of the visible spectrum where the flavin
prosthetic group makes a major contribution. Individual spectra correspond to WT cb5r (
____ ); G179A ( ----- ); G179P ( ….. ); G179T ( -.-.- ) and G179V ( -..-..-). (B) UV CD
spectra were recorded using enzyme samples (7 µM FAD) in 10 mM phosphate buffer,
containing 0.1 mM EDTA, pH 7.0. (C) Visible CD spectra were recorded using enzyme
samples (50 µM FAD) in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0.
Line styles shown in “B” and “C” are the same as those depicted in “A”.
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[139, 140]. Absorbance ratios (A280 nm/461 nm) were within the range 6.1+0.2 for all four
mutants and were comparable to that obtained for WT cb5r indicating a full complement
of the FAD prosthetic group.
To assess the secondary structural content of each of the mutant enzymes, CD
spectra were recorded in the UV wavelength range (190-300 nm). As shown in Figure
35B, all of the cb5r variants exhibited positive CD from 190-210 nm and negative CD
from 210-250 nm with all the spectra retaining both positive and negative intensities very
similar to that of the WT domain. The absence of any significant differences between the
spectra of the WT and mutant proteins suggested conservation of the secondary structure
architecture and that none of the G179 residue substitutions had any deleterious effects
on the folding of the diaphorase domain.
Visible CD spectroscopy was utilized to examine the environment of the FAD
prosthetic group. As shown in Figure 35C, all four mutants exhibited visible CD spectra
that were virtually indistinguishable from that of the WT domain and indicated that none
of the amino acid substitutions had any significant effect on the conformation of the
bound chromophore. Previous spectroscopic analyses of cb5r mutants containing altered
residues that are involved in FAD-binding, such as S127 [122], have revealed visible CD
to be a sensitive indicator of flavin conformation changes.
The extent of quenching of the intrinsic fluorescence due to the FAD prosthetic
group of cb5r has also proven to be a sensitive indicator of the retention of the native
flavin environment. To probe the flavin fluorescence quenching of the various G179
mutants, both excitation and emission fluorescence spectra were recorded prior to and
following heat denaturation of the various mutants. Prior to denaturation, WT cb5r and
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the G179 variants quenched the flavin fluorescence to varying degrees ranging from 95%
for the WT enzyme to only 60% for the G179V variant, with the G179A, P, and T
variants being quenched 89%, 81%,and 68% respectively.
To examine the influence of the various G179 residue substitutions on the
stabilities of the resulting proteins, thermal denaturation profiles were generated for WT
cb5r and each of the mutant proteins by measuring both changes in the intrinsic flavin
fluorescence emission intensity (λem=523 nm) and retention of NADH:FR activity
following incubation of the proteins at temperatures ranging from 0–100 °C. Changes in
the intrinsic fluorescence of the cofactor or the retention of NADH:FR activity following
thermal denaturation was an effective indicator of the stability of the core structure of the
protein. T50 values (the temperature at which 50% of maximum fluorescence or 50%
retention of NADH:FR activity was detected) increased in the order G179A < G179P <
G179T < WT < G179V with all variants exhibiting T50 values in the range between 52
and 57°C, which suggested that none of the substitutions had a dramatic effect on the
thermal stability of flavin binding. The G179T variant exhibited a T50 value of
approximately 54°C, in good agreement with the value of 55°C obtained for WT cb5r.
The A and P variants exhibited slightly lowered T50 values at 53°C and 52°C
respectively, while the V mutation caused an increase in the value to 57oC, suggesting a
potential small increase in stability. These results suggested that substitution of G179
with alanine, proline, threonine or valine residues had only modest effects on the thermal
stability of the different cb5r variants.
Initial-rate kinetic analyses were performed on all four cb5r G179 mutants to
evaluate the effects of the various residue substitutions on NAD(P)H utilization. Values
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derived for kcat and Km for both NADH:FR and NADPH:FR activities of the various
mutants are given in Table 13A and 13B respectively together with the corresponding
values obtained for WT cb5r.
With the exception of the G179A variant which retained 70% of WT activity with
a corresponding four-fold decrease in affinity for NADH, the remaining three variants
exhibited both substantially decreased NADH:FR activities and NADH affinities with the
G179V variant showing the most dramatic changes. NADH catalytic efficiencies, as
indicated by kcat/KmNADH, were observed to decrease in the order WT > G179A > G179P
> G179T > G179V with the G179V variant retaining only 0.01 % of the NADH:FR
efficiency of the WT protein. In contrast, NADPH:FR efficiencies, as indicated by the
values of kcat/KmNADPH, were only modestly altered and increased in the order G179P <
G179V < G179T < WT < G179A with the G179A mutant exhibiting the smallest
increase in NADPH:FR efficiency, corresponding to approximately 8%, when compared
to the WT protein. It should be noted that while none of the G179 variants displayed the
desired properties of rapid turnover of NADPH together with a high Michaelis constant
for NADH, the G179V variant exhibited both significantly decreased activity with
NADH coupled with a substantial decrease in NADH affinity combined with an
increased affinity for NADPH.
However, the values for the NAD(P)H specificity constant (defined as the ratio of
{kcat/KmNADPH}/{kcat/KmNADH}) listed in Table 15, and which reflect the magnitudes of the
individual kcat and Km values obtained for both NADH and NADPH, were observed to
increase in the order WT < G179A < G179P < G179T < G179V. As anticipated, the
relatively conservative substitution of G179 with alanine had the lowest impact on
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Table 13. NAD(P)H:FR and NADH:BR kinetic constants obtained for G179 mutants.

A.

cb5r
Variant
WT H4cb5r
G179A
G179P
G179T
G179V

kcat
(s-1)
800+17
595 + 18
42 + 2
33 + 2
12 + 1

NADH:FR
kcat/KmNADH
(s-1 M-1)
(µM)
6+1
1.4+0.3x108
25 + 2
2.3+0.2x107
595 + 40 7.1+0.8x104
662 + 37 5.1+0.5x104
1077 + 78 1.1+0.2x104
KmNADH

B.

WT H4cb5r
G179A
G179P
G179T
G179V

Nucleotide
Specificity
Constant

NADPH:FR

cb5r
Variant

KmFe(CN)6
(µM)
8+1
8+1
7+1
8+1
7+1

kcat
(s-1)

KmNADPH
(µM)

kcat/KmNADPH
(s-1 M-1)

∆a

33+5

924+15

3.6+0.3x104

2.6x10-4

1360 + 322
2317 + 702
507 + 145
375 + 25

3.9 + 0.2x104
8.4 + 0.4x103
2.6 + 0.1x104
2.2 + 0.1x104

1.7x10-3
1.2x10-1
5.1x10-1
1.9x100

48 + 8
17 + 3
12 + 2
8+1

a

The nucleotide specificity constant, ∆, is defined as the ratio
{(kcat/KmNADPH)/(kcat/KmNADH)}.
C.

NADH:BR
Variant
Kmcyt b5
kcat
-1
(s )
(µM)
WT H4cb5r 600 + 17
12 + 2
245 + 17
G179A
8+1
G179P
10 + 1
1 + 0.1
G179T
18 + 2
43 + 2
G179V
17 + 2 107 + 8

altering the degree of NAD(P)H selectivity, corresponding to only an approximately 7fold increase in NADPH selectivity. This can be contrasted with increases of 304-fold
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and 462-fold for the G179P and G179T variants, respectively, whereas the greatest
increase in NADPH selectivity, corresponding to 7,692-fold enhancement, was observed
for the G179V mutant.
To compare the interactions of the various G179 variants and WT cb5r with
various pyridine nucleotides, differential spectroscopy was utilized to monitor complex
formation. Alterations of the flavin visible absorbance spectrum, shown in Figure 36,
were detected for the WT enzyme during titrations with H4NAD and NAD+, but not with
H4NADP or NADP+. These tetrahydronicotinamide derivatives do not function as
hydride donors when substituted for NADH in either the NADH:FR or NADH:BR cb5r
assays but are valuable tools for examining the binding affinity for NADH and NADPH,
respectively. Both H4-nucleotides are close isosteric analogues and are assumed to
involve the same contacts at the active site as NADH or NADPH, but lack the positive
charge on the nicotinamide ring that is present on NAD+ and NADP+, respectively. In
contrast, for the G179 mutants, spectral differences indicating detectable complexes were
only observed for the G179A variant with H4NAD, yielding a Ks of 238 µM, which may
be compared with the corresponding value of 85 µM obtained for WT cb5r. Values for
the Ks determinations are given in Table 14.
These results suggested that pyridine nucleotides containing a 2’-phosporyl
groups were most readily accommodated by the G179V variant. That the WT cb5r
showed no detectable complex formation with any of the 2’-phosphorylated nucleotides
suggests a significant role for G179 in discriminating between NADH and NADPH.
To examine whether substitution of G179 influenced NAD(P)H utilization
through modulation of the flavin oxidation-reduction midpoint potential, potentiometric
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titrations were performed using the dye equilibration method for WT cb5r and the
different G179 variants in the presence of phenosafranine (Eo’= -252 mV) as indicator.
Flavin midpoint potentials (Eo’, n=2) were determined for the enzymes alone and in

Figure 36. Spectroscopic Titrations Obtained for the G179 Series of Variants in the
Presence of H4NAD and NAD+. Difference spectra were obtained for both WT cb5r and
the selected G179 mutants at equivalent flavin concentrations (50 µM FAD) in 20 mM
MOPS buffer, containing 0.1 mM EDTA, pH 7.0 following titrations with either H4NAD
(left panels) or NAD+ (right panels) as described in “Methods”. (A and B) WT cb5r; (C
and D) G179A; (E and F) G179T. G179P and G179V gave spectra identical to G179T.
The insert panels correspond to plots of the magnitudes of the observed spectral
perturbations (peak to trough measurements at the indicated wavelengths) versus ligand
concentration. The corresponding Ks values are given in Table 16.
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complex with NAD+. Qualitative analysis of the individual spectra obtained from the
various titrations indicated that the majority of the phenosafranine was reduced prior to
FAD reduction for all four G179 variants and WT cb5r in the absence of any pyridine
nucleotide, suggesting the flavin midpoint potentials were more negative than that of
phenosafranine, for all the cb5r variants examined. Analysis of the spectra obtained for
the G179A and G179P variants and WT cb5r in the presence of NAD+ revealed that the
majority of the flavin was reduced prior to the dye, suggesting that complex formation
significantly perturbed the flavin midpoint potentials to values more positive than that for
phenosafranine for these three proteins. In contrast, the presence of NAD+ had less effect
on the titration behavior of the G179T and G179V variants, suggesting little perturbation
or modulation of the FAD redox potential.

Table 14. Spectral Binding Constants (Ks) and Standard Midpoint Potentials (Eo′)
Obtained for the G179 Series Variants

cb5r
Variant

H4NAD

Ks
(µM)

NAD+

Ks
(µM)

WT H4cb5r 45 ± 10
553 ± 30
238 ± 33 1083 ± 260
G179A
NDa
G179P
NDa
a
G179T
ND
NDa
G179V
NDa
NDa

E°′ FAD/FADH2
(mV)

-NAD+ +NAD+
-271
-272
-270
-271
-274

-191
-208
-224
-254
-262

a

ND indicates that the spectroscopic binding constant could not be determined,
due to insufficient spectral change.

The flavin redox potentials (n=2) for the different G179 variants and WT cb5r
alone or as the enzyme-nucleotide complex were determined from the Nernst semi-log
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plots shown in Figure 37B and C. The standard midpoint potentials obtained for the
FAD/FADH2 couple in both the WT enzyme (Eo’= -272 mV) and the different G179
variants (Eo’= -270 mV to -274 mV) were approximately equivalent for all five proteins
in the absence of any pyridine nucleotide, the values spanning a range of only 4 mV. In
contrast, significant differences in flavin midpoint potential were observed for the WT
cb5r and the G179 variants in the presence of NAD+. In the presence of NAD+, the redox
potential of the FAD/FADH2 couple in the WT enzyme was positively-shifted by 78 mV
(Eo’= -193 mV) which may be compared to the values of -207 mV for the G179A variant,
-225 mV for G179P, -254 mV for G179T and -263 mV for G179V, respectively,
illustrating that the progressively decreased affinity for NAD+ observed in the G179
variants was reflected in progressively smaller perturbations of the flavin redox potential.
Values obtained for the midpoint potentials both in the absence and presence of NAD+
are given in Table 14.
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A

B

Figure 37. Oxidation-Reduction Midpoint Potentials for the FAD Prosthetic Group
in the G179 Series of cb5r Variants. Reductive dye-equilibration titrations of WT and
the different G179 variants of cb5r (40 µM FAD) were performed as described under
“Methods”. Individual spectra were collected at 2-3 min intervals during the time course
of the titrations. (B) Nernst plots obtained for the FAD/FADH2 couple (n=2) are shown
for the titrations of the various G179 mutants and correspond to WT cb5r ({), G179A
( ), G179P (U), G179T (V) and G179V (). (C) Nernst plots obtained for the
FAD/FADH2 couple (n=2) in the presence of NAD+ (2 mM) are shown for the titrations
of the various G179 mutants and correspond to WT cb5r (z), G179A (), G179P (c),
G179T (T) and G179V ()
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Summary of Mutagenesis of conserved residue G179: Role in Pyridine Nucleotide
Specificity
The preceding results provide the first documented insights into the role of G179
in maintaining both the structure and function of cb5r and contribute additional evidence
to support a role for this residue (or its equivalent) in modulating the pyridine nucleotide
selectivity within the flavoprotein transhydrogenase superfamily of enzymes.
A multiple alignment of the 50 currently known cb5r primary structures deposited
in GenBank revealed that of the approximately 275 residues that comprise the flavin- and
NADH-binding domains together with the intervening “hinge” region, G179 represents
one of only thirteen conserved residues within the cb5r sequences, suggesting a
potentially important role in functionality. Of the thirteen residues, four (Y93, T94, P95
and G124) and seven (G179, G180, G182, P185, N209, I215 and G274) are distributed
throughout the FAD- and NADH-binding lobes, respectively, while two (G143 and P144)
are present in the connecting “hinge” region. Several of these conserved residues are
components of the four sequence motifs that are characteristic of the flavoprotein
transhydrogenase family and have been the subject of previous studies that have
contributed to our understanding of the roles of individual residues such as Y93 [121],
T94 [43] and P144 [120].
To probe the role of G179 in substrate binding, hydride transfer, and
NADH/NADPH discrimination, we have substituted the glycine residue with alternate
amino acids that are primarily found at the equivalent position in other members of the
FNR superfamily. Analysis of 1293 sequences that contain the “NAD binding 1” domain,
identified within the Pfam database (PF00175) [141] and that contain the conserved
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“GxGxxP” nucleotide-binding motif, revealed that only a limited number of different
residues were observed at the position preceding this motif, which corresponded to G179
in cb5r. Proteins containing the “NAD binding 1” domain exhibited a marked preference
for residues that were either proline, threonine or alanine, in addition to the dominant
residue, glycine.
The results of our mutagenesis studies revealed that substitution of G179
primarily affected the kinetic properties of the enzyme with no significant adverse effects
on the properties of the FAD chromophore. Absorption and CD spectra and FAD/FADH2
redox potentials in the absence of NAD+ for all four G179 variants were comparable to
those of WT cb5r, as would be anticipated for mutations limited to the NADH-binding
lobe. In contrast, the four amino acid substitutions, A, P, T and V, were observed to
adversely impact NADH utilization, both in terms of decreasing kcat and increasing Km,
with the magnitude of the perturbations greatest for the P,T and V substitutions. The
changes in NADH affinity were also reflected in the absence of spectral changes
observed during the H4NAD and NAD+ titrations and the more modest shifts in the flavin
redox potential in the presence of NAD+.
The crystal structure of the cb5r-NAD+ complex [58], has revealed that G179 is
situated approximately 4-5 Å distant from the nucleotide opposite the pyrophosphate
moiety and in a cleft formed by the ribityl and ribose moieties of NAD+. G179 is not
involved in any direct contacts with the pyridine nucleotide, suggesting that side chain
substitutions should not adversely impact substrate utilization. However, G179 and G180
comprise part of a tight 180o turn within the polypeptide backbone that is situated at the
apex of strand Nβ1 within the NADH-binding lobe and which precedes helix Nα1 which
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forms part of the “GxGxxP” motif. Strand Nβ1 also makes extensive contacts with strand
Nβ5, which comprises part of the second conserved pyridine nucleotide-binding motif
corresponding to residues C273 to M278 (“CGxxxM”). This motif contains the activesite cysteine residue considered to be critical for accurately positioning the nicotinamide
moiety prior to efficient hydride transfer [104]. Analysis of the crystal structure indicates
that the close packing of side chains in this region effectively precludes accommodation
of side chains other than that of glycine, and to a limited extent that of alanine, and that
substitution by more bulky groups, such as those of P, T or V, would potentially result in
distortion of the backbone configuration in the region of this turn that would be
accompanied by displacement of the side chain of C273 with concomitant decreases in
both activity and substrate affinity.
While the results of our mutational studies could be adequately described in terms
of potential alterations in the positioning of residues comprising the two conserved
pyridine nucleotide-binding motifs, the observed changes in NADH/NADPH
discrimination were less obvious. Our prior studies of NADH/NADPH discrimination
have been limited to evaluating the contributions of D239 and F251 [123] towards
regulating pyridine nucleotide specificity. Analyses of a series of both single and double
mutants revealed that while F251 contributed modestly to specificity, construction of a
D239T variant resulted in an approximately 40,000-fold increase in the efficiency of
NADPH versus NADH utilization. In contrast, the results generated by our G179 mutants
revealed the greatest increase in NADPH/NADH discrimination, corresponding to an
approximately 8,000-fold increase, was achieved for the G179V variant.
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Both sequence and structural analyses have indicated that several residues
participate in NAD(H)/NADP(H) discrimination within the FNR superfamily. Changes in
NAD(P)(H) specificity have been described for other constituents including FNR [142],
cytochrome P450 reductase [143] and assimilatory nitrate reductase [144, 145], with the
latter the only example of pyridine nucleotide coenzyme studies that examined both
NADH- and NADPH-specific isoforms of the enzyme. For nitrate reductase, mutagenesis
of two residues, S920 and R932 in the NADPH-specific isoform, resulted in a 7.3x104fold change in nucleotide specificity whereas substitutions of the same residues in the
NADH-specific isoform resulted in only a 6.2x103–fold alteration in selectivity.
However, these studies of FNR family members have primarily focused on residues that
specifically interact with the 2’-phosphoryl group while additional amino acid residues
clearly participate in regulating pyridine nucleotide selectivity.
Sequence alignments of FNR family members indicate that most of the
constituents that favor NADP(H) as a substrate primarily contain the sequence
“TPVGxGxxP” whereas those that utilize NAD(H) retain a glycine prior to the motif.
Mutational studies of the residue prior to the “GxGxxP” motif, corresponding to G179
within cb5r, have previously been limited to analyses of T155 in Anabaena PCC7119
ferredoxin:NADP+ reductase [138]. In FNR, the hydroxyl group of T155 has been
suggested to function in NADP+/NAD+ selectivity by participating in a H-bond network
that is involved in maintaining the correct backbone architecture of a loop comprising
residues 261-268 (CGLRGMEE) within the nucleotide-binding lobe that is required for
correctly orienting the bound NADP+ for hydride transfer. Generation of the T155G
variant revealed displacement of this loop together with an increased affinity for NAD+
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and decreased affinity for NADP+. Within cb5r and other NAD(H)-utilizing FNR
variants, an alternate arrangement of the H-bond network is observed, together with a
hairpin-like loop structure, corresponding to residues 272 to 280 (CGPPPMIQ), rich in
proline residues. The organization of this proline-rich region would be disrupted by T, P
or V substitutions at G179, resulting in NADH binding in an altered conformation that
both decreased NADH activity and affinity whereas the catalytic efficiency with NADPH
would potentially remain unchanged. The current work complements the studies of
Anabaena FNR and illustrates that mutating the residue preceding the “GxGxxP” motif
can alter pyridine nucleotide specificity in favor of either NAD(H) or NADP(H) with
varying degrees of efficiency.
Finally, it should be noted that the efforts to alter the NADH/NADPH specificity
of cb5r have not generated changes of the magnitude produced for some other
dehydrogenases, such as S. cerevisiae format dehydrogenase, where construction of the
D196A/Y197R double mutant resulted in a 2,500,000-fold change in NAD+/NADP+
specificity [146]. However, it is clear that for cb5r, residues positioned both at the
pyridine nucleotide-binding site, such as D239 [123] and some distance away, including
G179, can each have a profound impact on NAD(P)H selectivity, suggesting that multiple
mutations may be required to effectively reverse the enzyme’s pyridine nucleotide
selectivity.
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Systematic analysis of the conserved NADH binding motif “180GxGxxP185”
In all members of the FNR family, a highly conserved motif of three residues,
corresponding to “GxGxxP”, can be identified, and has been shown to be involved in the
binding and association of the enzyme with NAD(P)H. Analysis of the crystal structure
of cb5r allows for visualization of the importance of this motif in the proper orientation
of the NADH substrate.

Located at the amino-terminus of the 16-residue helical

segment Nα1, this motif plays a vital role in correctly aligning and positioning the
NADH for efficient electron transfer.

The leading three residues, along with the

preceding residue G179, form a compact segment that effectively reverses the direction
of the polypeptide backbone, generating a “flattened” surface against which the NAD+
can position. The three ubiquitously conserved residues of this motif each participate in
hydrophobic interactions with the nicotinamide portion of the pyridine nucleotide
substrate, in the case of G180 and G182 (Figure 38), or, in the case of P185, the
isoalloxazine ring of the FAD cofactor (Figure 39). These interactions in conjunction
with the tendency for glycine and proline residues, in general, to play roles in organizing
and directing the backbone structure of polypeptides, suggest that the major part that the
GxGxxP motif plays in cb5r function is as a scaffolding around which the NADH
substrate is able to orient in order to result in efficient electron transfer.
In addition to the three ubiquitously conserved residues of this motif, the three
intervening residues, T181, I183, and T184, each show a high level of conservation, with
only a minor few substitutions seen in the sequences of other cb5r variants or in other
members of the FNR family. X-ray crystallographic studies of cb5r in the presence of
NAD+ have indicated that both T181 and T184 form potentially crucial hydrogen bonds
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Figure 38. Electrostatic Interaction of Amino Acid Residues G180, T181, and G182
with NAD+ Bound to Cytochrome b5 Reductase. Ligplot [99] of 1IB0. C, O, N, and P
atoms are represented as white, blue, red, and violet spheres, respectively, while covalent
bonds are violet sticks within NAD+ and orange sticks within amino acid residues of the
NADH-binding lobe. Hydrogen bonds are drawn as green dashed lines with distances
between atoms labeled.
Residues contributing to hydrophobic interactions are
represented as arcs with rays and colored red. Referenced residues highlighted with red
circle.
with the substrate and cofactor respectively. The side chain of T181 forms a hydrogen
bond interaction with nicotinamide ribose of NAD+ (Figure 38), while T184 forms two
side chain hydrogen bonds with the O4 and N5 atoms of the isoalloxazine ring of FAD
(Figure 39). Additionally, the T94 equivalent in porcine cb5r (T66) has previously been
shown to be involved in the stabilization of semiquinone intermediates within the
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reaction mechanism of cb5r [43]. This residue lies within 4.02Å of residue T184, and
also forms a backbone hydrogen bond to N5 of the isoalloxazine ring of FAD.
Additional mutagenesis studies of T94 demonstrated that substitution of this residue
hinders the release of a proton from the N5 position necessary for efficient electron
transfer and proper cb5r function. The similar natures of the residues suggest that T184
may play role similar to T94 in the actions of cb5r [105].

Figure 39. Electrostatic Interaction of Amino Acid Residues T184 and P185 with
FAD Bound to Cytochrome b5 Reductase Ligplot [99] of 1IB0. C, O, N, and P atoms
are represented as white, blue, red, and violet spheres, respectively, while covalent bonds
are violet sticks within NAD+ and orange sticks within amino acid residues of the
NADH-binding lobe. Hydrogen bonds are drawn as green dashed lines with distances
between atoms labeled.
Residues contributing to hydrophobic interactions are
represented as arcs with rays and colored red. Referenced residues highlighted with red
circle.
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Finally, residue I183 does not form any interactions with either the FAD cofactor
or the NAD+ as shown by x-ray crystallography. While this could indicate a limited, if
any, role for the residue, its high level of conservation and tendency to be substituted by
residues of similar structure and side chain characteristics (valine and leucine) would
suggest that the presence of non-polar residue at this position is necessary for proper
activity of cb5r, potential through affects, or lack there of, on neighboring residues in the
tertiary structure.
Overall, the high level of interaction of the residues of this motif with both the
cofactor and substrate suggest a pivotal role for this motif in the proper functioning of
cb5r. To probe the characteristics of the individual residues of this motif and the role
they play in the function of cb5r, a series of substitution mutants were generated for each
residue. Initial studies centered on an alanine scanning of the motif, in which each
residue was individually substituted with alanine, generating six variants for
characterization. Following the alanine scan, additional variants were generated based on
one of two criteria. For the ubiquitously conserved residues, the substitutions were based
upon the characteristic nature of the side chains and the proposed structural role of the
residues. For the intervening residues, variants were based upon naturally alternate
residues that occur naturally in equivalent positions in other cb5r variants or in members
of the FNR family. The mutants generated and characterized for this aim were G180A,
G180P, T181A, T181I, T181S, G182A, G182P, I183A, I183F, I183l, I183M, T184A,
T184H, T184S, T184V, P185A, and P185G.

129

Characterization of Alanine Substitution Mutants of 180GtGitP185
Mutant constructs encoding for the variants G180A, T181A, G182A, I183A,
T184A and P185A were generated through site-directed mutagenesis as described in
“Methods” utilizing the original four-histidine tagged cb5r expression construct and the
corresponding oligonucleotide primers listed in Appendix B. Nucleotide sequencing in
both directions confirmed the correct sequence and proper introduction of each mutation,
and each variant was further expressed in the E. coli strain BL21 (DE3)-RIL and purified
to homogeneity via Ni-NTA agarose chromatography and size exclusion FPLC.
Expression yields for each of the variants were comparable to that of WT cb5r.
Purification to homogeneity was further confirmed by SDS-PAGE analysis as
demonstrated by the appearance of single protein bands, which displayed molecular
masses comparable to that of WT cb5r (Mr = 31 kDa).
UV/visible absorption spectra were obtained for oxidized samples of WT cb5r
and each of the variants generated and are shown in Figure 40A. With the exception of
T184A, each of the variants displayed absorption spectra comparable to that of the WT
domain characterized by an aromatic absorption maxima at 272 nm in the UV region and
peaks in the visible region at 386, 460, and a pronounced shoulder at 485 nm, all
characteristic of simple flavoproteins, suggesting that none of the variants generated had
any significant effects on the spectroscopic properties of the flavin prosthetic group.
T184A, however, demonstrated an altered spectrum, with a blue-shifted λmax of 457 nm
compared to that of the WT cb5r visible λmax of 461 nm. Shifts within the visible
absorption spectra of flavoproteins have previously been attributed to changes in the
hydrophilicity of the flavin environment near the N(5) locus of the isoalloxazine ring
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[102]. The absorption ratios (A276/A461) for each viable mutant were within a range of
5.5 to 5.9 which indicated a full flavin complement.
To establish the effects of each mutation upon the secondary structure of the
oxidized protein, far UV CD spectra were recorded in the range of 190–300 nm for each
variant and WT cb5r. As shown in Figure 40B, spectra of all of the mutants correlated
well to the WT domain by displaying positive CD maxima at 196 nm and negative
maxima at 222 nm, indicating that the mutations introduced had no effect on the
secondary structure characteristics of the folded protein. The visible CD spectra of all the
variants, with the exception of T184A, again displayed spectra comparable to that of WT
cb5r, indicating that these mutations did not generate alterations in the environment of the
FAD-cofactor. As shown in Figure 40C, representative spectra demonstrated that each
variant retained a similar line shape as that of WT cb5r with positive maxima at 310 and
390 nm and negative maxima at 460 and 485 nm. The spectrum for T184A demonstrated
a similar line shape to WT, with the negative maxima shifting similarly to the shift seen
in the UV-Visible Absorbance spectra.
In order to determine how the GtGitP alanine variants affected the overall
catalytic efficiency, initial-rate kinetic analyses were performed as described in
“Methods.” Kinetic values obtained from these assays are reported in Table 15. As
expected, all of the generated variants resulted in a decreased specific activity when
compared to WT cb5r, though over a wide range. For the NADH:FR assays the catalytic
efficiencies, kcat/KmNADH, for the variants were determined to range from 1.9 to 45.7%
that of the catalytic efficiency of the WT domain. The large range of effects resulted in
most cases from a combination of decreased turnover and decreased affinity.
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Figure 40. Ultra-Violet, Visible, and Circular Dichroism Spectra Obtained for the
WT cb5r and the “GtGitP” Alanine Variants. (A) Oxidized samples of WT and
mutant cb5rs (10 µM), (B) (7 µM), and (C) (60 µM) FAD in 10 mM phosphate with 0.1
mM EDTA, pH 7.0 buffer. The inset shows and expanded region of the visible spectrum
where the flavin cofactor makes a significant contribution. Individual spectra correspond
to (____) H4cb5r; (____ ____) G180A; (__ __ __) T181A; (_ _ _ _) G182A; (. . . . .) I183A; (__.__.__)
T184A; and (__. .__. .__) P185A.
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G182A, notably, increased the affinity for substrate, having a Km equal to two-thrids that
of WT cb5r. There was a definite trend showing that the ubiquitously conserved residues
had a great impact on the rate of turnover than the intervening residues. This trend did
not necessarily apply to the affects on Km, however, as negative impact was seen in all
mutants with the exception of G182.
Table 15. NADH:FR Kinetic Constants and Thermal Stability (T 50) Values for the
“GtGitP” Alanine Variants.

cb5r
Variant
WT H4cb5r
G180A
T181A
G182A
I183A
T184A
P185A

NADH:FR
kcat
(s-1)

KmNADH

KmFeCN6

800 ± 17
178 ± 15
487 ± 8
288 ± 7
640 ± 7
341 ± 12
47 ± 2

6±1
68 ± 4.3
20 ± 1.1
4.5 ± 0.3
12.7 ± 0.9
7.8 ± 0.1
15.6 ± 1.2

8±1
7±1
7±1
7±1
7±1
7±1
8±1

(µM)

(µM)

T50
kcat/KmNADH
-1
-1

(°C)

1.4 ± 0.3 x 108
2.6 ± 0.4 x 106
2.4 ± 0.2 x 107
6.4 ± 0.6 x 107
5.1 ± 0.4 x 107
4.4 ± 0.2 x 107
3.0 ± 0.3 x 106

56
52.5
53.8
52.2
51.6
53.5
51.7

(s M )

To analyze the overall protein stability of each of the variants, thermal
denaturation profiles were generated utilizing thermal NADH:FR profiling in tandem
with the loss of intrinsic flavin fluorescence emission quenching, following incubation of
the proteins at temperatures ranging from 0-100 ºC. Changes in the intrinsic fluorescence
of the FAD prosthetic group monitored together with the retention of NADH:FR activity
following thermal denaturation yielded a T50 value, the temperature at which there is 50%
of maximum fluorescence or 50% retention of NADH:FR activity. The resulting graphs
are presented in Figure 41. All variants demonstrated slightly decreased T50 values
ranging from 51.6 to 53.8ºC for the I183A and T181A mutants respectively (Table 15).
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Though decreased, these values are still comparable to WT cb5r T50 of 55ºC, only
suggesting slight decrease in stability.

Figure 41. Thermal Stability Profiles Obtained for the WT cb5r and the “GtGitP”
Alanine Mutants. Oxidized samples of G180A, T181A, G182A, I183A, T184A, and
P185A and WT H4cb5r (5 µM FAD) were incubated at the indicated temperatures, and
aliquots were withdrawn and assayed for both residual NADH:FR activity (closed
symbols) and intrinsic flavin fluorescence (open symbols) in 10 mM phosphate buffer,
containing 0.1 mM EDTA, pH 7.0 using excitation and emission wavelengths of 450 nm
and 523 nm, respectively. Points correspond to: (●,○) H4cb5r; (■, □) G180A; (▲, ∆)
T181A; (▼, ) G182A; (♦, ◊) I183A; (hexagon) T184A; and (+) P185A.

As demonstrated through the kinetic analyses, each of variants displayed an affect
on the affinity of the enzyme for the NADH substrate. Thus, spectral binding constants
were determined for each of the mutants utilizing differential spectroscopy in order to
compare the affinities for both the substrate NADH and product NAD+. As described in
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“Methods”, the NADH isosteric analog H4NAD was utilized to monitor complex
formation and establish a spectral binding constant [106]. Differential spectroscopy was
utilized to monitor complex formation during titrations with either H4NAD or NAD+.
The results are illustrated in Figures 42 and Figure 43. For each of the variants, the
titrations performed in the presence of H4NAD yielded spectra with altered line shape
compared to that of WT cb5r (Figure 41). The alterations ranged in magnitude, with
G180A, G182A, and T184A showing the most drastic alterations, adopting line shapes
characteristic of ADP-Ribose, APAD+, and NAD+ respectively. Less drastic alterations
were noticed in T181A, I182A, and P185A, each having spectra reminiscent of WT in the
presence of H44NAD, with alterations confined to the 450 to 500nm region. These
alterations presented shifted positive maxima at ~415nm (T181A) or ~450nm (I1183A
and P185A) compared to the WT spectra possessing positive maxima spectra at ~480nm.
The line shapes appeared to be hybrids of H4NAD with other NAD+ analogs, including
PAAD+ (T181A) and ADP-ribose (I183A).
Titrations performed with the variants in the presence of the product NAD+ again
produced spectra with line shapes differing from that of WT (Figure 42). In the cases of
G182A I183A T184A and P185A, the major difference was not as much in the line shape
as it was in the magnitude between spectra of increasing concentration of titrant. G182A
and T184A retained spectra most similar to that of WT, while I183 and P185A showed a
significant decrease in the magnitude of the deflections.

In addition to the decreased

magnitude, the spectra of P185A were also some what similar to that of WT in the
presence of APHD+. Spectra for G180A and T181A were drastically different than that of
WT, having spectra more comparable to WT titrations with 5’-ADP (G180A) or only
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Figure 42. Spectroscopic Titrations Obtained for the WT cb5r and the “GtGitP”
Alanine Variants in the Presence of H4NAD. Titrations of all mutants (50µM) were
carried out as previously described in 10mM phosphate buffer containing 0.1mM EDTA,
pH 7.0 at 23 °C. Difference spectra were recorded following the addition of solution
containing H4NAD (5mM). The inset panel corresponds to a plot of the magnitude of the
spectral perturbations at the indicated wavelengths versus pyridine nucleotide
concentration where a difference spectrum was observed. Plots of the relative
absorbance changes observed are as follows: (A) WT H4cb5r; (B) G180A; (C) T181A;
(D) G182A; (E) I183A; (F) T184A; and (G)P185A
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marginally similar to titration with PAAD+ (T181A).

The values obtained for the

respective binding constants (Ks) for all variants are given in Table 16. Interestingly, the
Ks values obtained for the variants in the presence of H4NAD were 1-2 times greater than
that of the WT cb5r value of 45µM, indicating an affinity and mode of binding similar to
the WT domain. Additionally, P185A demonstrated increased affinity, with a Ks value
less than that of WT. A greater effect was observed in the titrations performed in the
presence of NAD+ with the variants, excluding T184A, yielding Ks values of >3-fold
higher than WT.

Table 16. Spectral Binding Constants (Ks) and Standard Midpoint Potentials (Eo′)
Obtained for the “GtGitP” Alanine Variants.

cb5r
Variant

E°′ FAD/FADH2

Ks
H4NAD

NAD+

(mV)

Ks
Ks
-NAD+ +NAD+
(µM)
(µM)
-191
-271
533±30
WT H4 cb5r 45±10
-220
80.3±7 1974±121 -265
G180A
-202
62.5±3.9 1760±155 -270
T181A
-233
-265
74.1±4.4 802±73
G182A
-214
114±12 1817±198 -265
I183A
-217
-265
400±21
106±9.8
T184A
-214
-270
800±27
34±1.4
P185A

To examine the effects of the structural changes on the flavin prosthetic group of
each variant, oxidation-reduction potentials for the FAD cofactor were determined
utilizing the dye-equilibration potentiometric titration method for WT cb5r and the
“GtGitP” mutants in the presence of phenosafranine (E°′= -252 mV). Flavin midpoint
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Figure 43. Spectroscopic Titrations Obtained for the WT cb5r and the “GtGitP”
Alanine Variants in the Presence of NAD+. Titrations of all mutants (50µM) were
carried out as previously described in 10mM phosphate buffer containing 0.1mM EDTA,
pH 7.0 at 23 °C. Difference spectra were recorded following the addition of solution
containing NAD+ (30mM). The inset panel corresponds to a plot of the magnitude of the
spectral perturbations at the indicated wavelengths versus pyridine nucleotide
concentration where a difference spectrum was observed. Plots of the relative
absorbance changes observed are as follows: (A) WT H4cb5r; (B) G180A; (C) T181A;
(D) G182A; (E) I183A; (F) T184A; and (G)P185A
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potentials (Eº′, n=2) for the FAD/FADH2 couple were determined both in the absence and
presence of NAD+ from the linear Nernst plots of the log [FADox/FADred] versus the
potential (mV) and are shown in Figure 44. Values established for all redox potentials
are shown in Table 16. Analysis of the midpoint potentials of the alanine variants in the
absence of any pyridine nucleotide indicated that FAD reduction occurred after the
reduction of phenosafranine, resulting in values comparable to that of WT cb5r, within
the + 5mV standard error.

Midpoint titrations carried out in the presence of NAD+ all

displayed a more negative shift in the redox behavior for all of the variants yielding
values ranging from -220 for G180A to -202 for T181A. These values are similar to the
reported value of -220 mV for that of free flavin [133].
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Figure 44. Oxidation-Reduction Midpoint Potentials for the FAD Prosthetic Group
in the “GtGitP” Alanine Variants. Reductive dye titrations were performed at 25 °C as
described in “Materials and Methods” using phenosafranine as the indicator dye in 100
mM phosphate buffer containing 0.1 mM EDTA, pH 7.0. Nernst plots in the absence (A)
and presence (B) of 2 mM NAD+. Plots correspond to (●) H4cb5r; (■) G180A; (▲)
T181A; (▼) G182A; (♦) I183A; (x) T184A; and (+) P185A.
142

Characterization of additional structural variants of the “GtGitP” NADH-binding motif
of cb5r
As stated above, various substitutions of the residues of the “GtGitP” motif were
generated in order to further define the roles that the individual residues as well as the
collective motif play in the functioning of cb5r. Following the alanine screening study
described above, additional mutations were created based upon the structural quality of
the naturally occurring residue (in the case of G180, G182, and P185) or based upon
alternative naturally occurring residues in FNR family members or in species variants of
cb5r based on multiple sequence alignments (in the case of T181, I183 and T184). In the
interest of clarity, only data from the residues that generated a significant effect on cb5r
structure or function as compared to WT or that are representative of multiple results
have been reported in the following figures. The values of the spectral, kinetic, thermal
stability and electrochemistry parameters for all generated variants are reported in the
respective tables and in the text.
Mutant constructs encoding the variants G180P, T181I, T181S, G182P, I183F,
I183L, I183M, T184H, T184S, T184V, and P185G were generated through site-directed
mutagenesis as described in “Methods” utilizing the original four-histidine tagged cb5r
expression construct and the corresponding oligonucleotide primers listed in Appendix B.
Nucleotide sequencing in both directions confirmed the correct sequence and proper
introduction of each mutation, and each variant was further expressed in the E. coli strain
BL21 (DE3)-RIL and purified to homogeneity via Ni-NTA agarose chromatography and
size exclusion FPLC. Expression yields for each of the variants were comparable to that
of WT cb5r. Purification to homogeneity was further confirmed by SDS-PAGE analysis
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as demonstrated by the appearance of single protein bands, which displayed molecular
masses comparable to that of WT cb5r (Mr = 31 kDa).
UV/visible absorption spectra were obtained for oxidized samples of WT cb5r and each
of the variants. Selected spectra are shown in Figure 45A. With the exception of T184H
and V, each of the variants displayed absorption spectra comparable to that of the WT
domain by an aromatic absorption maxima at 272 nm in the UV region and peaks in the
visible region at 386, 460, and a pronounced shoulder at 485 nm, all characteristic of
simple flavoproteins, suggesting that none of the variants generated had any significant
effects on the spectroscopic properties of the flavin prosthetic group. The T184 variants,
however, demonstrated an altered spectrum, with shifted λmax of 463 and 459 nm for the
T184H and T184 V variants, respectively, as compared to that of the WT cb5r visible
λmax of 461 nm. These shifts were similar to that seen in the T184A mutant, as well as
that seen in T94H [105], and again reflect previously reported results attributable to
changes in the hydrophilicity of the flavin environment near the N(5) locus of the
isoalloxazine ring [102]. The absorption ratios (A276/A461) for each viable mutant were
within a range of 5.5 to 5.9 which indicated a full flavin complement.
In order to establish the effects of each mutation upon the secondary structure of
the oxidized protein, far UV CD spectra were recorded in the range of 190–300 nm for
each variant and WT cb5r. Spectra of all of the mutants correlated well to the WT
domain by displaying positive CD maxima at 196 nm and negative maxima at 222 nm,
indicating that the mutations introduced had no effect on the secondary structure
characteristics of the folded protein. As with the T184A mutant, the T184H variant was
the only variant that demonstrated visible CD spectra significantly different than
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Figure 45. Ultra-Violet, Visible, and Circular Dichroism Spectra Obtained for the
Wild-Type and the T184H, T184S, and T184V cb5r Variants. (A) Oxidized samples
of WT and mutant cb5rs (10 µM), (B) (7 µM), and (C) (60 µM) FAD in 10 mM
phosphate with 0.1 mM EDTA, pH 7.0 buffer. The inset shows and expanded region of
the visible spectrum where the flavin cofactor makes a significant contribution.
Individual spectra correspond to (____) H4cb5r; (__ . __ . __) T184H; (____ ____) T184S; and
(__. .__. .__) T184V. T184S spectra are representative of the spectra of variants not shown.
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that of WT cb5r, having an altered line shape as well has shifted negative maxima in the
450-470nm range, indicating that this mutation generated alterations in the environment
of the FAD-cofactor. Additionally, T184H showed an effective removal of the positive
maxima at 310nm, further indicating perturbations to the FAD binding region. Figure
45B and C depicts selected spectra to highlight the effects on the above described
characteristics. In each panel, the spectrum for T184S variant represents the spectra of
the additional mutants investigated, each being comparable to WT cb5r. Also included
are the T184H and T184V variants which showed altered spectra. Representative spectra
of the additional mutants demonstrated that each variant retained a similar line shape to
that of WT cb5r with positive maxima at 310 and 390 nm and negative maxima at 460
and 485 nm. In some cases the magnitude of the positive of negative deflections were
mildly altered, but not to a significant extent.
In order to determine how the GtGitP alanine variants affected the overall
catalytic efficiency, initial-rate kinetic analyses were performed as described in
“Methods.” Kinetic values obtained from these assays are reported in Table 17. As
expected, all of the generated variants resulted in a decreased specific activity when
compared to WT cb5r, though over a wide range. For the NADH:FR assays the catalytic
efficiencies, kcat/KmNADH, for the variants were determined to range from <.1% to 47.9%
of the catalytic efficiency of the WT domain. The large range of effects resulted in most
cases from a combination of decreased turnover and decreased affinity. The introduction
of a proline residue at G180 or G182 had drastic effects and the rate of turnover of
substrate, though only mild effects on binding of substrate. I183M and T184H both
caused a significant decrease in affinity for substrate, with Km values 6 times that of WT
146

cb5r. In both cases, this was accompanied by a decrease in the rate of activity, especially
in the case of T184H. T184V also showed a significant decrease in kcat as compared to
WT.

Table 17. NADH:FR Kinetic Constants and Thermal Stability (T50) Values
Obtained for the G180P, T181I/S, G182P, I183F/L/M, T184H/S/V, and P185G
Variants.

cb5r
Variant
WT H4cb5r
G180P
T181I
T181S
G182P
I183F
I183L
I183M
T184H
T184S
T184V
P185G

NADH:FR
kcat
(s-1)
800 ± 17
0.28 ± 0.03
310 ± 8.3
655 ± 18.3
0.07 ± .01
2 30 ± 11.7
617 ± 20.0
608 ± 28.3
24.2 ± 2.3
785 ± 23.3
52.3 ± 3.83
208 ± 5.0

KmNADH
(µM)
6±1
17 ± 4.3
22 ± 1.1
13.6 ± 0.3
7.9± 0.9
10 ± 0.1
11.8 ± 1.2
37.2 ± 0.3
31.9± 0.9
14.4± 0.1
5.1± 1.2
3.1 ± 1.2

T50

KmFeCN6
(µM)

kcat/KmNADH
(s-1 M-1)

(°C)

8±1
8±1
7±1
7±1
7±1
8±1
8±1
7±1
7±1
8±1
8±1
7±1

1.4 ± 0.3 x 108
1.7 ± 0.4 x 104
1.4 ± 0.1 x 107
4.8 ± 0.3 x 107
8.6 ± 0.2 x 103
2.3 ± 0.1 x 107
5.3 ± 0.8 x 107
1.6 ± 0.2 x 107
7.7 ± 0.1 x 105
5.5 ± 0.6 x 107
1.0 ± 0.1 x 107
6.7 ± 0.9 x 107

56.0
52.1
53.2
50.8
51.5
45.1
48.4
44.5
53.2
52.1
56.2
49.9

To analyze the overall protein stability of each of the variants, thermal
denaturation profiles were generated utilizing thermal NADH:FR profiling in tandem
with the loss of intrinsic flavin fluorescence emission quenching, following incubation of
the proteins at temperatures ranging from 0-100 ºC. Changes in the intrinsic fluorescence
of the FAD prosthetic group monitored together with the retention of NADH:FR activity
following thermal denaturation yielded a T50 value, the temperature at which there is 50%
of maximum fluorescence or 50% retention of NADH:FR activity.
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All variants

demonstrated varied levels of decreased temperature stabilities with T50 values ranging
from 44.5.6 to 56.2ºC for the I183M and T184V mutants respectively (Table 17). The
I183 variants seemed to elicit the greatest effect on the thermal stability, with all
substitutions causing a 5 to 12ºC decrease in T50 value. The graphs of the T50 data for the
I183 series of variants are shown in Figure 46. Additionally, the graphs of T181S and
T184H are shown to illustrate the range obtained for the remaining variants.
As demonstrated through the kinetic analyses, several variants displayed altered
affinities for substrate. To further investigate this alterations, spectral binding constants
were determined for each of the mutants utilizing differential spectroscopy in order to
compare the affinities for both the substrate NADH and product NAD+. As described in
“Methods”, the NADH isosteric analog H4NAD was utilized to monitor complex
formation and establish a spectral binding constant [106]. Differential spectroscopy was
utilized to monitor complex formation during titrations with either H4NAD or NAD+.
The results are illustrated in Figures 47 and Figure 48 respectively.
Titrations performed in the presence of H4NAD yielded spectra with a line shape
similar to that of WT cb5r for the majority of the variants. The T181S, T184H/S/V, and
P185G variants each showed spectra very similar to that of WT, with magnitude
differences being the main disparity among the spectra. The I183 series of variants
demonstrated an altered line shape that had qualities similar to that of WT in the presence
of H4NAD. I183L and I183M generated spectra that were similar to H4NAD between
380 and 420nm, but was more similar to WT in the presence of NAD+ in the region of
420 to 480nm. This hybrid quality to the spectra indicated an altered mode of binding.
I183F generated spectra similar to that of WT titrated with NHD+. G180P, G182P and
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Figure 46. Thermal Stability Profiles of Wild-Type cb5r and Selected Variants of
the “CGpppM” Motif. Oxidized samples of each variant and WT H4cb5r (5µM FAD)
were incubated at the indicated temperatures, and aliquots were withdrawn and assayed
for both residual NADH:FR activity (closed symbols) and intrinsic flavin fluorescence
(open symbols) in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0 using
excitation and emission wavelengths of 450 nm and 523 nm, respectively. Selected
variants shown for clarity. The graphs of T181S and T184 represent the boundaries of the
range within which the remaining variants fit. The I183 variants demonstrated the most
significant impact on thermal stability. Points correspond to: (●,○) H4cb5r; (■, □)
T181SA; (▲, ∆) I183F; (▼, ) I183L; (♦, ◊) I183M; and (x) T184H.

T181I each generated spectra that were significantly different that that of WT titrated
with H4NAD. The spectra of T181P was nearly identical to that of T181A in the
presence of H4NAD, differing only in magnitude. G180P and G182P each generated
spectra unlike any other previously analyzed NAD+ analog, suggesting a drastic alteration
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to the binding environment for NADH. The values obtained for the respective binding
constants (Ks) for all variants are given in Table 18.
Titrations performed for the variants in the presence of the product NAD+ again
produced diverse spectra with lines shapes both similar to and differing from that of WT.
Residues T181S, I183F/L/M, T184S, and P185G each generated spectra that mirrored
that of WT cb5r titrated with NAD+, differing mainly in magnitude of positive and
negative deflections only, with minor alterations in the overall line shape of the spectra.
T184H generated spectra similar to that expected for H4NAD, only differing in the
absence of the negative maxima at 395nm. The remaining variants each generated
unique spectra significantly different from WT, with the exception of G180P, which
failed to generate a spectroscopically-active species during the titration within detectable
concentrations. T181I again generated spectra similar to that obtained from T181A. The
spectra generated for G182P in the presence of NAD+ showed a high level of similarity to
the spectra it generated in the presence of H4NAD. T184V generated spectra appearing
as hybrids of the spectra obtained for WT in the presence of NAD+ with spectra from
titrations with PAAD+. The values obtained for the respective binding constants (Ks) for
all variants are given in Table 18.
To examine the effects of the structural changes on the flavin prosthetic group of
each variant, oxidation-reduction potentials for the FAD cofactor were determined
utilizing the dye-equilibration potentiometric titration method for WT cb5r and the
“GtGitP” mutants in the presence of phenosafranine (E°′= -252 mV). Flavin midpoint
potentials (Eº′, n=2) for the FAD/FADH2 couple were determined both in the absence and
presence of NAD+ from the linear Nernst plots of the log [FADox/FADred] versus the
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Figure 47. Spectroscopic Titrations Obtained for the WT cb5r and Selected
Variants of the “GtGitP” Motif in the Presence of H4NAD. Titrations of all mutants
(50µM) were carried out as previously described in 10mM phosphate buffer containing
0.1mM EDTA, pH 7.0 at 23 °C. Difference spectra were recorded following the addition
of solution containing H4NAD (5mM). The inset panel corresponds to a plot of the
magnitude of the spectral perturbations at the indicated wavelengths versus pyridine
nucleotide concentration where a difference spectrum was observed. Plots of the relative
absorbance changes observed are as follows: (A) WT H4cb5r; (B) G180P; (C) T181I; (D)
G182P; (E) I183F; (F) I183L; and (G) T184S (representative of spectra of variants not
shown)
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Figure 48. Spectroscopic Titrations Obtained for the WT cb5r and Selected
Variants of the “GtGitP” Motif in the Presence of NAD+. Titrations of all mutants
(50µM) were carried out as previously described in 10mM phosphate buffer containing
0.1mM EDTA, pH 7.0 at 23 °C. Difference spectra were recorded following the addition
of solution containing NAD+ (30mM). The inset panel corresponds to a plot of the
magnitude of the spectral perturbations at the indicated wavelengths versus pyridine
nucleotide concentration where a difference spectrum was observed. Plots of the relative
absorbance changes observed are as follows: (A) WT H4cb5r; (B) G180P; (C) T181I; (D)
G182P; (E) T184H; (F) T184V; and (G) T181S (representative of spectra of variants not
shown)
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potential (mV). Variants yielding significant alterations to the midpoints are shown in
Figure 49. Graphs of the midpoint determination for P185G are representative of the
majority of the variants. Values established for all redox potentials are shown in Table
18. Analysis of the midpoint potentials of the variants in the absence of NAD+ indicated
that FAD reduction occurred after the reduction of phenosafranine, resulting in values
comparable to that of WT cb5r, within the + 5mV standard error. Midpoint titrations
carried out in the presence of NAD+ resulted in values that were more negative, as
compared to WT, for the majority of the variants, with values ranging from -228 for
G180P to -196 for T181S.
Table 18. Spectral Binding Constants (Ks) and Standard Midpoint Potentials (E°′)
Obtained for the G180P, T181I/S, G182P, I183F/L/M, T184H/S/V, and P185G cb5r
Variants.

cb5r
Variant

E°′ FAD/FADH2

Ks
Ks H4NAD
(µM)

(mV)

KsNAD+
(µM)

533 ± 30
45 ± 10
WT H4 cb5r
NDa
370 ± 16.7
G180P
72.5 ± 7.9 1387 ± 124
T181I
63.3 ± 3.4 308 ± 5.1
T181S
211 ± 12
G182P
544 ± 89
29.7 ± 3.2
I183F
29 ± 1.5
35.7 ± 1.9
I183L
154 ± 19
36.3 ± 2.1
I183M
113 ± 14
35.1 ± 2.2 103 ± 4.9
T184H
24.8 ± 1.9
T184S
233 ± 17
62.6 ± 5.1
T184V
810 ± 23
22.6 ± 3.1
P185G
55 ± 1.6
a

-NAD+ +NAD+
-271
-275
-271
-272
-275
-276
-276
-275
-276
-276
-275
-271

-191
-227
-203
-196
-210
-209
-206
-201
-228
-198
-217
-209

ND indicates that the spectroscopic binding constant could not be determined, due to
insufficient spectral change.
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Figure 49. Oxidation-Reduction Midpoint Potentials for the FAD Prosthetic Group
in the Wild-Type cb5r and Selected Variants of the “GtGitP” Motif. Reductive dye
titrations were performed at 25 °C as described in “Methods” using phenosafranine as the
indicator dye in 100 mM phosphate buffer containing 0.1 mM EDTA, pH 7.0. Nernst
plots in the absence (A) and presence (B) of 2 mM NAD+. Plots correspond to (A) (●)
H4cb5r; (■) G180P; (▲) G182P; (▼) I183L; (♦) T184H; (x) T184V; and (+) P185G. (B)
(●) H4cb5r; (■) G180P; (▲) T181S; (▼) G182P; (♦) I183F; (x) T184H; and (+) P185G.
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Summary of Systematic analysis of the conserved NADH binding motif “180GxGxxP185”
Glycine and proline residues each confer structural qualities to the backbone of
polypeptides. Glycine, lacking a side chain, allows for a high level of rotational freedom
in the backbone, allowing a polypeptide more rotational freedom and conferring a
“plastic” like quality to the protein. Additionally, the lack of side chain eliminates steric
problems, and allow for “openness” in a protein useful, for example, in allowing substrate
to contact and bind appropriately to a protein. Proline residues, being secondary amines,
possess a distinctive cyclical structure to the side chain which confers a exceptional level
of conformational rigidity to a protein. Therefore, the presence of the residues in a highly
conserved protein domain indicates that the structural characteristics imbued by the
residues are essential for proper function. Using cb5r as a model, we can see that, in part,
the function of the GxGxxP motif in cb5r and other FNR family members would be to
create a “perch” onto which the NADH can sit to be positioned for efficient electron
transfer with the flavin cofactor. Homology modeling of the mutants of G180 (Figure
50) and G182 (Figure 51) further demonstrates how the distinct individual characteristics
of glycine residues confer the necessary structural features for the proper association of
NADH. From these models, it is evident that the slightest alterations to the side chain at
position 180 or 182, as demonstrated by alanine substitutions of these residue (Figures
50B and 51B), cause electrostatic interference with the proper fitting of the NAD+
molecule into the binding site. This effect is intensified in the proline substitutions
(Figures 50C and 51C), where actual physical steric hindrances can be noted. In the case
of G180, the effect appears mostly directed toward the pyrophosphate moiety of NAD+,
potentially

repositioning

the

nicotinamide
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and/or

adenine

moieties,

whereas

Figure 50. Structures of WT cb5r and G180A and G180P Variants with NAD+
Generated in silica. The molecular model of cb5r displaying the charged surfaces of (A)
residue G180 (blue stick) (B) cb5r variant G180A (green stick) and (C) cb5r variant
G180P (magenta stick) in association with NAD+ generated utilizing the automated
comparative protein modeling server SWISS-MODEL [111] and analyzed using the
molecular modeling software Web Lab Viewer Pro [134]. Model depicts surface
representation of the residue in transparent wire mesh display style and NAD+ in
transparent display style. Models generated from cb5r in complex with FAD and NAD+
(1IB0) where the acidic residues are red, basic residues are blue, and neutral residues are
white.
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alterations of G182 appear to affect the nicotinamide moiety directly. This observation
is further supported by the differential spectroscopy results. For G180A, spectra obtained
from titrations with NAD+ were similar to those of WT cb5r titrated with 5’-ADP. Since
5’-ADP is a structural analog of NAD+ lacking the ribose of the adenine moiety and the
nicotinamide ring, a variant demonstrating spectra similar in appearance to it indicates
that the variant is affecting the proper orientation of the NAD+, preventing either of those
groups from properly fitting. The lack of detectable spectral difference for G180P again
further indicates that placement of any obstruction in the 180 position prevents the
substrate from being able to properly bind.

The G182 variants again showed a

correlation between the molecular modeling and the differential spectroscopy in that the
spectra obtained for both G182A and G182P titrated with NAD+ were mirror images of
the spectra of WT with ADP-ribose.

This similarity indicates that the substitutions at

position 182 do indeed affect the proper association of NAD+ by affecting the aligning of
the nicotinamide moiety. As this is the portion of the molecule involved in the electron
transfer reaction with FAD, incorrect orientation of the nicotinamide ring would
drastically decrease the catalytic efficiency of the enzyme. This was evidenced in the
NADH:FR assays for these residues, yielding catalytic efficiencies less than 1% that of
WT. From this we can conclude that the two glycine residues of “GxGxxP” motif are
vital to the proper placement of the NADH to ensure correct interaction of the
nicotinamide moiety with the isoalloxazine ring of FAD.
The other conserved residue in the GxGxxP motif, P185, appears to be important
in maintaining the structural integrity of the secondary structure of cb5r in the proximity
of the pyridine nucleotide binding pocket. Substitutions of this residue did not show any
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Figure 51. Structures of WT cb5r and G182A and G182P Variants with NAD+
Generated in silica. The molecular model of cb5r displaying the charged surfaces of (A)
residue G182 (blue stick) (B) cb5r variant G182A (green stick) and (C) cb5r variant
G182P (magenta stick) in association with NAD+ generated utilizing the automated
comparative protein modeling server SWISS-MODEL [111] and analyzed using the
molecular modeling software Web Lab Viewer Pro [134]. Model depicts surface
representation of the residue in transparent wire mesh display style and NAD+ in
transparent display style. Models generated from cb5r in complex with FAD and NAD+
(1IB0) where the acidic residues are red, basic residues are blue, and neutral residues are
white.
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negative impact on the ability to associate and bind to NADH. In fact, substitution of this
position with glycine resulted in enhanced binding affinity as shown by a 2-fold increase
in KmNADH in the NADH:FR assay and increased Ks values in the titration with H4NAD,
indicating that the relaxing affects of glycine residue on the rigidity of the backbone
structure allowed for the NADH to associate better. This, however, was actually a
negative consequence overall, as it prevented the proper alignment of the NADH and
FAD resulting in highly diminished catalytic activity. A structural model of P185 and its
position in relation to NAD+ and FAD is shown in Figure 52. The isoalloxazine ring is in
proximity of the proline residue. Substituting the proline with a glycine would remove
the electrostatic interactions allowing more “openness”’ to the binding pocket of NADH
and FAD. This would explain the ability of the mutants to bind NADH with higher
affinity. Further evidence of the structural importance of P185 is shown in the decreased
stability observed in thermal denaturation studies. The relaxing of the backbone resulting
from substitution of the proline caused the FAD cofactor to become more “open” to the
environment, and as a result more easily removed, as demonstrated by an average T50
value 5 °C lower than WT.
The effects of substitutions of residue I183 on the function of cb5r also result
from structural perturbations, however with a decreased magnitude as compared to
substitution of P185.

Except in the case of I183F, the substitutions examined

demonstrated a mild decrease in rate of turnover NADH.

Additionally, with the

exception of I183M, the substitutions only mildly decreased substrate affinity. Both of
these substitutions represent non-conserved mutations in respect to side chain
characteristics. Introduction of an aromatic ring (I183F) or a polar sulfur group (I183M),
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Figure 52. Structure of WT cb5r residue P185 in Association with NAD+ and FAD
Generated in silica. The molecular model of cb5r displaying the charged surfaces of
P185 in association with NAD+ and FAD generated utilizing the automated comparative
protein modeling server SWISS-MODEL [111] and analyzed using the molecular
modeling software Web Lab Viewer Pro [134]. Model depicts surface representation of
the residue in transparent wire mesh display style and NAD+ and FAD in transparent
display style. Models generated from cb5r in complex with FAD and NAD+ (1IB0)
where the acidic residues are red, basic residues are blue, and neutral residues are white.
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produced a more severe impact on catalytic activity than the smaller non-polar
substitutions (I183A/L). This indicated that the effect of these mutations resulted from
the physical structure of the side chain.

The side chain of I183 extends toward

neighboring residues A178 and F207. Introduction of a large aromatic ring in this
location would result in steric conflicts among these residues, causing an alteration in the
local tertiary structure, sufficient to affect the functioning of the protein. Additionally,
the substitution with methionine at this position introduces a sulfur group near residue
T184, disrupting its association with FAD. The main impact of the substitution of I183
occurs as a result of decreased stability as shown by the thermal denaturation results. All
substitutions lead to a decrease in T50 values ranging from 6-12oC. While not directly
involved with catalytic function or substrate binding, the presence of a small non-polar
residue at position 183 is clearly required to assure folding into the proper tertiary
structure allowing for efficient activity of cb5r.
The potential importance of residues T181 and T184 are self-evident from studies
of the X-ray crystal structure of cb5r. Since the residues are involved in hydrogen bond
formation with the substrate and cofactor, respectively, T181 and T184 should be vital in
maintaining proper catalytic activity of the enzyme. The results of the characterization
support such a hypothesis. In the case of T181, it is evident that the polarity of the
residue is vital to correct function.

Substitution with serine yielded only mild

impairments across all spectral and catalytic parameters. Because the hydroxyl group of
serine would face in the opposite direction of that of threonine, the distance from the N3
oxygen of the nicotinamide ribose is increased by 1.07Å, and bond formation is impaired
Figure 53. Replacement of non polar residue complete eliminates the ability of bond
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Figure 53. Structures of WT cb5r residue T181 and Variant T181S in Association
with NAD+ Generated in silica. The molecular model of cb5r displaying (A) residue
T181 (green stick representation and (B) Variant T181S (blue stick representation) in
association with NAD+ generated utilizing the automated comparative protein modeling
server SWISS-MODEL [111] and analyzed using the molecular modeling software Web
Lab Viewer Pro [134]. Model indicates distance of the side chain oxygen (red stick) of
each residue to the N3 oxygen of NAD+ ribose. NAD+ depicted in stick formation with
CPK coloring. Models generated from cb5r in complex with FAD and NAD+ (1IB0).
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formation, resulting in more drastic impairments. In the case of both T181A and T181I,
the affinity for substrate was decreased, with Km values 3 times greater than that of WT.
Additionally, both bound H4NAD in altered conformations indicating that the presence of
a threonine residue and its hydroxyl group are necessary for aligning NADH properly
into the binding site. The similarity of the resulting differential spectra for both variants
in to the spectra obtained for WT titrated with PAAD+, which lacks the N7 nitrogen of
NAD+, points to the possibility that the substitutions cause the NADH to adopt an
orientation causing this nitrogen to be out of position. As this nitrogen is involved in the
electron transfer process between NADH and FAD, alteration of its position would lead
to inefficient transfer.
We proposed that substation of residue T184 would have a significant effect on
the environment of the FAD cofactor of cb5r, and this was clearly demonstrated in the
spectral shifts observed in both UV/Visible absorbance and circular dichroism
spectroscopy studies. In addition, substitution of T184 resulted in drastically decreased
rates of turnover. The reason for these observation is the removal of two hydrogen bonds
to the isoalloxazine ring of FAD. T184 forms bond with O4 and N5 of the FAD ring
system, the latter of which is the location to which one hydrogen is added in the electron
transfer process. Removal of this interaction, demonstrate through the T184A variant,
results in a moderately decreased catalytic efficiency, likely due to destabilization of the
NAD+-FAD- semiquinone intermediate in a manner similar to that of T94 [43]. T184H
yielded more drastic effects on the rate of turnover, decreasing it by 35-fold as compared
to WT.

The introduction of a large positive residue in this location would more severely

alter the electron transfer process than merely removing the bond normally present. The
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alteration in the FAD environment was further confirmed by the results of the
oxidation/reduction potential of the FAD/FADH2 couple which yielded a midpoint
potential comparable to that of free flavin (-220 mV) in the absence and presence of
NAD+, indicating an unfavorable electron transfer environment. Little effect was seen on
the ability to associate with NADH or H4NAD, indicating that the decrease in catalytic
efficiency and electron transfer is mainly due to the missing stabilizing presence of the
threonine side chain.
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Properties of the Type I recessive congenital methemoglobinemia mutants A178T
and A178V.
Preceding the highly conserved

180

GxGxxP185 NADH-binding motif is an equally

highly conserved residue of which two mutations have been identified which lead to
clinical presentation of Type I RCM in two patients. The first of these mutations arises
from a G535A mutation in exon 6 of the DIA1 gene. The mutation has been found in two
unrelated individuals. The first patient was a newborn girl of North African origin who
presented with severe cyanosis, having low methemoglobin (metHb) reductase levels and
31% metHb in her circulating erythrocytes. The mutation predicts an A178T substitution.
This substitution occurs in the Nβ2 sheet immediately preceding the NADH
specificity/binding motif. The patient was found to be homozygous for the mutation,
with both parents being heterozygous and presenting with normal metHb levels but
decreased enzyme activity.

No neurological abnormalities were noted by age of 9

months, leading to diagnosis as Type I RCM [147]. The second patient was a male
newborn of Turkish decent. He was cyanotic within one hour of birth, and had a metHb
concentration of 25%. The patient responded well to treatment with methylene blue (0.5
mg/kg), reducing metHb levels to 2%. A second rise in metHb levels was successful
treated with ascorbic acid (20mg/kg/day), bringing the levels back down to 5-10%. No
neurologic impairment was noted by age of 8 months, the age at the time of study [148].
In both cases, DNA samples from a pool of unrelated individuals were analyzed for the
presence of the mutation. The mutation was not found in any of the additional subjects,
and thus was determined to not be a polymorphism.
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In another patient, a C to T substitution was discovered at the second position of
codon 178 in exon 6 leading to a replacement of A178 by valine. The patient, 29 years
old at time of study, was of Thai origin and was first diagnosed at age 4. Born to a
healthy mother, the patient was born full term and had been cyanotic since birth. Her
only elder brother is healthy without cyanosis. Preliminary investigations indicated that
the mutant retained near WT activity and substrate affinity, noting little difference
between the two. Thermal stability studies indicated that the mutant was less stable than
the WT enzyme, and thus was concluded to be the causative agent for the cyanosis. As
with the A178T mutation, the A178V mutation was looked for in additional individuals
and ruled out as being a polymorphism [149]. The identification of the A178V mutation
along with the finding of the A179T mutation, together with the reported mutations at
codon 204 [150, 151], make codons 179 and 204 the only ones within the cb5r gene
where more than one mutation has been identified.
To further elucidate the effects of the naturally occurring A178T and A178V
mutations on the functioning of cb5r, variants of each mutation were generated as
described in “Methods,” utilizing the original four-histidine tagged cb5r expression
construct and the corresponding oligonucleotide primers listed in Appendix B. These
variants were characterized on the basis of kinetic, spectral, and thermal stability
parameters.
UV/visible absorbance spectra were obtained for oxidized samples of the purified
RCM variants A178T and A178V and were compared with the spectra obtained for the
corresponding WT domain (Figure 54A). All three variants exhibited spectra identical to
that of the WT domain, characterized by absorption maximum detected at 273 nm in the
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Figure 54. Ultra-Violet, Visible, and Circular Dichroism Spectra Obtained for the
Wild-Type and the RCM Type I Associated Variants A178T and A178V. (A)
UV/visible absorption spectra were obtained for oxidized samples of cb5r and the
A178T and A178V mutants at equivalent flavin concentrations (1.7 µM FAD) in 10 mM
phosphate buffer, containing 0.1 mM EDTA, pH 7.0. The inset shows an expanded
region of the visible spectrum where the flavin prosthetic group makes a major
contribution. Individual spectra correspond to WT cb5r (____); A178T (-- --); and A178V
( - .. - .. - ); (B) UV CD spectra were recorded using enzyme samples (7 µM FAD) in 10
mM phosphate buffer, containing 0.1 mM EDTA, pH 7.0. (C) Visible CD spectra were
recorded using enzyme samples (50 µM FAD) in 10 mM phosphate buffer, containing
0.1 mM EDTA, pH 7.0. Line styles shown in “B” and “C” are the same as those
depicted in “A”.
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UV range of the spectrum, and a peak at 461 nm with an associated pronounced shoulder
in the range of 485-500 nm in the visible region of the spectrum, the latter peak
attributable to protein- bound flavin. The A273 nm/A461 nm absorbance ratios of the variants
were within the range of 5.9 ± 0.2, comparable to values previously obtained for WT rat
cb5r of 5.7 ± 0.2 [121], indicating a full complement of the FAD prosthetic group.
To assess any alterations in the secondary structural content of the different type I
RCM cb5r variants, circular dichroism spectra were recorded in the UV wavelength
range (190-300 nm). As shown in Figure 54B, all three variants exhibited positive CD
spectra from 190-210 nm and negative CD spectra from 210-250 nm with the spectra
retaining both positive and negative intensities very similar to that of the WT domain.
The A178T variant produced a spectrum with increased magnitude of the negative CD
component. The absence of any significant differences between the spectra of various
mutants and the WT domain suggested conservation of the secondary structure
architecture and that none of the amino acid substitutions or deletions had any substantial
effects on the folding of the protein. Visible CD spectroscopy was utilized to
examine the environment of the FAD prosthetic group. As shown in Figure 54C, all
three variants generated exhibited visible CD spectra that were virtually indistinguishable
from that of WT cb5r, indicating that none of the amino acid substitutions had any
significant effect on the conformation of the bound FAD prosthetic group.
To assess the effect of the mutations on the catalytic function of the enzyme,
initial-rate kinetic constants for the NADH:FR activity were determined for the WT cb5r
and for each purified variant. The values obtained for the NADH:FR activities are
presented in Table 19. Of the two mutations, the A178T variant demonstrated the
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greatest decrease in both kcat and KmNADH, retaining approximately 34% of WT catalytic
efficiency (kcat/KmNADH). Decreased functionality was observed for both the rate of turn
over and the affinity for substrate, having both parameters decreased by approximately
60% when compared to WT. The impact of the A178V variant was less severe in nature,
retaining 64% of WT efficiency, and a near equivalent rate of turnover to that of the WT
enzyme.

Table 19. NADH:FR Kinetic Constants and Thermal Stability (T50) Values of the
Type I RCM Associated Mutants A178T and A178V

cb5r
Variant

NADH:FR
kcat
(s-1)

KmNADH
(µM)

6.0 ± 1
WT H4cb5r 800 ± 17
A178T
493 ± 8.3 10.4 ± 0.8
A178V
763 ± 3.3 8.6 ± 0.9

KmFeCN6
(µM)
8±1
7±1
7±1

T50
kcat/KmNADH
(s-1 M-1)

(°C)

1.4 ± 0.3 x 108 56.1
4.8 ± 0.4 x 107 55.0
8.9 ± 0.3 x 107 49.2

To examine the influence of the various amino acid substitutions on protein
stability, the thermal NADH:FR inactivation profile coupled with the increase in intrinsic
flavin fluorescence and emission intensity of each of the variants was monitored and was
compared to values obtained for the WT enzyme. The results obtained for the thermal
denaturation profiles and changes in intrinsic flavin fluorescence are shown in Figure 55.
Changes in the intrinsic fluorescence of the cofactor or the retention of NADH:FR
activity following thermal denaturation was an effective indicator of the stability of the
core structure of the protein. T50 values (the temperature at which 50% of maximum
fluorescence and 50% retention of NADH:FR activity was detected) are reported in Table
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19. A178T demonstrated equivalent stability as compared to WT while A178V proved
to be less stable, having a T50 value 7 °C lower than that of WT.
Differential spectroscopy was used to evaluate the effect of the RCM mutations
on the binding affinity for both the isosteric NADH analog H4NAD and NAD+. As
shown in Figure 56, both of the mutations resulted in similar line shapes for the spectra
obtained from the titrations with H4NAD, with minor alterations detected in the 415-

Figure 55. T Thermal Stability Profiles of the Type I RCM Associated Variants
A178T and A178V. Oxidized samples of WT H4cb5r (5 µM FAD) and cb5r RCM
variants were incubated at the indicated temperatures, and aliquots were withdrawn and
assayed for both residual NADH:FR activity (closed symbols) and intrinsic flavin
fluorescence (open symbols) in 10 mM phosphate buffer, containing 0.1 mM EDTA, pH
7.0 using excitation and emission wavelengths of 450 nm and 523 nm, respectively.
Points correspond to (●,○) H4cb5r; (■, □) A178T; and (▲, ∆) A178V
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490nm region. Both mutants exhibited an increased Ks value, with A178V being only
slightly elevated and A178T being 2 fold higher when compared to WT cb5r (Table 20).
In the case of titration with NAD+, both mutations maintained a similar line shape
to that of WT, however, at rather diminished intensities. The resulting spectral binding
constants followed the same pattern seen in the H4NAD titrations, with A178V having a
value equivalent to WT and A1178T having a value 3 times that of WT (Table 20)
Potential effects of structural changes on the properties of the flavin prosthetic
group were examined by determining the oxidation-reduction potentials for the FAD
cofactor as described in the “Methods” section. Flavin midpoint potentials (E°′, n = 2)
for the FAD/FADH2 couple were determined for the variants alone and in the presence of
NAD+. Spectra obtained during a representative titration of the WT cb5r protein are
shown in Figure 57. In the absence of NAD+, each of the mutations exhibited midpoint
potentials equivalent to that of WT, with values of -275 and -276mV for the A178T and
A178V mutants respectively. In the presence of NAD+ however, both mutations
demonstrated a positive shift in the midpoint potential, but not to the same extent seen in
the WT domain in the presence of NAD+, with values of -212mV and -201 mV for the
A178T and A178V mutants respectively. Midpoint values are reported in Table 20.
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Summary of Properties of the Type I recessive congenital methemoglobinemia mutants
A178T and A178V.
Previous investigations [147-149] identified two unique point mutations in the
DIA1 gene of individuals of North African and Turkish decent (A178T) and from Thai
decent (A178V) displaying disease phenotype for Type I RCM. The two mutations
resulted from single point mutations in the DIA1 gene coding for cb5r protein, and were
found to be unique to the patients, and not polymorphisms in the respective populations.
Analysis of the structure of the mutants through the use of UV/Visible absorbance
and circular dichroism spectroscopy indicated that the mutants did not differ significantly
in overall secondary structure from the WT protein, and incorporated the FAD co-factor
in a similar conformation. Initial-rate kinetic studies indicated that the mutants retained
greater than 50% of the rate of turn-over exhibited by the WT enzyme, and did not
significantly differ in the binding affinity for the reducing substrate as indicated by
similar KmNADH values. Differential spectroscopy indicated that the A178V mutant bound

Table 20. Spectral Binding Constants (Ks) and Standard Midpoint Obtained for the Type
I RCM Associated Mutants A178T and A178V.

cb5r
Variant
WT H4cb5r
A178T
A178V

Ks

(µM)

Ks H4NAD

KsNAD+

45 ± 10
55 ± 5
49 ± 5

553 ± 30
1530 ± 37
545 ± 1
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E°′ FAD/FADH2
(mV)

-NAD+ +NAD+
-271
-275
-276

-191
-212
-201

Figure 56. Spectroscopic Titrations Obtained for the WT cb5r and the Type I RCM
Associated Variants A178T and A178V in the Presence of H4NAD and NAD+.
Titrations of all mutants (50µM) were performed in split cell optical cuvettes in 10mM
phosphate buffer containing 0.1mM EDTA, pH 7.0 at 23 °C. Difference spectra were
recorded following the addition of a solution of H4NAD (5mM) (A, C, E) or NAD+
(30mM) (B, D, F). The inset panel corresponds to a plot of the magnitude of the spectral
perturbations at the indicated wavelengths versus pyridine nucleotide concentration
where a difference spectrum was observed. Plots of the relative absorbance changes
observed are as follows: (A, B) WT cb5r; (C, D) A178T; and (E, F) A178V.
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H4NAD in a conformation similar to WT and with equal or affinity. However, the
A178T mutant, while binding the analog in a similar conformation, did so with a
decreased affinity. In titrations with NAD+, the results indicated high level of similarity
between the A178V mutant and WT enzyme, with the A178T mutant again showing a
decreased affinity for the product. Midpoint potential determinations further highlighted
the similarity between A178V and WT and the difference between A178T and WT. The
potential in the presence of NAD+ for A178T was closer to that of free flavin than to WT,
suggesting inefficiency in the ability to transfer electrons in the mutant. A178V also
showed a more negative potential in the presence of NAD+ as compared to WT, but to a
lesser degree, a fact mirrored in its retention of catalytic efficiency similar to that of WT
as shown by the NADH:FR assays. From this data, it can be concluded that it is the
presence of the polar hydroxyl group on the side chain of A178T that resulted in the
decrease in activity. From homology modeling studies, we generated structures of each
mutant to compare to WT to illustrate what potential effects would occur, as shown in
Figure 58.

The introduction of the threonine side chain caused an electrostatic

interference with the backbone of I183 (Figure 58B). The introduction of a negative
charge in this region would cause an alteration in the helical structure, as evidenced by
the increased negative maxima seen in the circular dichroism spectra in the far UV
region. While not a major alteration, it is strong enough to cause a displacement in the
nearby “GxGxxP” motif preventing the substrate from binding in the appropriate
orientation.

While differential spectroscopy indicated that A178T bound H4NAD

similarly to WT, the slight alterations seen in the 415-490nm area indicate a minor
alteration in the conformation of the complex. Thus, we proposed that the causative
178

Figure 57. Oxidation-Reduction Midpoint Potentials for the FAD Prosthetic Group
in the WT cb5r and the Type I RCM Associated Variants A178T and A178V.
Reductive dye titrations were performed at 25 °C as described in “Materials and
Methods” using phenosafranine as the indicator dye in 100 mM phosphate buffer
containing 0.1 mM EDTA, pH 7.0. Nernst plots in the absence (closed symbols) and
presence (open symbols) of 2 mM NAD+. Plots correspond to (●,○) H4cb5r; (■, □)
A178T; and (▲, ∆) A178V.

agent of RCM in the case of the A178T mutation is a result of a minor displacement of
the correct orientation of the NADH binding motif “GxGxxP,” leading to inefficient
electron transfer from the bound NADH. Since this is a minor alteration, the overall
effect results in a type I RCM.
Correlating with previous studies [149], the A178V mutant retained the catalytic
properties of the WT protein, with only slightly decreased efficiency.
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The main

difference observed in the A178V mutant was in its thermal stability. The mutation
proved to be less stable than WT as determined by thermal denaturation. Having a T50
value 7 °C lower than WT, the mutant protein would not be able to remain efficient in
circulating erythrocytes, thus leading to a mild cyanotic phenotype in patients. In other
cells of the body, degraded protein would be able to be cleared and newly translated
protein, with efficiency similar to that of the WT, would be able to compensate. Thus, as
concluded by Higasa et. al. [149], the A178V results in type I RCM simply due to
destabilization effects. However, homology modeling did not yield any indication as to
where this destabilizing effect would occur. The most likely cause is again an affect on
I183. As shown in Figure 58C, the presence of the branched side chain of valine could
sterically hinder the neighboring I183 residue, alterations of which have been
demonstrated to lead to decreased thermal stability. To more accurately determine the
cause of the destabilization, a crystal structure of the mutant enzyme would facilitate
comparison of the A178V and WT structures.
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Figure 58. Structures of WT cb5r Residue A178 and RCM Variants A178T and
A178V Generated in silica. The molecular model of cb5r displaying (A) residue A178
(B) Variant A178T and (C) Variant A178V in association with NAD+ generated utilizing
the automated comparative protein modeling server SWISS-MODEL [111] and analyzed
using the molecular modeling software Web Lab Viewer Pro [134]. The model indicates
electrostatic surfaces of the residues in relation to residue I183. Residues and NAD+
depicted in stick formation with CPK coloring. Models generated from cb5r in complex
with FAD and NAD+ (1IB0).
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The role of the NADH binding motif 273CGxxxM278
Within the cb5r primary structure, several sequence motifs have been identified
that are involved in either flavin binding (“91RxYTSxxSN97”) or FAD/FMN specificity
(“124GRXXST127”) or function in modulating reduced pyridine nucleotide binding
(“180GxGxxP185” and “273CGxxxM278”). The second of these conserved motifs that are
involved in regulating pyridine nucleotide affinity, corresponds to a six amino acid
“273CGpppM278” residue motif that comprises the residues C273 to M278 in the carboxylterminal lobe of rat cb5r (Figure 59).
Analysis of the structure of the diaphorase domain complexed with NAD+ (PDB
ID=1IB0) has revealed that the majority of the residues comprising the conserved
“CGxxxM” motif do not provide any direct electrostatic or hydrogen bond contacts with
either the nicotinamide or ribose moieties of the bound NAD+, with the notable exception
of G274. However, the residues do form a loop connecting Nβ4 with the final α helical
‘return’ in the NADH binding domain. This loop is generated by three sequential proline
residues which effectively induce a kink into the backbone of the protein, causing an
immediate redirection and initiating the following helical structure (Figure 59B).
Additionally, the residues in this motif provide an extensive framework of hydrophobic
contacts that are involved in binding the reducing substrate, NADH, specifically orienting
the nicotinamide portion of the reduced pyridine nucleotide for subsequent efficient
hydride transfer to the FAD prosthetic group (Figure 59A). Within the “CGxxxM” motif,
the conserved glycine, corresponding to G274, forms two critical hydrogen bonds with
bound NAD+, its backbone oxygen binding with the N7 nitrogen of the nicotinamide
moiety. Also, C273 has been suggested to be important in maintaining equilibrium
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Figure 59. Electrostatic Interaction of the “CGpppM” Motif with NAD+. (A)
Ligplot [99] of 1IB0. C, O, N, and P atoms are represented as white, blue, red, and violet
spheres, respectively, while covalent bonds are violet sticks within NAD+ and orange
sticks within amino acid residues of the NADH-binding lobe. Hydrogen bonds are drawn
as green dashed lines with distances between atoms labeled. Residues contributing to
hydrophobic interactions are represented as arcs with rays and colored red. Residues of
the motif are circled in red. (B) Schematic diagram of a portion of the R. norvegicus cb5r
X-ray crystal structure (PDB code IIB0) showing the arrangements of the amino acids
that comprise the conserved “CGPxxxM” motif . Amino acids and the complexed NAD+
are shown in “stick” representation using the CPK color scheme. Hydrogen bonds are
drawn as dashed green lines. Secondary structure of the protein is shown using line
ribbon scheme, colored according to secondary structure with helices colored red, sheets
colored blue, and turns colored white.
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between the unstacked configuration of bound NADH and the charge transfer complex
[104].
To probe the role of this conserved motif in cb5r structure and function and to
examine the effects of substituting these residues on the enzyme’s function, we have
applied site-directed mutagenesis of the H4cb5r construct using the corresponding
oligonucleotide primers listed in Appendix C as described in “Methods” as a tool to
replace or alter the properties of each residue. This was done in two stages. First, the
individual residues were each replaced with alanine (alanine-scanning mutagenesis). The
resulting mutants were examined on the basis of the effects of these substitutions on the
spectroscopic properties of the FAD prosthetic group and the interactions of cb5r with the
physiological substrate, NADH. Based on the results of the alanine-scanning, additional
mutants were constructed and again analyzed using the same parameters to give further
insight into the function of the individual residues as well as the motif in its entirety.
These additional variants consisted of the four substitution mutations C273M, C273S,
G274P, and G274S and two insertion mutations in which an alanine or glycine was
inserted between residues P277 and M278. These single residue insertion mutants were
generated as a result of other members of the FNR superfamily, such as cytochrome P450
reductase and methionine synthase reductase, exhibiting a motif with the structural
“CGxxxxM” configuration.
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Characterization of Alanine Substitution Mutants of the 273CGpppM278motif
Mutant constructs encoding the C273A, G274A, P275A, P276A, P277A, and
M278A, cb5r variants, corresponding to the residues in the conserved “CGPPPM”
sequence motif, were generated using site-directed mutagenesis of the original fourhistidine tagged cb5r construct. Dideoxy sequencing confirmed the fidelity of the
constructs.

The mutant proteins were subsequently expressed in the E. coli strain

BL21(DE3)-RIL and purified by metal–chelate affinity chromatography and gel filtration
FPLC. Evaluation of the expression yield of the variants indicated an expression
efficiency comparable to that of the WT cb5r domain, indicating production of stable
protein products which could be purified to apparent homogeneity as indicated by the
presence of single protein bands following SDS–PAGE analysis (results not shown).
UV/visible absorbance spectra were obtained for both the oxidized samples of the
alanine variants and WT cb5r as a control and are presented in Fig 60A. All of the
variants exhibited spectra comparable to that of the WT enzyme with aromatic absorption
maximum observed at 273 nm in the UV region of the spectrum, and peaks at 461 nm
with an associated pronounced shoulder in the range of 485–500 nm in the visible region
of the spectrum, attributable to protein-bound flavin.
To compare the secondary structural characteristics of the alanine variants with
that of the WT protein, circular dichroism (CD) spectra were recorded in the UV
wavelength range (190–300 nm). As shown in Fig. 60B, the alanine variants exhibited
positive CD from 190 to 210 nm and negative CD from 210 to 250 nm with the spectra
retaining both positive and negative intensities very similar to those of the WT domain.
The absence of any significant differences between the spectra of the WT and mutant
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Figure 60. UV/Visible Absorption and CD Spectra of WT cb5r and the Alanine
Mutants of the CGpppM Motif. (A) UV/vis absorption spectra were obtained for
oxidized samples of cb5r and the various mutants at equivalent flavin concentrations (1.7
µM FAD) in 10 mM phosphate buffer, containing 0.1 mM EDTA at pH 7.0. The inset
shows an expanded region of the visible spectrum where the flavin prosthetic group
makes a major contribution. Individual spectra correspond to WT cb5r (___), C273A (__ __
__
), G274A (_ _ _ _), P275A (------), P276A (……..), P277A (_ . _ . _. ), M278A (-..-..-..-.) (B)
UV CD spectra were recorded using enzyme samples (7 µM FAD) in 10 mM phosphate
buffer, containing 0.1 mM EDTA at pH 7.0. (C) Visible CD spectra were recorded using
enzyme samples (50 µM FAD) in 10 mM phosphate buffer, containing 0.1 mM EDTA at
pH 7.0. Line styles shown in B and C are the same as those depicted in A.
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proteins suggested the conservation of secondary structure and that the alanine residue
substitutions had no deleterious effects on the folding of the diaphorase domain. Similar
results were observed for the corresponding visible CD spectra. Circular dichroism
measurements were performed in the near-UV/visible range (300–600 nm) in order to
probe possible effects of the mutations on both flavin conformation and polarity of the
prosthetic group microenvironment. As shown in Fig. 60C, the spectra of the mutants
were unperturbed when compared to that of WT cb5r, exhibiting positive maxima at 310
and 390 nm and negative maxima at approximately 460 and 485 nm,. suggesting no
significant change in either the polarity of the flavin environment or the conformation of
the bound prosthetic group.
To examine the influence of the residue substitutions on the stability of the
resulting proteins, thermal denaturation profiles were generated for the alanine variants
and WT cb5r

by measuring changes in both intrinsic flavin fluorescence emission

(Figure 61A) and retention of NADH:ferricyanide reductase

activity (Figure 61B)

following incubation of the proteins at temperatures ranging from 0 to 100 °C. The
temperature (T50) at which 50% of maximum fluorescence was detected or 50% of the
protein’s NADH:FR activity was retained, were effective indicators of the stability of the
core structure of the protein. Each of the variants displayed a reduced thermal stability
related to that of the WT (Table 21) with G274A maintaining a T50 value of 53 °C,
comparable to that of WT cb5r, followed by the variants C273A, P276A, and P277A
variants which were approximately 4 °C lower than that of WT cb5r suggesting that these
residue substitutions had a moderate effect on the thermal stability. The most severally
affected variants of the NADH-binding motif were P275A and M278A, with T50 values
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of 49 °C and 46 °C, respectively. These more significant decreases suggest that the
alanine substitutions at amino acid residues P275 and M278 severely affected the overall
stability of the protein.

Figure 61. Thermal Stability Profiles Obtained for the WT cb5r and the Alanine
Variants of the “CGpppM” Motif. Oxidized samples of C273A, G274A, P275A,
P276A, P277A, M278A, and WT H4cb5r (5µM FAD) were incubated at the indicated
temperatures, and aliquots were withdrawn and assayed for both residual NADH:FR
activity and intrinsic flavin fluorescence in 10 mM phosphate buffer, containing 0.1 mM
EDTA, pH 7.0 using excitation and emission wavelengths of 450 nm and 523 nm,
respectively. Points correspond to: (●) H4cb5r; (■) C273A; (▲) G274A; (▼) P275A; (♦)
P276A; (x) P277A; (+) M278A.
As a measure of catalytic efficiency, NADH:FR activities were determined for the WT
cb5r and alanine variants. Kinetic constants derived from these assays are reported in
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Table 21. All variants exhibited a decreased NADH:FR turn-over rate when compared to
that of WT cb5r, with C273A and G274A being the most severely affected.

The

substitution of an alanine for a cysteine at residue 273 had the most deleterious affect on
the enzymes catalytic activity, showing a 38-fold decrease as compared to WT enzyme.
P275A resulted in the most moderate affects on catalytic activity, having maintianed a
kcat comparable to that of WT, indicating turnover was not significantly inhibited in the
variant.
Table 21. NADH:FR Kinetic Constants and Thermal Stability (T50) Values
Obtained for the Alanine Variants of the “CGpppM” Motif.

cb5r
Variant
WT H4cb5r
C273A
G274A
P275A
P276A
P277A
M278A

NADH:FR
kcat
(s-1)
800 ± 17
20 ± 1.0
88 ± 2.1
750 ± 50
650 ± 22
617 ± 9.4
202 ± 10

KmNADH KmFeCN6
(µM)
(µM)
6.0 ± 1
9.4 ± 0.8
65 ± 2.1
22 ± 0.8
14 ± 1.1
34 ± 1.1
24 ± 1.0

8±1
8±1
8±1
8±1
8±1
8±1
8±1

T50
kcat/KmNADH
(s-1 M-1)

(°C)

1.4 ± 0.3 x 108
2.3 ± 0.4 x 106
1.4 ± 0.3 x 106
3.5 ± 0.5 x 107
4.8 ± 0.8 x 107
1.8 ± 0.1 x 107
8.4 ± 0.8 x 106

56.1
51.0
53.2
49.1
50.9
50.7
46.3

Binding efficiency, as determined by examining the Michaelis constants (Km),
demonstrated a decreased affinity for NADH for all variants. G274A demonstrated the
most significant impact, having a Km value 10-fold greater than that of WT protein,
indicating a significant decrease in the affinity for the reducing substrate. The additional
variants exhibited Km’s as shown in Table 21. The C273A demonstrated a Km near that
of WT cb5r, suggesting substrate affinity was not significantly affected. In contrast, the
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Michaelis constant for the artificial electron acceptor, ferricyanide, was similar to that of
WT cb5r, suggesting that the mutation did not affect the binding of the oxidizing
substrate.
Catalytic efficiency, reflected in the kcat/KmNADH value, was decreased in all
variants as compared to WT cb5r. The effect of the G274A substitution was most
notable, the variant retaining only 0.3% of WT cb5r NADH:FR catalytic efficiency.
These results suggested that the lower catalytic efficiency observed for the mutants was
the result of both the decreased affinity for, and decreased utilization of NADH.
To confirm the effects of the alanine substitutions on the affinities for either NADH or
NAD+, spectral binding constants (Ks) were determined using differential spectroscopy.
Representative spectra obtained from the titrations of the alanine variants and the WT
enzyme with either H4NAD or NAD+ are shown in Figures 62 and 63 respectively. With
the exception of G274A, all the variants demonstrated some degree of spectral change
following the addition of H4NAD (Figure. 63). C273A exhibited a spectrum similar to the
titration with NAD+. P275A, P276A, P277A, and M278 all demonstrated line shape
similar to that of WT, with diminished intensities. G274A had insufficient changes for
analysis. The binding constants for H4NAD suggested that C273A and P277A bound the
substrate more efficiently than WT, with Ks values of 40 µM and 35 µM H4NAD
respectively.
Titrations of the C273A, P276A, and P277A variants with NAD+ generated lineshape similar to WT cb5r, but with decreased positive and negative intensities. P275A
exhibited spectral changes of greatly diminished intensity. Variants G274A and M278
exhibited insufficient spectral change to determine the spectroscopic binding constants
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Figure 62. Spectroscopic Titrations Obtained for the WT cb5r and the Alanine
Variants of the “CGpppM” Motif in the presence of H4NAD. Difference spectra were
obtained for the C273A, G274A, P275A, P276A, P277A, and M278A cb5r mutants at
equivalent flavin concentrations of (50 µM FAD) in 20 mM MOPS buffer, containing 0.1
mM EDTA, pH 7.0 following titrations with H4NAD as described in “Methods”. The
insert panels correspond to plots of the magnitudes of the observed spectral perturbations
(peak to trough measurements at the indicated wavelengths) versus ligand concentration.
The corresponding Ks values are given in Table 22.
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for NAD+. The binding constants (Table 22) for NAD+ suggest all variants that exhibited
spectral changes bind product better than WT, with the exception of P275A which had a
Ks of 1,048 µM.

Table 22. Spectral Binding Constants (Ks) and Standard Midpoint Potentials (E°′)
Obtained for Alanine Variants of the “CGpppM” Motif.

cb5r
Variant

E°′ FAD/FADH2

Ks

(µM)

Ks

H4NAD

Ks

(mV)

NAD+

553 ± 30
WT H4cb5r 45 ± 10
40 ± 3
131 ± 9
C273A
*
ND
ND*
G274A
P275A
165 ± 36 1048 ± 441
P276A
152 ± 14 247 ± 25
P277A
35 ± 3
213 ± 11
M278A
65 ± 2
314 ± 21

+

-NAD

+NAD+

-271
-268
-271
-268
-271
-277
-273

-191
-225
-221
-193
-200
-201
-223

*

ND indicates that the spectroscopic binding constant could not be determined, due to
insufficient spectral change.

Potential effects of structural changes on the properties of the flavin prosthetic
group were examined by determining the oxidation-reduction potentials for the FAD
cofactor as described in the “Methods” section. Flavin midpoint potentials (E°′, n = 2)
for the FAD/FADH2 couple were determined for the variants alone and in the presence of
NAD+. The flavin redox potentials (n = 2) for the WT cb5r and the variants for the
FAD/FADH2 couple were determined from the Nernst semi-log plots of the log
([oxidized]/[reduced])FAD versus potential (mV) and are shown in Figure 64. Without the
addition of NAD+ to the titration, all variants demonstrated midpoint potentials
equivalent to that of WT, with values of ranging form -277 and -268 mV. In the presence
of NAD+ however, the C273A, G274A and M278A mutations demonstrated only a slight
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Figure 63. Spectroscopic Titrations Obtained for the WT cb5r and the Alanine
Variants of the “CGpppM” Motif in the presence of NAD+. Difference spectra were
obtained for the C273A, G274A, P275A, P276A, P277A, and M278A cb5r mutants at
equivalent flavin concentrations of (50 µM FAD) in 20 mM MOPS buffer, containing 0.1
mM EDTA, pH 7.0 following titrations with NAD+ as described in “Methods”. The insert
panels correspond to plots of the magnitudes of the observed spectral perturbations (peak
to trough measurements at the indicated wavelengths) versus ligand concentration. The
corresponding Ks values are given in Table 22.
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Figure 64. Oxidation-Reduction Midpoint Potentials for the FAD Prosthetic Group
in the WT cb5r and the “CGpppM” Alanine Variants. Reductive dye titrations were
performed at 25 °C as described in “Materials and Methods” using phenosafranine as the
indicator dye in 100 mM phosphate buffer containing 0.1 mM EDTA, pH 7.0. Nernst
plots in the absence (A) and presence (B) of 2 mM NAD+. Plots correspond to (●)
H4cb5r; (■) C273A; (▲) G274A; (▼) P275A; (♦) P276A; (x) P277A; and (+) M278A.
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degree of positive shift in the midpoint potential, resulting in midpoint potentials near
that of free flavin. The three proline substitutions did result in a positive shift, having
midpoint potentials within 10 mV of that for WT in the presence of NAD+. Midpoint
values are reported in Table 22.
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Characterization of the C273M/S, G274P/S A-insertion, and G-insertion variants.
Mutant constructs encoding the C273S, C273M, G274P, G274S, P277–alanine
insertion (A-insertion), and P277–glycine insertion (G-insertion) cb5r variants, were
generated using site-directed mutagenesis using the oligonucleotide primers listed in
Appendix C. Evaluation of the expression yield of the variants indicated an expression
efficiency comparable to that of the WT cb5r domain for most of the variants indicating
production of a stable protein product which could be purified to apparent homogeneity
as indicated by the presence of a single protein band following SDS–PAGE analysis
(results not shown). Variants C273M and C273S displayed lower expression efficiency,
but were still purified to apparent homogeneity as indicated by a single band following
SDS-PAGE.
UV/visible absorbance spectra were obtained for both the oxidized variants and
WT cb5r as a control and are presented in Figure 65A. All of the variants exhibited
spectra comparable to that of the WT enzyme with an aromatic absorption maximum
observed at 273 nm in the UV region of the spectrum, and a peak at 461 nm with an
associated pronounced shoulder in the range of 485–500 nm in the visible region of the
spectrum, attributable to protein-bound flavin.
To compare the secondary structural arrangement of the variants with that of the
WT protein, circular dichroism (CD) spectra were recorded in the UV wavelength range
(190–300 nm). As shown in Figure 65B, the variants exhibited positive CD from 190 to
210 nm and negative CD from 210 to 250 nm with the spectra retaining a line shape very
similar to that of the WT domain. The intensities of the negative CD maxima at 222 nm
were increased in the case of the C273S and A insertion variants, indicating potential
197

Figure 65. Ultra-Violet, Visible, and Circular Dichroism Spectra Obtained for the
WT cb5r and the cb5r Variants C273S, C273M, G274P, G274S, A insertion, and G
insertion. (A) UV/Visible absorption spectra were obtained for oxidized samples of cb5r
and the various mutants at equivalent flavin concentrations (1.7 µM FAD) in 10 mM
phosphate buffer, containing 0.1 mM EDTA at pH 7.0. The inset shows an expanded
region of the visible spectrum where the flavin prosthetic group makes a major
contribution. Individual spectra correspond to WT cb5r (___), C273S (__ __ __), C273M (_ _
__
), G274P (------), G274S (……..), A insertion (_ . _ . _. ), G insertion (-..-..-..-.) (B) UV CD
spectra were recorded using enzyme samples (7 µM FAD) in 10 mM phosphate buffer,
containing 0.1 mM EDTA at pH 7.0. (C) Visible CD spectra were recorded using enzyme
samples (50 µM FAD) in 10 mM phosphate buffer, containing 0.1 mM EDTA at pH 7.0.
Line styles shown in B and C are the same as those depicted in A.
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minor alterations of secondary structure. The absence of any significant differences
between the line shape of the spectra of the WT and the remaining mutant proteins
suggested the conservation of secondary structure and that the residue substitutions had
no significant deleterious effects on the folding of the diaphorase domain.
Circular dichroism measurements were performed in the near-UV/visible range
(300–600 nm) in order to probe possible effects of the mutation on both flavin
conformation and polarity of the prosthetic group microenvironment. As shown in Figure
65C, the mutants maintained a line shape similar to that of WT cb5r, exhibiting positive
maxima at 310 and 390 nm and negative maxima at approximately 460 and 485 nm. The
intensities of these maxima, however, differed from that of the WT domain, indicating
potential alterations in either the polarity of the flavin environment or the conformation
of the bound prosthetic group.
To examine the influence of the residue substitutions on the stability of the
resulting protein, thermal denaturation profiles were generated for both variants and WT
cb5r (Figure 66). Each variant displayed a reduced thermal stability relative to that of
WT (Table 23). G274S, A insertion, and G insertion maintaining T50 values of 54 °C, 53
°C., and 55 °C respectively, comparable to that of WT cb5r, The C273M, G274P, and
C273S variants were on average 4 °C lower than that of WT, suggesting that these
residue substitutions had a slight effect on the thermal stability. The T50 values for each
variant are given in Table 23.
As a measure of catalytic efficiency, NADH:FR activities were determined for the
WT cb5r and all variants. Kinetic constants derived from these assays are reported in
Table 23, and indicated that all the variants exhibited a marked decrease in NADH:FR
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turn-over compared to that of WT cb5r, with G274P being the most severely affected,
showing a 1200-fold decrease when compared to WT cb5r. The remaining variants
exhibited increasing kcat values on the order of: G274P<C273S<A-insertion<Ginsertion<G274S<C273M<WT.

Figure 66. Thermal Stabilty Profiles Obtained for the WT cb5r and cb5r Variants
C273S, C273M, G274P, G274S, A-insertion, and G-insertion. Oxidized samples of
C273S, C273M, G274P, G274S, A-insertion, G-insertion, and WT H4cb5r (5µM FAD)
were incubated at the indicated temperatures, and aliquots were withdrawn and assayed
for both residual NADH:FR activity and intrinsic flavin fluorescence in 10 mM
phosphate buffer, containing 0.1 mM EDTA, pH 7.0 using excitation and emission
wavelengths of 450 nm and 523 nm, respectively. Points correspond to: (●) H4cb5r; (■)
C273M; (▲) C273S; (▼) G274P; (♦) G274S; (x) A insertion; (+) G insertion.
The Km value for the G insertion demonstrated the most significant decrease in
affinity, having increased 97-fold with respect to WT NADH utilization, from 7 µM to
689 µM. The additional variants exhibited Km values as shown in Table 23. The C273M
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demonstrated a Km near that of WT at 10 um, suggesting substrate affinity was not
significantly affected. The Michaelis constant for the artificial electron acceptor,
ferricyanide, was similar to that of WT cb5r for all variants, suggesting that the mutation
did not affect the binding of the oxidizing substrate.

Table 23. NADH:FR Kinetic Constants and Thermal Stability (T50) Values
Obtained for the C273M/S, G274P/S, A-insertion and G-insertion Variants of the
“CGpppM” Motif.

cb5r
Variant
WT H4cb5r
C273M
C273S
G274P
G274S
A-insert
G-insert

kcat
(s-1)

NADH:FR
KmFeCN6
(µM)
(µM)

KmNADH

800 ± 17 6.0 ± 1
213 ± 4.1 10 ± 1
10 ± 4.1 17 ± 2
0.62 ± 0.1 74 ± 4
67± 3.2 76 ± 2
17 ± 1.4 571 ± 22
22 ± 1.1 689 ± 33

8±1
7±1
8±1
8±1
7±1
8±1
7±1

T50
kcat/KmNADH
-1
-1

(°C)

1.4 ± 0.3 x 108
2.1 ± 0.2 x 107
6.0 ± 0.7 x 105
8.5 ± 0.2 x 103
8.8 ± 0.6 x 105
2.9 ± 0.4 x 104
3.2 ± 0.4 x 104

56.1
52.0
52.2
51.1
54.1
53.8
55.3

(s M )

Catalytic efficiency, reflected in the kcat/KmNADH value, was markedly decreased in
all variants as compared to WT cb5r, with the exception of C273M which retained 15%
of WT cb5r NADH:FR catalytic efficiency.

The effect of the glycine to proline

substitution at residue 274 on the overall NADH:FR catalytic efficiency of the enzyme
was most significant, retaining only 0.006% of WT cb5r NADH:FR catalytic efficiency.
These results suggested that the lower catalytic efficiency observed for the mutants was
the result of both the decreased affinity for, and decreased utilization of NADH.
To determine the effects of the mutations on NADH and NAD+ binding, spectral
binding constants (Ks) were determined using differential spectroscopy as discussed
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above. Representative spectra obtained from the titrations of the variants and the WT
enzyme with either H4NAD or NAD+ are shown in Figures 67 and 68 respectively. With
the exception of C273M, none of the variants demonstrated spectral changes following
the addition of H4NAD, as shown in Figure 67. C273M demonstrated a line shape similar
to that of WT, with diminished intensities. The remaining variants had insufficient
changes for analysis. The binding constants for H4NAD suggest that C273M binds the
substrate in a comparable manner to WT, with a Ks values of 70 µM H4NAD.
Perturbations of the flavin visible absorbance spectrum were only detectable for
the WT enzyme, C273M, the A-insertion, and the G-insertion variants in the presence of
NAD+ (Figure 68). For each of these variants, complex formation with NAD+ resulted in
spectra with severely decreased intensity with reference to WT cb5r. The C273S, G274P,
and G274S variants exhibited insufficient spectral change to determine spectroscopic
binding constants for the various pyridine nucleotides. The binding constants, shown in
Table 24, obtained for NAD+ suggested all variants that exhibited spectral changes bind
product better than WT.
Potential effects of structural changes on the properties of the flavin prosthetic
group were examined by determining the oxidation-reduction potentials for the FAD
cofactor as described in the “Methods” section. Flavin midpoint potentials (E°′, n = 2)
for the FAD/FADH2 couple were determined for the variants alone and in the presence of
NAD+. The flavin redox potentials (n = 2) for the WT cytochrome b5 reductase and
generated variants for the FAD/FADH2 couple were determined from the Nernst semi-log
plots of the log ([oxidized]/[reduced])FAD versus potential (mV) and are shown in Figure
69. In the absence of NAD+, all variants demonstrated midpoint potentials equivalent to
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Figure 67. Spectroscopic Titrations Obtained for the WT cb5r and cb5r Variants
C273S, C273M, G274P, G274S, A insertion, and G insertion in the Presence of
H4NAD. Difference spectra were obtained for the various C273S, C273M, G274P,
G274S, A insertion, and G insertion - cb5 mutants at equivalent flavin concentrations of
(50 µM FAD) in 20 mM MOPS buffer, containing 0.1 m EDTA, pH 7.0 following
titrations with H4NAD as described in “Methods”. The insert panels correspond to plots
of the magnitudes of the observed spectral perturbations (peak to trough measurements at
the indicated wavelengths) versus ligand concentration. The corresponding Ks values are
given in Table 24.
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Figure 68. Spectroscopic Titrations Obtained for the WT cb5r and cb5r Variants
C273S, C273M, G274P, G274S, A insertion, and G insertion in the Presence of
NAD+. Difference spectra were obtained for the various C273S, C273M, G274P, G274S,
A insertion, and G insertion - cb5 mutants at equivalent flavin concentrations of (50µM
FAD) in 20 mM MOPS buffer, containing 0.1 m EDTA, pH 7.0 following titrations with
NAD+ as described in “Methods”. The insert panels correspond to plots of the
magnitudes of the observed spectral perturbations (peak to trough measurements at the
indicated wavelengths) versus ligand concentration. The corresponding Ks values are
given in Table 24.
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that of WT, with values of ranging from -272 to -265 mV. In the presence of NAD+ however,
all the mutations failed to have a significant positive shift in the midpoint potential, resulting
in midpoint potentials near or more negative than that of free flavin. These results clearly
indicated that these amino acid substitutions significantly affect the ability of NADH to bind
in the proper orientation for efficient electron transfer. The
Table 24. Spectral Binding Constant (Ks) and Standard Midpoint Potentials (E°′)
Obtained for the C273M/S, G274P/S, A-insertion and G-insertion Variants of the
CGpppM Motif.

cb5r
Variant
WT H4cb5r
C273M
C273S
G274P
G274S
A-insert
G-insert

E°′ FAD/FADH2

Ks

(µM)

Ks

H4NAD

45 ± 10
70 ± 9
ND*
ND*
ND*
ND*
ND*

Ks

(mV)

NAD+

554 ± 30
267 ± 24
ND*
ND*
ND*
170 ± 37
182 ± 31

*

+

-NAD

+NAD+

-271
-268
-272
-272
-272
-269
-265

-191
-254
-255
-232
-257
-243
-234

ND indicates that the spectroscopic binding constant could not be determined, due to
insufficient spectral change.
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Figure 69. Oxidation-Reduction Midpoint Potentials for the FAD Prosthetic Group
in the WT cb5r and cb5r Variants C273S, C273M, G274P, G274S, A insertion, and
G insertion. Reductive dye titrations were performed at 25 °C as described in “Materials
and Methods” using phenosafranine as the indicator dye in 100 mM phosphate buffer
containing 0.1 mM EDTA, pH 7.0. Nernst plots in the absence (A) and presence (B) of 2
mM NAD+. Plots correspond to (●) H4cb5r; (■) C273M; (▲) C273S; (▼) G274P; (♦)
G274S; (x) A-insertion; and (+) G-insertion.
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values obtained for the midpoint potentials of the variants are reported in Table 24.
The differential spectroscopy studies in the presence of NAD+ for both insertion
variants as well as the M278A demonstrated a marked increase in the affinity for NAD+.
Based on this, and the decrease in catalytic efficiency and rate of turnover of substrate
seen in the three variants, we proposed that these mutants are deleterious due to product
inhibition. To further probe the properties of product inhibition, initial rate enzyme
kinetics were performed in the presence of varying concentrations of NAD+ to determine
if the competitive inhibition properties of the NAD+ product was capable of giving rise to
the alterations observed in the overall catalytic efficiencies and Ks values of these
variants. As shown in Figure 70, the Lineweaver-Burke plots obtained for WT cb5r and
the M278A, A-insertion and G-insertion mutants all displayed a model of competitive
inhibition represented by a single intercept at the y-axis showing no change in Vmax in the
presence of varying concentrations of NAD+.

Ki values [x-intercept = -(Ki)] were

established for the WT cytochrome b5 reductase and corresponding variants through the
secondary plot of the Km values for each assay against that of the concentration of the
NAD+ inhibitor. The Ki values obtained which corresponded to 675, 349, 193, and 120
µM for the WT domain, M278A, A-insertion and G-insertion variants, respectively. The
results were in good agreement with the catalytic efficiencies and Ks values obtained and
confirmed that NAD+ is not able to disassociate from the complex efficiently and thus
acts as an inhibitor in the cb5r reaction pathway.
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Figure 70. Enzyme Inhibition Assessment in the Presence of NAD+ for the M278A,
A-insertion, and G-insertion Variants. Panels A-D represent the Lineweaver-Burke
plots obtained from the initial rate kinetic analyses in the presence of various
concentrations of NAD+. Concentrations of NAD+ correspond to (●) 0 µM; (■) 50 µM;
(▲) 100 µM; (▼) 250 µM; (♦) 500 µM; and (+) 1000 µM for panel (A) [WT cb5r]; (●) 0
µM; (■) 25 µM; (▲) 50 µM; (▼) 100 µM; (♦) 250 µM; and (+) 500 µM for panels [B
and C] [M278A and A-insertion], respectively, and (●) 0 µM; (■) 25 µM; (▲) 50 µM;
(▼) 100 µM; and (♦) 500 µM for panel (D) [G-insertion]. Panel (E) represents a replot
of the observed KmNADH determined from each Lineweaver-Burke plot in (A-D) versus
the concentration of inhibitor (NAD+) where the inhibition constant (Ki) can be
determined by the equation: x-intercept = -(Ki), and the y-intercept = Km.
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Summary of the Role of NADH binding motif 273CGxxxM278
The product of the DIA1 gene, the flavoprotein cytochrome b5 reductase, has been
shown to be a critical enzyme in mammalian metabolism since an extensive number of
mutations have been identified in the gene that result in the disease recessive congenital
methemoglobinemia. Of the over forty mutations that have been identified, the majority
correspond to individual amino acid substitutions or deletions, in addition to a number of
nucleotide alterations that result in the presence of either premature stop codons
(truncation mutants) or incorrect gene processing. These mutations in the DIA1 gene
have been classified as producing either the type I or type II forms of RCM. The former
are the more benign form of the disease with cyanosis representing the dominant
symptom, while in contrast, the latter variant is physiologically more severe resulting in
impaired neurological development and finally death. Previous studies of the majority of
the known cb5r methemoglobinemia mutants that utilized a novel cb5/cb5r fusion protein
(NCR) have indicated that the variants that impact the NADH-binding site are some of
the most compromised mutants in terms of the level of retained specific activity.
Of the four primary sequence motifs that have been found to be characteristic of
the pyridine nucleotide transhydrogenase family of flavoproteins, the carboxy-terminal
“CGxxxM” motif is one of two motifs involved in pyridine nucleotide binding. It is clear
from the x-ray structure obtained for the WT cb5r that adverse effects involving the
“CGxxxM” motif are unavoidable if substitutions of the conserved “C”, “G” or “M”
residues occur. Alterations in the nature of the amino acid side chains of residues in the
“CGxxxM” motif have been shown to account for the substantially-weakened binding of
NADH to the various alanine variants, when compared to the NADH-affinities of the WT
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proteins. If the combination of hydrogen-bonding to the nicotinamide moiety and
hydrophobic interactions between NAD(H) and this motif are a significant factor in
modulating NADH binding, then any perturbation of the molecular structure surrounding
this binding site would adversely affect the affinity for NADH, and prediction that is
verified by the results obtained for the various alanine-scanning variants.
In the WT protein, the hydrophobic C273 side chain is positioned approximately
4.2 Ao from the si face of the FAD isoalloxazine ring system, and is in van der Waals
contact with the nicotinamide moiety of NAD+. This suggested the possibility that C273
is involved in controlling the equilibrium between the unstacked configuration of bound
NADH and the charge transfer complex. In the C273A variant, the absence of a thiol side
chain would be expected to result in an incorrect orientation of the bound NADH that
would decrease the rate of electron transfer and reduce catalytic efficiency. Furthermore,
the presence of the sulfur group in the C273M was unable to recover the activity seen in
the C273A, indicating that the positioning of the sulfur is key to allowing the NADH to
adopt the correct orientation for efficient enzymatic activity.
The G274 residue of the native cb5r is found participating in hydrogen bonding
between the backbone oxygen of the residue with the nitrogen N7 of the nicotinamide
moiety. Substitutions of this residue would result in minor deviations of the backbone
which would affect this hydrogen bond formation. The introduction of even the small
side chain methyl group of alanine to this position could result in a physical hindrance to
the binding of NADH, or cause the NADH to misalign in the binding pocket, placing the
nicotinamide moiety in a position incompatible with electron transfer. The substitution
of the various amino acids described in the data indicated that these newly introduced
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side chains of increasing size and, in the case of proline and serine, additional
characteristics, such as rigidity and polarity, may result in a sterically hindered
environment, consequently disrupting the hydrogen bonding. Figure 71 illustrates these
effects. G274P introduces a high level of conformational rigidity via the secondary
amine structure of its side chain. This causes a kink in the peptide backbone affecting the
downstream orientation of the protein. In the immediate vicinity, it also introduces a
physical hindrance to the binding of NADH, though to a lesser extent than previously
seen in the G180P and G182P mutations. The position of the proline oxygen backbone
would also likely shift slightly further away from the N7 nitrogen of the nicotinamide
ring, altering the hydrogen bond formation between the two atoms.

The severe

deleterious effect of the mutation on the catalytic efficiency demonstrates the impact that
these collective effects have. In addition, the G274A and G274S substitutions cause
equally severe deleterious effects on the catalytic activity through decreasing turnover
efficiency and diminishing binding affinity of the substrate through similar processes of
altering the hydrogen bonding distance and introducing physical obstructions to the
binding area. Moreover, the inability to maintain spectral differences for each of the
substitutions further indicates a disruption of the hydrogen bonding essential for substrate
binding.
The role of the three sequential proline residues proved to be important, but not
vital, to the proper function of the enzyme, in as far as that the removal of the proline
without replacement by a large side chain, in this case the alanine substitutions, did not
drastically impact the catalytic, spectroscopic, thermal stability, or electron transfer
properties of the protein. It is important to note, however, that residue P275, though in
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Figure 71. Structures of WT cb5r and cb5r variants G274A, G274P and G274S
with NAD+ Generated in silica. The molecular model of cb5r displaying the charged
surfaces of (A) residue G274 (B) cb5r variant G274A (C) cb5r variant G274Pand (D)
cb5r variant G274S in association with NAD+ generated utilizing the automated
comparative protein modeling server SWISS-MODEL [111] and analyzed using the
molecular modeling software Web Lab Viewer Pro [134]. Model depicts surface
representation of the residue and NAD+ in transparent display style. Distance between
N7 nitrogen of the nicotinamide and the backbone oxygen of each residue are shown in
green. Models generated from cb5r in complex with FAD and NAD+ (1IB0).
this study the least affected by substitution, has been identified as a site of a mutation
leading to type I RCM. The proline to leucine substitution was observed to have no
213

detectable effects on either the spectroscopic or thermodynamic properties of the flavin
prosthetic group in the absence of NAD+. In addition, protein folding and stability were
unaffected by the mutation. In contrast, the proline to leucine substitution exhibited a
profound effect on both the affinity of cb5r for the reducing substrate and its catalytic
efficiency. The substitution P275L was shown through homology modeling to create a
“hump” leading to steric hindrance preventing NADH from properly seating into the
binding pocket [105].
The role methonine 278 plays in enzyme activity and substrate binding can be
appreciated by examining the effects of a substitution of the residue. M278A exhibits a
moderate decrease in rate of turnover. The increased Km for NADH coupled with a
increase in Ks for H4NAD suggested that M278 plays a role in modulating the binding of
substrate. Further, the lack of decrease of intensity of spectral changes upon the addition
of NAD+, coupled with an increased spectral binding constant, indicated a change in
binding affinity caused by substitution of M278.
To further examine the role of the residue, insertion mutants were generated
which caused M278 to be shifted downstream one residue, placing it out of its native
register. Regardless of the inserted residue, the effect of the insertion was to decrease the
rate of turnover to approximately 3% of WT, as well as decrease the affinity for substrate
by 90 fold on average. While no noticeable changes were observed upon the addition of
H4NAD, the addition of NAD+ yielded spectral changes at lower concentrations of NAD+
than in the case of WT, indicating a preference for the product in the case of both
insertion mutants.

Additionally, NADH:FR assays in the presence of NAD+

demonstrated that all three mutants had increased inhibition constants for NAD+ as
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compared to WT, indicating that the decreased turnover rate is, at least in part, the result
of product inhibition. Thus, it is possible that M278 functions in release of NAD+ after
transfer of electrons to the flavin prosthetic group.
Secondary effects could also play a role in the reduced affinity of the various
“CGxxxM” variants for NADH. Such effects could be propagated through small
displacements in the neighboring loops which make up nearby sections of the NADH
binding site. For example, a small reorientation of the α-helical region following the
“CGxxxM” motif could reduce the space available for binding the adenine moiety,
forcing some reorganization of the loop containing F251, the stacking residue for adenine
in the WT.
The possible contribution of secondary effects of this kind could be investigated
by measuring the affinity of phosphorylated adenenines for the site. In cb5r homologues,
such as cytochrome P450 reductase and ferredoxin:NADP+ reductase, partial NADPH
analogs such as 2’-AMP and 2’,5’-ADP are inhibitors (and in some cases activators)
because they compete with NADPH. The FAD and pyridine nucleotide binding sites in
these enzymes have features which cb5r lacks, including a stacking residue supplied by
the carboxyl-terminal region for the FAD isoalloxazine and interdomain hydrogen bonds
to the pyridine nucleotide.
While the substitution of the individual residues in the “CGxxxM” motif were
anticipated to have a substantial impact on the Km for NADH owing to the perturbation of
the position of the subsequent residues that correspond to C273 to M278, they were not
anticipated to have any substantial impact on the spectroscopic or thermodynamic
properties of the flavin prosthetic group. As expected, none of the “CGxxxM” motif
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substitution mutants adversely affected the wavelength maxima determined for the FAD
prosthetic group in either the visible absorption or CD spectra. This result demonstrated
that altering the nature of amino acid residues situated opposite the isoalloxazine ring
would not be expected to have a significant effect on the redox properties of the flavin
prosthetic group, a prediction that was tested by performing oxidation-reduction titrations
for the various mutants, and is also reflected in the turn-over value of the variants.
Overall, the results of these studies indicate the important contribution of the
residues that comprise the “CGxxxM” reduced pyridine nucleotide-binding motif and
suggest that any naturally occurring mutations in these residues are likely to be manifest
in RCM with different degrees of severity.
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4. CONCLUSIONS AND FUTURE DIRECTIONS

These studies were designed to provide additional structural and functional insight
into the highly conserved motifs found within cytochrome b5 reductase, and other
members of the FNR super-family with respect to the mode of NADH-binding and the
enzymes catalytic function. This objective was accomplished using two approaches. The
first approach involved the generation of an array of cb5r variants with substitutions of
amino acid residues found within the conserved motifs based on alternative residues
observed to occur at the same position in other members of the FNR family as well as
within other species, structural difference among between residues, removal or addition
of polar groups, and the introduction of positive charges.

The second approach

incorporated the analyses of naturally occurring recessive congenital methemoglobinemia
mutants that are located within, or in close proximity to, the conserved motifs. Through
this method of characterization, we were able to establish a role for each of the previously
uncharacterized amino acid residues found in the NADH-binding motifs in addition to
suggest the molecular basis for the disease for each of the RCM variants.

The

construction and characterization of the canine cytochrome b5 reductase protein was also
designed in order to compare and contrast the differences and similarities in structure and
function among mammalian protein variants.

217

Previous studies on the human, bovine, and porcine variants of cb5r have
elucidated discrepancies in the kinetic constants of proteins that would otherwise appear
to be nearly identical in nature. The primary structure of these different variants retained
a high level of sequence similarity among the residues, and demonstrated conserved
sequence motifs involved in binding of its flavin cofactor and the reduced substrate,
NADH.
With the sequencing of the dog genome, potential gene transcripts had been
identified that maintained sequence similarity to the cb5r sequence. The theoretical
sequences for the canine cb5r variant indicated a high level of dissimilarity in the amino
terminal portion of the sequence.

This work was designed to examine these

dissimilarities as well as provide a comparison of the characterization of the gene
products from two mammalian species, under identical conditions, in an effort to
determine the differences and similarities in their structural and functional parameters.
In constructing the canine variant, it was shown that the dissimilarity in the amino
terminus reported in the original GenBank sequence was in error, and likely due to
incorrect sequencing. The canine variant retained a primary structure nearly identical to
that of the rat and human variants, with a small degree of disagreement with each
sequence at a limited number of residues. Comparison of the results obtained from the
spectroscopic, kinetic, and thermal stability studies confirmed predictions generated from
the pair-wise sequence alignments that the structural and functional properties of the
recombinant canine cb5r diaphorase domain should be directly comparable to those of the
corresponding rat domain. The similarity in the kinetic properties is particularly
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significant and suggests that other cb5r variants exhibiting similarly conserved sequences
should exhibit comparable kinetic properties.
Analysis of the crystal structure of cb5r reveled that two residues, Y112 and
Q210, formed hydrogen bonds with the pyrophosphate backbone of NAD+, forming an
anchoring attachment from the external surface of the protein. This, combined with the
high level of conservation of these residues within FNR family members and other cb5r
sequences, suggested that these residues may play a vital role in the correct binding with
NADH and, consequently, efficient electron transfer with cb5r. This work examined
several substitutions of each residue to determine the importance of the residues and their
potential roles in enzyme structure and function.

Characterization of the variants

indicated that the hydroxyl group of Y112 was necessary for binding NADH in the
proper orientation. Substitution of this residue resulted in moderately decreased kinetic
constants, indicating inefficient transfer of reducing equivalents. The Q210 variants also
showed a decrease in function, however to a lesser degree, indicating that Y112 is more
critical in orienting the reduced substrate than Q210.
Proximal to the two pyrophosphate associating residues are two residues shown to
be mutated in patients presenting with type I RCM. The two mutations, corresponding to
T116S and E212K, were detected in the same patient presenting with cyanosis and
increased serum methemoglobin concentrations. The T116S mutation had previously
been demonstrated to occur in approximately 27% of the African American population,
and thus was identified as a polymorphism. These individual variants were investigated
to determine the causative nature of each mutant leading to the presentation of disease.
Additionally, the double mutant, T116S/E212K, was generated and characterized to
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further elucidate the condition of the patient. Subsequent characterization revealed that
both mutations affected the function of the protein. For the T116S variant, the affects
were mild, but still significant enough to cause a disease condition. Catalytic efficiency
was decreased by half, and the ability to transfer electrons was shown to be somewhat
impaired. Similarly, E212K showed impaired function, to a slightly greater extent than
the T116S variant. Most notable was the decrease in stability of the E212K mutation,
which is likely the causative agent in the presentation of RCM for the patient, as protein
in the circulating erythrocytes gradually breaks down overtime and cannot be replaced.
The double mutant showed an even great decrease in functionality, indicating that the
T116S does indeed add to the effects of the E212K mutation.
Multiple sequence alignments of FNR family members and cb5r sequences
revealed that several structural motifs exist that are vital for the binding and association
of flavin cofactors and pyridine nucleotide substrates.

One of these motifs,

corresponding to “180GtGitP185” in cb5r, is located in the NADH-binding lobe of cb5r.
Based on analysis of the x-ray crystal structure, these residues are shown to form
hydrophobic interactions and direct connections with both the FAD cofactor and the
NAD+ molecule associated with cb5r. The general structural nature of the conserved
residues of this motif suggested that a vital role for this motif is to form a scaffold onto
which the NADH can bind to properly align for subsequent electron transfer.
Additionally, the two threonine residues located in the motif, T181 and T184, bind to
NAD+ and FAD, respectively, aiding in the proper positioning of each group.
Furthermore, T184 binds to N5 of the isoalloxazine ring of FAD, the location of one of
the electrons in the reduced FAD.

Substitution of the residue of this region with
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structural alternatives as well as naturally occurring alternate residues in the FNR family
members confirmed the importance of each residue. Both G180 and G182 are necessary
to provide a relatively clear area around which the NADH can bind in order to properly
position the nicotinamide portion of the molecule. Proline substitution of each of these
residues resulted in displacement of the nicotinamide moiety, decreasing catalytic
efficiency. Likewise, the proline residue, P185, confers structural rigidity in the middle
of the helix Nα1. Removal of the residue removes the necessary structural needs to
maintain the proper folding in the immediate region of the residue. A higher degree of
“openness” is generated as a result, allowing for better association of NADH, but not in
the proper orientation. The structural importance is further demonstrated in the reduced
thermal stability seen in the variants of this residue. I183, likewise, causes structural
integrity, with substitution leading to decreased stability while maintaining a moderate
level of catalytic ability of WT. This was expected, as this residue does not participate in
any direct interaction with the FAD or NAD+ groups, but is located in a structural
component leading to the stability of the protein and the proper orientation of both
groups. The –OH group of T181 was shown to be vital in anchoring the NADH in the
proper orientation to align the N7 nitrogen of the nicotinamide ring for the subsequent
electron transfer. This was demonstrated by differential spectroscopy of the variants
T181A and T181I adopting a line shape similar to PAAD+ which lacks this nitrogen.
Substitution of T184 demonstrated a great impact upon the association of FAD and on the
function of the protein. T184 interacts with FAD in two locations, one of which is the
site of a hydrogen added during the reduction reaction. Removal of the –OH group
caused a destabilizing effect on the semiquinone intermediate, decreasing catalytic
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efficiency. Replacement with histidine caused even more severe impairment, causing the
mutant to have a midpoint potential about equal to that of free flavin.
Preceding the GxGxxP motif is another highly conserved glycine residue G179.
This residue helps to form the transition in the helical structure of the motif. It is highly
conserved among FNR family members and across species sequences. The function of
this residue was investigated by replacement with naturally occurring alternate residues
and characterized for kinetic, spectral and thermal stability properties. It was shown that
replacement of this residue lead to decreased affinity for substrate and decreased catalytic
function. Substitution with alanine caused the least deleterious effects on the function of
the protein while the other substitutions, (P, T, and V) effectively caused NADH to be
unable to efficiently bind. Interestingly though, substitution with valine lead to increased
affinity of NADPH over NADH, indicating that this residue plays a role in substrate
specificity.
Immediately preceding G179 is another residue, A178, which has been shown to
be occur as two distinct mutations, A178T and A178V, that result in presentation of type
I RCM. Presentation in each patient was mostly restricted to cyanosis with elevated
methemoglobin levels. Both were shown to be distinct mutations and not polymorphisms.
Previous studies of A178V demonstrated that the variant maintained near WT catalytic
function, and only differed by having a lower thermal stability than WT. To further
explore the effects of these mutations on the function of cb5r, the two mutants were
generated and characterized based on kinetic, spectral, and thermal stability properties
and compared to WT. It was shown that, as previously reported, the A178V mutant
maintained near WT activity, though not to the extent as previously reported.
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Additionally, the only alteration was a decreased stability to temperature, indicating that
the causative nature of disease of this mutant is a result of degradation of protein in the
circulating erythrocytes. A178T, on the other hand, demonstrated equivalent stability,
yet showed a more significant decrease in kinetic function. The presence of the –OH
group of A178T causes electrostatic and/or steric interference of the neighboring
GxGxxP motif, leading to dysfunction.

This interference leads to decreased ability to

bind NADH properly and thus decreases catalytic activity. Though greater than the
effects of A178V, the A178T mutation is itself mild, and thus would likely not cause
severe consequences in the patient.
The second conserved motif present in the FNR family members and specifically
in cb5r is the “273CGpppM278” motif. As shown from x-ray crystallography this motif,
while not directly associating with NAD+, generates an extensive framework of
hydrophobic interactions with the bound NAD+ properly orienting it into the binding
pocket. The only direct bonding occurs between the backbone of residue G274 and the
N7 of the nicotinamide of NAD+. To investigate the importance of this motif, variants
were generated based upon side chain properties of each residue to determine what role
each play. Additionally, two insertion mutants were created to investigate the presence
of an additional residue in this motif that occurs in several member of the FNR family.
Characterization of these residues indicated that each of the three sequential proline
residues are necessary to generate the correct orientation of the tertiary structure of the
protein in the proximal vicinity, allowing the necessary rigidity to generate a kink in the
protein changing its direction and initiating a helical structure. Alterations of these
residues yield mildly decreased function of the protein, but not to a significant extent as
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other mutations did. The presence and position of the sulfur group of C273 was shown to
be important to the function of the enzyme as removal or repositioning of the group, as
done by C273A and C273M variants respectively, yielded drastically diminished activity.
Likewise, the presence of G274 was shown to be vital to the proper orientation of
NADH. Introduction of any side chain to this region resulted in the inability of NADH to
effectively bind to cb5r, and in effect prevented the protein from functioning, with the
G274P mutant retaining less that .01% catalytic efficiency of WT. The effect seems to
result from three different effects. First, the movement of the backbone altered the
position of the oxygen involved in hydrogen bonding with the NAD+ nicotinamide N7.
Secondly, the presence of additional atoms on the side chains of any residue substituted
in this region could generate a physical obstacle toward the binding of NADH. Finally,
in the case of proline, introduction of rigidity at this position would result in alteration of
the folding of the protein in the immediate region, generating potential downstream
effects that lead to decreased function, as well as affecting the nearby structural motifs
GxGxxP also involved in the binding of NADH and the proper placement of the
nicotinamide moiety.
The alanine substitution combined with the two insertion mutants shed light on
the function of M278. The results demonstrated that the decrease in catalytic efficiency
was coupled with an increased affinity for binding of NAD+. Inhibition studies indicated
that these mutants had lower inhibition constants than WT, indicating that NAD+ was not
dissociating form the enzyme as well as it does in WT.

This suggests that M278

potentially plays gate keeping role in the process of associating with substrate and
dissociating product.
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These data provide valuable insight into the structural and functional properties of
the highly conserved motifs of cytochrome b5 reductase that are involved in NADHbinding and orientation as well as a determination of the molecular basis of the disease
recessive congenital methemoglobinemia.

These results support logical conclusions

based on the kinetic, spectral, thermodynamic, and molecular modeling properties of each
of the generated variants. The data presented in this research provided a broad analysis
of the motif using alanine scanning as well as specifically tailored substitutions to
provide information on the structural and catalytic role of each individual residue.
However, in order to complete this work and support our conclusions crystal structures of
several of the variants, both in the absence and presence of NAD+ should be obtained.
This would provide the most concrete evidence to support the conclusions presented in
this work.
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Appendix A
List of oligonucleotide primers used to generate the Y112, T116, Q210, and E212K
variants. Nucleotides underlined and in bold encode the mutated bases generated to
introduce the proper mutation. Silent mutations in italics add (+) or eliminate (-) the
indicated restriction site.
Mutation

Primer Sequence (5’→ 3’)

Restriction Site

Y112A*
Y112D
Y112F*
Y112H
Y112L*

GTG
GTG
GTG
GTG
GTG

T116A
T116S*

C TTC AAG GAC GCG CAT CCC AAG
GTT TAC TTC AAG GAT TCG CAT CCC AAG

+Hga I
+Tfi I

Q210A*
Q210R*
Q210V*

CTT TTC GCC AAC GCG TCC GAG AAA GAC
CTT TTC GCC AAC CGG TCC GAG AAA GAC
CTT TTC GCC AAC GTG TCC GAG AAA GAC

+Afl III
+Age I
+Afl III

E212A
E212K*

CC AAC CAG TCC GCG AAA GAC ATC C
GCC AAC CAG TCC AAA AAA GAC ATC CTG

+BstU I
-Hpy188I

GTC
GTC
GTC
GTC
GTC

AAG
AAG
AAG
AAG
AAG

GTT
GTT
GTT
GTT
GTT

GCA
GAC
TTC
CAC
CTC

TTC
TTC
TTC
TTT
TTC

238

AAG
AAG
AAG
AAA
AAG

GAC
GAC
GAC
GAC
GAC

ACG
ACG
ACG
ACG
ACG

+Bsm I
+Hinc II
+Mbo II
+Dra I
+Mbo II

Appendix B
List of oligonucleotide primers used to generate the A178, G179, G180, T181, G182,
I183, T184, and P185 variants Nucleotides underlined and in bold encode the mutated
bases generated to introduce the proper mutation. Silent mutations in italics add (+) or
eliminate (-) the indicated restriction site.
Mutation

Primer Sequence (5’→ 3’)

Restriction Site

A178T*
A178V*

GTA GGC ATG ATC ACT GGA GGG ACA GGC
GTA GGC ATG ATT GTG GGA GGG ACA GGC

+Bcl I
-HpyCH4 V

G179A*
G179P*
G179T*
G179V*

ATG
ATG
ATG
ATG

+Pvu
+Bpm
+Nci
+Btg

G180A*
G180P*

ATG ATT GCA GGA GCG ACA GGC ATC ACC
ATG ATT GCA GGA CCG ACA GGC ATC AC

-Mnl I
+Ava II

T181A*
T181I*
T181S*

ATG ATT GCA GGA GGG GCA GGC ATC ACC
ATG ATT GCC GGA GGG TUC GGC ATC ACC
ATG ATT GCC GGA GGG TCA GGC ATC ACC

+Mwo I
+Msp I
+Msp I

G182A*
G182P

GCA GGA GGG ACA GCC ATC ACC CCA ATG
GCA GGA GGG ACA CCC ATC ACC CCA ATG

-SfaN I
-SfaN I

I183A*
I183F
I183L
I183M

GGA
GGA
GGA
GGA

GGG
GGG
GGG
GGG

ACA
ACA
ACA
ACA

GGC
GGC
GGC
GGC

GCC
TTC
CTC
ATG

ACC
ACC
ACC
ACC

CCA
CCA
CCA
CCA

ATG
ATG
ATG
ATG

CTG
CTG
CTG
CTG

-SfaN
-SfaN
-SfaN
-SfaN

T184A*
T184H
T184S*
T184V

GGG
GG
GGG
GGG

ACA
ACA
ACA
ACA

GGC
GGC
GGC
GGC

ATC
ATC
ATC
ATC

GCC
CAC
TCC
GTC

CCA
CCA
CCA
CCA

ATG
ATG
ATG
ATG

CTG
CTG
CTG
CTG

CAG
C
CAG
CAG

-Msl
-Msl
-Msl
-Msl

P185A*
P185G

GGG ACA GGC ATC ACC GCA ATG CTG CAG
GGG ACA GGC ATC ACC GGA ATG CTG CAG

ATT
ATT
ATT
ATT

GCA
GCT
GCA
GCC

GCT
CCA
ACC
GTG

GGG
GGG
GGG
GGG

ACA
ACA
ACA
ACA
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GGC
GGC
GGC
GGC

ATC
ATC
ATC
ATC

ACC
ACC
ACC
ACC

II
I
I
I

I
I
I
I

I
I
I
I

+BsrD I
+BsaW I

Appendix C
List of oligonucleotide primers used to generate the C273, G274, P275, P276, P277,
M278, A-insertion, and G-insertion variants Nucleotides underlined and in bold encode
the mutated bases generated to introduce the proper mutation. Silent mutations in italics
add (+) or eliminate (-) the indicated restriction site.
Mutation

Primer Sequence (5’→ 3’)

Restriction Site

C273A*
C273M*
C273S*

CTG ATA CTG ATG GCG GGA CCC CCA CCG
CTG ATA CTG ATG ATG GGC CCA CCA CCG
CTG ATA CTG ATG AGC GGA CCC CCA CCG

+BsmF I
+Apa II
+BsrB I

G274A*
G274P*
G274S*

CTG ATA CTG ATG TGT GCA CCC CCA CCG
CTG ATA CTG ATG TGT CCA CCC CCG CCG
CTG ATT CTG ATG TGT TCA CCC CCA CCG

-Ava II
-Fau I
+Tfi I

P275A*

CTG ATG TGT GGG GCC CCA CCG ATG ATC

+Apa I

P276A*

ATG TGT GGA CCG GCA CCG ATG ATC CAG

-Ban I

P277A*

TGT GGA CCC CCA GCA ATG ATC CAG TTT

+BsrD I

M278A*

GGA CCC CCA CCG GCG ATT CAG TTT GCC

-Tfi I

A ins*
G ins*

GGA CCC CCA CCG GCC ATG ATC CAG TTT
GGA CCC CCA CCG GGC ATG ATC CAG TTT

+Eae I
+Nci I
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